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1» The aim of the present studies was to investigate
the urinary excretion ofluteinising hormone (LH) in
human subjects in normal and pathological conditions
using two bioassay systems, the ventral prostate weight
(VPW) and the ovarian aecorbic acid depletion (OAAD)
tests.
2. A number of difficulties were encountered in the
performance of thee* assays. These included lack of
sensitivity, low precision and high toxicity of urinary
extracts. An attempt was made to improve the
reliability criteria of the tests and at the same time
extraction methods from urine were re-investigated.
3. With reference to the VPW test the most important
modifications introduced involved (a) the administration
of cortisone acetate to the experimental animals thus
considerably reducing the mortality rate of the
experimental animals, and (b) the reduction of the
interval between hypophysectomy and assay proper thus
increasing the sensitivity of the overall procedure.
Minor modifications were concerned with the strain of
animal used and the diet employed.
4. Modification to the OAAB method Included (a)
a reduction of the time interval between the injection
of the test materials and the sacrifice of the animals
from 4 to 3 hours, (b) restriction of weight range of
experimental animals between 35 and 45 g. and (c)
ii.
reduction of log dose interval from log1Q5 (0,69897)
to log1C)4 (0,60206), Cortisone acetate affected the
response of the animals when administered simultaneously
with LH, hut when large amounts of corticosteroids were
added to urine and extracted no effect on LH activity
was found,
5, The urine collected routinely for clinical studies
was found to be heavily contaminated with bacteria,
and this resulted in marked toxicity of the urinary
extracts. The collection of urine to which Hibitane
had been added inhibited such growth and reduced
toxicity. Moreover, dialysis of the urine prior to
extraction served as a first step of purification,
removing from the urine materials which might affect the
mode of action of LH in bioassay procedures,
6, The clinical conditions investigated using the
modified assay procedures included the perimenopauee,
the postraenopause and the effects of oral contraceptives
and Clomiphene on pituitary gonadotrophic function* In
addition, studios were made on urinary LH levels in
male subjects with a 47»XYY chromosomal karyotype and in
patients suffering from Turner's syndrome,
7, In four subjects late in their reproductive life
urinary LH was grossly elevated and in two of them
ovulation as judged by urinary steroid assays occurred
normally in the presence of high LH readings f in one
abnormally high LH and oestrogen excretion values co-
Hi.
existed. No significant difference in overall LH
excretion was noted between the perimenopausal subjects
and a series of four postmenopausal women,
8. Urinary LH levels were estimated in four women
during and following long term therapy with oral
contraceptives administered in the Mclassical" or
sequential forms or as a "pure" gestagen. In three
subjects there was definite evidence for the resumption
of ovulation in the first post-treatment cycle; none
of the four patients showed significant suppression of
urinary LH activity as a result of medication. In a
fifth woman the administration of chlorraadinone acetate
continuously in low dosage for a short period of time
had no significant effect on either LH or oestrogen
output; ovulation as judged by urinary pregnanediol
assays may have inhibited,
9. Clomiphene did not exhibit any significant effect
on urinary LH excretion when administered to a series of
five patients suffering from abnormal gynaecological
conditions associated with infertility. It was con¬
cluded that the site of action of Clomiphene was on the
ovaries rather than on the pituitary-hypothalamic axis.
10, LH levels in three phenotypic males with a 47#XYY
chromosomal constitution were found to be grossly
elevated, being significantly higher (P< 0,001) than
those found In normal male subjects,
11, In Turner's syndrome L1I Values were variable in
individual subjects, being either within or below the
Iv,
postmenopausal range; no apparent correlation existed
between the chromosomal karyotype and the LH output.
In one of the four patients studied a bilateral ovarian
transplantation was performed; this being associated





The possible existence of an extra-ovarian factor
capable of regulating ovarian activity was postulated by
Meape in 1897* Foa (1901) observed rapid follicular
growth and development in immature ovaries when grafted
into adult animals# As early as 1912, Aschner (1912)
was able to demonstrate atrophic onanges in the 'genital
organs' of dogs following hypophysectomy• Enlargement
of the ovaries and formation of numerous corpora lutea
in normal rats treated with extracts of pituitary tissue
were reported by Evans during the early 1920s (Evans,
1924). At about the same time Smith (1926) and Zondek
and Asohheim (1927) demonstrated that pituitary extracts
or implants were capable of influencing the gonads.
In 1931, Eevold et al. produced evidence to support
the hypothesis that gonadal development was influenced
by two hypophyseal hormones, whioh were called follicle-
stimulating hormone (FbH) and luteinising hormone (LH)
or interstitial cell stimulating hormone (IOSH). Tech¬
niques involving fractional precipitation with organic
solvents and inorganic salts combined with pH adjustment,
have demonstrated that extracts of sheep and swine
pituitary glands contain these two gonadotrophin prin¬
ciples (Fevold et al., 1951; Van Dyke and Wallen-
Lawrence, 1933; Bates et al., 1934). Meanwhile
2.
evidence has been presented to indicate that the hypo¬
physeal factor responsible for luteal function was not
one of the known gonadotrophins. Dresel (1955) and
Lahr and Kiddle (1936) showed that purified hormone
preparations would inhibit oestrous cycles in normal
adult mice and rats and found that the ovaries of such
animals contained a number of large corpora Xutea.
Aatwood and Fevold (1939) put forward the suggestion
that while LH is responsible for the conversion of
follicles into corpora lutea, a third hypophyseal gonado-
trophin termed prolactin or luteotrophio hormone (DTK) is
concerned with luteal function. The Third International
Conference on the Standardisation of Hormones, held in
Geneva in 1959» decided to adopt the term "gonadotropbin"
for the various gonad-stiraulating principles.
1. Pituitary Gonadotrophins
Research into the cellular origins of the pituitary
gonndotrophin hormones has not been easy, nor in many
cases have the results been clear-cut. During the past
decade, however, advances have resulted from the intro¬
duction of histoehemical and biophysical techniques. It
is now believed that prolactin is produced by the acido¬
phil cells of the anterior pituitary (Lacour, 1950;
Purves and Griesbach, 1952j Hymer et al», 1961j Barnes,
1962) while PSH and LH are secreted by the basophil cells
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(Farquhar and iiinehart, 1934; Barnes, 1962).
Some 23 years ago Marshall (1942) suggested that
the hypothalamus exerted a controlling influence over
the secretion of the pituitary gland. It has heen
demonstrated that the pituitary stalk connecting the
median eminence of the tuber cinereum with the anterior
pituitary gland contains a minute portal system of blood
vessels (Pops, and Fielding, 1930, 1933). These workers
postulated that nerve traots in the hypothalamus probably
release humoral substances into the portal vessels and
that these substances are transported in this way into
the anterior pituitary itself. Regulation of hormone
secretion is therefore controlled by oheraotraneraitters
stimulating the cells of the anterior pituitary.
Evidence to support a hypothesis that secretion of
luteotrophln may be controlled by a different mechanism
%
has been presented by Meites et al. (1963). Theae
workers claim that the secretion of prolactin may be
depressed by the hypothalamus and have shown that it
increases when the connection between the hypothalamus
and the anterior pituitary is severed. The existence
of a follicle-stimulating releasing factor (FSH-BF) is
not yet well established, but there is Borne evidence to
suggeat that the secretion of FSH might be dependent
upon hypothalamic control (Igarashi and MoCann, 1964a;
Igarashi et al.. 1964} McCann et al., 1964). Evidence
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is accumulating which supports the existence of an LH
releasing factor (Taleisnik and KcCann, 1961; Halasz
and Gorski, 1967} Bosono et al.. 1967). Recently
McCann et al. (1968) in an extensive review concluded
that the basal secretion of LH is mediated via the basal
tuberal region of the hypothalamus and that, in females,
a more rostral region which includes the euprachiasxnatic
area is responsible for the 'ovulatory burst' of LH.
The biological activities of the gonadotropins
have not been completely elucidated mainly due to in¬
sufficient purity of the available hormones. "Evans ejt
al. (1939) observed that the ovary of the hypophysecto-
mised rat is much more sensitive to FSH than to LH, and
that administration of PSH to hypophysectomised, immature
rats caused follicular growth without luteinieation or
corpus luteura formation. This observation was confirmed
by Simpson (1961) and Smith and Bradbury (1963). This
specific effect of FSH led to the development of a bio-
assay method for its determination (Evans et al., 1939;
Simpson, 1961). However, Loetroh (1965) reported that
in the hypophysectomised rat, highly purified sheep FSH
and LH were by themselves Ineffective in causing any
©estrogenic effect on the uterus, stimulating follicular
development or affecting ovulation. It was found that
as little as 0.02 j.ig. of LH added to FSH (3 jug.) resulted
in oestrogen secretion as evidenced by uterine enlarge-
5.
merit; 0.2 jug. produced a maximum stimulation, 1*0 jug.
initiated luteiniaation of large follicles, and a final
dose of 3.0 jig. LH two days later brought about ovula¬
tion. These data suggest that PSH alone cannot induce
follicular stimulation, either as judged by its capacity
to initiate follicular development or to promote the
secretion of gonadal hormones. Both phenomena appear
to be stimulated by an PBH-LH mixture, although the
ratio between the two hormones in the mixture does not
seem to be critical (Carter et al.. 1961). The largest
body of data on gonadotropin action on the ovary of
different species, in vitro, is that of Bav&rd and his
co-workers (Savard et al.. 1963; Marsh et al.t 1966;
Marsh and Bavard, 1966). The steroidogenic effect of
PSH observed by them was thought to be due to contamina¬
tion by LH.
Several investigators have clearly demonstrated
that the presence of the pituitary gland is required for
the maintenance of spermatogenesis (Smith, 1930; Greep
and Pevold, 1937). The subject has been reviewed by
Greep (1961) and Albert (196i). Albert (1961) in his
review concluded that spermatogenesis is regulated
entirely by pituitary gonadotrophins which exert direct
supervision over the rate of both mitotic and meiotic
activity and indirect control over spermatid maturation
or spermiogenesis mediated by the activity of the Leydig
6.
ceils. Nevertheless, Cutuly and Gutuly (1940) and
Clermont and Morgentaler (1955) stated that the first
steps of spermiogenesia may proceed in the absence of
hypophyseal hormones.
While most authors agreed that LH acta on the
seminiferous epithelium indirectly through the androgens
produced by the Leydig cell (see review, Greep, 1961),
the role of FSH remains the object of divergent opinions.
Kelson (1952) suggested that FSH might be responsible
only for the proliferation of spermatogonia. On the
other hand Greep (1961) stated that FSH acts on the
spermiogenic cells in the testes with the aarae
selectivity that it exhibits for germinal tissues in the
female gonad. Recently Clermont and Harvey (1967)
investigated the effect of testosterone propionate, FSH
and XiH on the maintenance of spermatogenesis in hypo-
physectomlaed rats. They concluded that testosterone
was the hormone immediately affecting the seminiferous
epithelium, LH presumably stimulated the Leydig cells to
secrete androgens, which in turn acted on the semini¬
ferous tubules. The effect attributable to FSH was
most probably due to the contamination of the preparation
injected by LH. Lorfman et al. (1967) reported that
pretreatment of immature male rats with human chorionic
gonadotrophin (HCG) produced intense stimulation of the
conversion of cholesterol to pregnenolone. This effect
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could not be elicited by either FSH or LH alone, but was
evident when the rats were treated with a mixture of FSH
and LH*
These diverse opinions regarding the effects of
gonadotrophins on the gonads are probably due to a
number of factors. Undoubtedly the lack of purity of
the hormones utilised is largely responsible for many
findings that are contradictory in nature. Moreover
there is a remarkable variability of the response to
injected hormones in different species, strains and even
individual animals (Lostroh et al., 1963). The com¬
plexity of the target tissues involved in gonadotrophic
stimulation makes it difficult to Interpret experimental
findings with any great certainty. For example, sperma¬
togenesis is not a simple phenomenon, it includes an
elaborate system of proliferating and self-renewing
spermatogonia, a long and intricate mechanism of cell
division (meiosis) and a complex series of cytological
changes when spermatids metamorphose into spermatozoa.
The effect of LH on the ovary is somewhat better
established. Thus LH in the absence of the pituitary
gland and of FSH, acts chiefly on the interstitial
tissue of the ovary (Baillie and Griffiths, 1964; Boss
et al.. 1965; Deane and Hubin, 1965; Rubin et al., 1965;
Balogh et al., 1966). The mechanism of action of LH
appears to lie in its effect on the enzymes of the ovary
S.
leading to the induction of steroidogenesis (Balogh ens
al., 1966). Savard and his colleagues (Savard et al.,
1965* Marsh et al.. 1966; Marsh and Savard, 1966) have
also shown by means of acetate incubations of human and
bovine corpora lutea and by human ovarian stroma that LH
and HCG cause an overall increase in the biosynthesis of
steroids in vitro.
2. Human Urinary Gonadotrophina from Bon-pregnant
Sources
It has been generally assumed that the gonadotrophic
material excreted in the urine of non-pregnant human
subjects is derived from the pituitary gland. Relatively
small amounts of gonadotrophic material have been found
in urine from normal adult male and from non-pregnant
female subjects, while smaller amounts have been measured
in the urine of young children of both sexes. The
highest levels of activity have been found in the urine
of menopausal and post-menopausal women. Crude concen¬
trated extracts of urinary gonadotrophin show both PSH
and LH activities in varying proportions.
In I960, Lunenfeld et al. demonstrated that gonado-
trophins derived from the urine of menopausal and post¬
menopausal women, designated as human menopausal gonado¬
trophin (HSfO) was effective in inducing ovarian stimula¬
tion. Subsequent work carried out by lunenfeld (1963)
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and other investigators demonstrated that HMG, when
given in combination with HCG, could cause ovarian stimu¬
lation and ovulation (Grooke, 1964} Passeto and
Montanino, 1J64; Diczfalusy, 1965; Seuwrith et al.,
1965).
3. Human Chorionic Gonadotrophln
In 1927 a gonad-stimulating substance, present in
comparatively large amounts in the blood and urine of
pregnant women, and capable of producing ovarian folli¬
cular maturation, luteinieation and haemorrhage of the
ovarian stroma in immature female mice, was demonstrated
by Aachheim and Zondek (1927). Following this important
discovery there was much speculation regarding the source
of this material. Aschheim and Zondek (1927) suggested
that the gonadotrophic factor was derived from the
pituitary. Subsequently it became apparent that, like
the adenohypophysis, the chorionic tissue also was
capable of elaborating gonadotrophic substances. Many
convincing reports have now been presented which demon¬
strate that the gonadotrophic principle present iri the
body of the pregnant women is derived from chorionic
tissue and not from the pituitary (Engle, 1929; Collip,
1930, 1935; Deanesly, 1935). Production of gonad-
stimuiating material in vitro was shown to take place in
placental tissue (Sannicandro, 1934; Gey et^al., 1938;
10.
Jones and Bucher, 1943; Stewart et al.. 1948). Histo-
ohemical studies by a number of workers (Wislocki and
Bennett, 1943; Zilliacua, 1953), including intraocular
transplantation experiments (Stewart, 1951), confirmed
the placental production of the gonadotrophic substance.
The human placental gonadotrophin is generally designated
as human chorionic gonadotrophin (HCG).
The role of HCG during pregnancy has not been
entirely clarified. However, it appears that the
hormone plays a significant role in maintaining the
function of the corpus luteum during the first weeks of
gestation. In a review of the subject, Lunenfeld and
Donini (1966) concluded that during the later stage of
pregnancy, HCG might contribute to the proper functioning
of certain enzyme systems that are responsible for
progesterone and oestrogen biosynthesis in the feto¬
placental complex. The specific action of LH and HCG
on steroidogenesis in numan corpora lutea of the
menstrual cycle and of ectopic pregnancy has been
described by Savard et al. (1965).
The administration of HCG to normally menstruating
women, depending on dosage and timing, will induce
luteinisation of their cells (granulosa cells and
follicles). In the presence of fresh corpora lutea,
HCG may have a trophic effect, causing a prolongation of
its functional life. When HCG is administered to women
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with anovulatory cycles it may, in combination with HMG
or PM89 or human pituitary FSH, promote luteinisation of
follicular cysts, follicular rupture and ovulation (for
references see Loraine and Bell, 1968).
4. Pregnant Hare's Serum Gonadotrophin (PMSG)
Zondek (1930) and Cole and Hart (1930) independently
discovered the presence of a potent gonadotrophic
material in the serum of pregnant mares. The erroneous
concept that the gonadotrophic material present in the
serum of pregnant mares is not excreted in the urine of
these animals has been so prevalent (Albert, 1961a) that
the term "serum gonadotrophin" has been widely used in
connection with this particular gonadotrophic substance.
However, Zondek (1931) and Schmidt-Elraendorff et al.
(1962a) have demonstrated the presence of this material
in the urine as well as in the serum of these animals.
The mode of action of PMSG on the gonads is not well
understood. Engle and Hamburger (1935), in experiments
on Rhesus monkeys, observed a pure follicle-stimulating
action. Experiments on human subjects were soon under¬
taken during which the hormone was given intramuscularly
and several days later laparotomy was performed. Thus
Watson et al. (1938) observed not only formation of
follicular cysts but alao luteinisation on the theca and,
in some cases, of the granulosa too. Furthermore, Davis
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and Koff (1938) were able to induce ovulation and forma¬
tion of corpora lutea by the intravenoua injection of
PMSG. These observations were confirmed by Siegler and
Fein (1939)* During the last two decades, PMSG has
been extensively used for the induction of ovulation,
and this subject has been reviewed by Rydberg (1966).
Methods of Purification and Kxtraction
(a) FSH: The extraction of crude pituitary powders in
mixtures of ethanol and acetate buffers has proved to be
a most useful method for the purification of gonado-
trophlns (Koenig and King, 1950). In addition, the
technique leads to a virtually complete separation of
gonadotrophins from other hormones, notably growth
hormone, corticotrophin and prolactin. Since PSH,
alone of the pituitary hormones, is not precipitated by
50$ saturated ammonium sulphate, the purification of
pituitary gonadotrophin was originally achieved by this
salting-out procedure. Later, the use of ion-exohange
celluloses were described (Steelman et al.. 1959); from
solutions of low ionic strength only LH is adsorbed on
to carboxymethyl cellulose (CM-C), while it is eluted
before FSH from columns of diethylaminoethyl cellulose
(HEAL-C). Other methods used include electrophoresis
on starch, polyacrylamide gels or ethanolized cellulose,
gel filtration and chromatography (Li et al.. I960; Butt
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et al., 1961? Butt et al.t 1963? Reichert and Parlow,
1963a? Roos and Gemiell, 1964). fractional precipita¬
tion with ammonium sulphate has heen employed for the
purification of ovine PSH and the product has been
further purified by chromatography on DEAE-C and other
ion exchange materials (Ellis, 1958? Woods and Simpson,
I960; Relchert and Parlow, 1963) and by gel filtration
on Sephsdex 0-100 (Courrier, 1964). It is difficult to
compare the biological potencies of the different
preparations obtained since a variety of standard
preparations and several bioassaya have been used.
According to Butt (1968), who converted the reported PSH
potencies into international units (i.u.), the prepara¬
tion of Woods and Simpson (I960) had the highest relative
potency per rag. pituitary tissue (830-1170 i.u.).
Although the potency of the preparation obtained by
Heiohert and Parlow (1963) was relatively low
(36 i.u./mg.), contamination of LH appeared to be at a
minimum (0.3 i.u./mg.).
Preparations of human PSH of high potency have been
obtained by Roos and Gemzell (1964^1 Parlow et al. (1965)
and Butt (1968). According to Butt (1968) the prepara¬
tion of Roos and Gerasell (1964) has a potency of 3,900
to 5,200 i.u./mg.; however, the IH contamination was
expressed as i.u. HOG ( 6.0 i.u./rag.) which cannot be
converted to i.u. IiH. The preparation of Barlow et al.
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(1965) had a relative potency of 1930-2440 i.u./mg. but
the investigators did not report the LH contamination,
the preparation of Butt (1968) contains 450 to 600 i.u.
FSH/rag. and 250-500 i.u. LH/mg. It is stable almost
indefinitely at room temperature if kept dry; in solu¬
tion at -15 C it retains its potency for at least a year.
The two components can be separated by gel electro¬
phoresis, and the FSH fraction has a potency of
120 i.u./mg. with less than 3.0 i.u. LH/mg.
(b) LH: Ovine pituitary LH preparations were obtained
over twenty years ago by fractionation with ammonium
sulphate; the preparations appeared to be homogeneous
according to the physical snd biological criteria of
purity then available (Li et al., 1940, 1942). later
methods have employed ion exchange resins and celluloses
as in the purification of FSH (Squire and Li, 1959;
Woods and Simpson, 1961; Ward et al.. 1961). Reichert
and Parlow (1963a) concentrated the LH by fractionation
with metaphosphoric acid and ethanol followed by gel
filtration using Seph&dex G-100. Butt (1968), who con¬
verted the reported potencies to i.u. per mg., found
that the most potent material (6,300 - 6,800 i.u./mg.)
was prepared by the method of Reichert and Parlow
(1963a). This material also had the lowest contamina¬
tion with FSH ( 0.3 i.u./mg.).
Methods used for the preparation of human LH are
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baaed on the extraction either with ammonium acetate plus
ethanol (Hartree et al., 1964) or with ammonium aulphate
(Reichert and Parlow, 1964), but in each, ion-exchange
celluloses are employed for subsequent purification.
Acoording to Butt (1968) the preparation of the former
investigators had a relative potency of 3,200 i.u./mg.
against 4,800 i.u./mg. of the latter workers; however,
Hartree's material was practically free from contamina¬
tion by FSH ( 0.14 i.u./mg.) or TSH (6 x 10"*' i.u./mg.).
Since FSH and LH have not been isolated completely
free from other pituitary hormones or impurities, it has
not so far been possible to determine their precise
chemical composition. They appear to be proteins con¬
taining carbohydrate (Butt, 1968). According to Morris
(1955) the molecular weight of ovine FSH is 67,000 and
its isoelectric point is 4.5, while that of porcine F3H
is 29,000 with an isoelectric point lying between 5.1
and 5.2 (Steelman and Segaloff, 1959)*
In contrast to FSH, LH appears to be more stable in
a highly purified form, and no losses have been reported
following freeze-drying. It has been reported that
purified LH fractions, even when contaminated with
proteinase activity, undergo no loss of potenoy on
storage after lyophilization (Reichert and Parlow,
1964a).
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Extraction of human pituitary gonadotrophins (HPS) from
urine
Many methods have been proposed for the extraction
of gonadotrophins from urine, to facilitate the assay of
the material present in the urine of patients under
investigation. These procedures fall into three main
groups.
(a) Ultrafiltration through collodion membranes
(Gorbman, 1945)t Following filtration the membrane,
together with the residue, was removed from the filter
and placed in an alcohol-ether solution. The alcohol-
ether dissolved the collodion membrane and the gonado¬
trophins were precipitated.
(b) Adsorption methods: These involve adsorption on
kaolin followed by acetone precipitation. f*wo main
variants of this technique have been proposed.
(i) The method of Albert (1955, 1956). The pH of
urine is adjusted to 4.5 prior to adsorption of
on to kaolin. Elution is performed by NH^OH,
the eluate is adjusted to pH 5.5 and the IPG is
precipitated with acetone.
(ii) The method of loraine and Brown (1959) in
which HPG is adsorbed on to kaolin at pH 4, eluted
by ?TaOH at pH 11.3 and the active material is
precipitated at pW 4 with acetone.
Crude kaolin extracts have been purified by Albert
17.
et al. (1961) using ammonium acetate and ethanol. This
procedure produces materials of higher specific activity;
it also reduces toxicity but generally results in a loss
of variable amounts of biological activity ranging from
10 to 40 per cent (Albert et al., 1961a; McArthur et
al., 1967).
(c) Precipitation methods: Techniques depending on
precipitation are preferred in some laboratories because
the extracts are of a relatively low toxicity. The re¬
agents include tannic acid (Johnsen, 1958), and zinc
acetate (Courrier, 1964).
The method of Johnsen (1958) has been widely used
by many investigators, and the extracts prepared are less
toxic to experimental animals than those obtained by the
majority of other extraction techniques (see Borth and
Menzi, 1964; McArthur et al.. 1967a). Borth and Menssi
(1964), who studied pooled urine obtained from normal
subjects, used as the end point of their bioassay the
mouse uterus test. The extraction methods compared
were (i) the alcohol precipitation-dialysis method of
Klinefelter et al. (1943)i (ii) the kaolin-acetone
method of Albert (1956) as modified by Borth et al.
(1961), (iii) the benzoic and tungstic acids method of
Butt (1958), (iv) the tannic acid method of Johnsen
(1958), and (v) the kaolin-acetone method of Loraine and
Brown (1959). Toxicity of the extracts was noted in
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varying degree with all extraction methods except those
prepared by the method of Johneen (1958). The accuracy
of this technique has been examined recently by Herbst
et al. (1967) who conducted recovery experiments
involving the addition of Pergonal (a standard prepara¬
tion obtained from human menopausal urine) to pools of
normal male urine. It was found that approximately 100
per cent of the LH activity, but only 50 per cent of the
PSH activity, was recovered. McArthur et al. (1967)
reported that they obtained a much more satisfactory
recovery with the tannic acid procedure than with kaolin
adsorption (Albert, 1955) especially in toxic urines.
Albert et al. (1965) and Albert and Rosemberg (1965)
reported that tannation of Pergonal appeared to increase
the LH potency 2.4-fold but did not affect the PSH
potency. This observation was not confirmed by McArthur
et al. (1967). In fact the latter group of investiga¬
tors found that their recovery of activity by the tannic
acid method showed a loss of activity slightly greater
for LH than for PSH.
Standard Preparations
'ituitary FSK an:' LH
Some of the earliest preparations of ovine pituitary
PSH and LH were produced by Armour Laboratories (Chicago)
and were termed PSH 264-151X and LH 227-80 respectively.
19.
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Later preparation available from the American National
Institute of Health have been designated NIR-FSH-S1-S8
and NIH-LH-S1-S8. At the time of writing international
standard preparations of human pituitary PSH and LH are
not available.
Urinary Gonadotrophins
In the past kaolin adsorption was employed for the
purification of urinary gonadotrophin of pituitary-
origin (Dekanski, 1949). The product was designated
HMG-24 (Human Menopausal Gonadotrophins-24) and it was
selected as the first International Reference Prepara¬
tion (IRP) (Bull. W.H.O. I960).
Another product designated Pergonal-23 was prepared
by Donini (Serono-Rome) from post-menopausal urine by a
method depending on kaolin adsorption followed by
chromatography. Rosemberg and Engcl (1961$) and Schmidt-
Slraendorff et al. (1962) have shown that Pergonal-23 has
a higher specific activity than HMG-24 and was probably
a more suitable choice for an International Reference
Preparation. The Expert Committee on Biological
Standardisation selected Pergonal-23 as the Second
International Reference Preparation for Human Menopausal
Gonadotrophin (2nd IRP-HMG). A potency of 40.0 inter¬
national units (i.u.) of PSH and LH activity was
assigned to each ampoule of this urinary preparation.
HCG preparations: The first international standard
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was established in 1938, when 0.1 mg. of a preparation
of HCO containing lactose was defined as the unit. The
second international standard has recently been intro¬
duced, is of medium potency and relatively impure.
Collaborative assays showed that each ampoule (approxi¬
mately 6.8 mg.) contained 5,300 i.u. (Butt, 1968).
:"MSG preparation; This preparation was introduced
in 1939 and the unit was defined as the activity of
0.25 mg. of the reference standard (Bull. F.H.O. 1939).
Methods claimed to be specific for the assay
of human pituitar;; gonadotrophins
A. Biological Methods
1. Bioassaya for FSH
a) Follicular growth in h2rpophysectomised immature
female rats (Evans et al.t 1939; Simpson, 1961): In
this method immature rate are hypophysectomised at 26-27
days of age. An interval of seven to eight days is
allowed for regression of follicles below antrum size and
for interstitial cells to become deficient. ^he
material for assay is then administered to the animals
daily for 3 days, and the animals killed 72 hours later.
Simpson (1961) reported that the method is specific,
reproducible, and, when compared with the "augmentation
test" (see below), gave parallel results. In view of
the observation of Lostroh (1965) (3ee p. 4.) that highly
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purified FSH was unable to induce follicular development
in hypophyaectomi3ed rats, the specificity of the method
must be questioned. Furthermore, it is unlikely that
this method would be suitable for FSH determinations In
extracts prepared from urine because the animals would
be unable to tolerate the large doses of urine which
would have to be admiaiotered. The method is tedious
and laborious? it is unsuitable for clinical applica¬
tion and is no longer used.
b) Augmentation teste in rats and mice: The
principle of this assay was first defined by Bates and
Schooly (1942). They concluded that when HCO with its
luteinising action is present in excess, any further
increase in ovarian weight over the plateau of response
attributable to LH must be due to FSH. Steeliaan and
Pohley (1953) described an ovarian augmentation assay
system for FSH in rats based on this early work* They
found that intact immature rats were more satisfactory
than hypophysectomised animals and that the aseay was
specific for FSH. Brown (1955) adapted the Steelman-
Pohley assay for use in mice, and Sehraidt-Elmendorff et
al. (1962) reported that this latter modification had a
satisfactory degree of precision ( generally below 0.2).
Subsequently, Brown and Wells (1966) concluded from the
assay of mixtures of purified human pituitary FSH and !H
assayed against FSH alone that there was no evidence
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that the assay system weed was not specific for FSH.
c) Tests depending upon the uterust
(i) Igarashi and McCann (1964) reported a technique for
the estimation of FSH, which was claimed to be specific.
The method is based on the synergism between FSH and a
small amount of HCO on the uterus of intact immature
mice. The test material mixed together with HCS is
Injected into intact immature female mice. The method
suffers from two disadvantages, firstly the precision is
low (/ « 0.34 1 0.04) and secondly that large amountB of
LH appear to interfere with the response. These dis¬
advantages were pointed out by the originators and were
confirmed by Ross and Brown (1967).
(ii) The method described by Lamond and Bindon (1966)
also makes use of the increase in uterine weight of
immature mice treated with PSH and HCH. In thia pro¬
cedure hynophysectomised rather than intact animals are
used. Ross and Brown (1967) investigated the specifi¬
city of this method and compared it with the augmentation
test in mice. The addition of LH in the laraond-Bindon
assay resulted in differences in slope between the
responses obtained following the administration of pure
?SH and for PSH and LH mixtures. If comparisons were
made between pure PSH and a mixture consisting of PSH +
1/3 LH there was a significant difference in slope
(?<0.05). However, probably due to the limited number
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of assays performed they were unable to show complete
lack of specificity.
2. Blonssaya for LH
a) The repair of interstitial tissue in hypo-
physectomlsed immature female rat test (Kvana et al.,
1939? Rimnson, 1961): '"'he aniraals and experimental
procedure used in the assay for LH are the same as those
used in the assay for ?8W (see page 20) except that
injections in thiB method are given Intraperitoneally
rather than subcutaneously. There is convincing
evidence that LH exerts a specific effect on the inter¬
stitial tissue of the ovary (see page 7) and for this
reason this assay seems to be highly specific. However,
the technique is no longer used because of its laborious
nature.
b) Bat Ovarian Hyneraemla teat (Ellis, 1961a, b)t
In this assay standard and test materials are injected
intravenously in immature rata together with radio-
iodinated serum albumin. The content of radio-iodinated
serum albumin In the ovaries is then used to assess the
extent of hypersemla. The technique is claimed by its
originator to be specific for LH. Parlow and Keichert
(1963) showed that the hyperaemis test is 0.4 times ae
senoitive as the ovarian ascorbic acid depletion assay,
and evidence was presented suggesting that sheep kRH
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augmented the response to sheep LH.
c) Tests depending on superovulatlon in rata and
aioe (Zarrow et al., 1958; Soliman, I960; Cunningham,
1962): Brown and Wells (1965) showed that the method of
Cunningham (1962) is not specific for LH, since PSH also
induces a response.
d) The ovarian cholesterol depletion test (Bell et
al., 1964): The technique follows a similar procedure
to that for the ovarian ascorbic acid test (see page 26),
but the depletion of oholesterol rather than ascorbic
acid is measured. According to Skosey and Ooldetein
(1966), the dose-response curve of the assay is multi¬
phasic rather than linear, and is independent of the
strain of animal used (Wistar and holtzman). It was
concluded that the teat is not suitable for use in
clinical atudies.
e) The ventral prostate weight test (VPW) in
immature hypophysectomised rats (Creep et al.. 1941):
This method has been widely used for the determination
of LH activity in both pituitary tissue and urinary
extracts (for references see Kosemberg et al., 1964;
Albert et al.t 1965; Loraine and Bell, 1966; Christian¬
sen, 1967} Be Groot, 1967a; Hutchinson et al., 1968).
The specificity of the method haa been questioned
by a number of investigators (Pasqualini, 1953; Segaloff
et al., 1956; Grayhack et a.t.. 1955) who have claimed
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that weight increase is a form of growth and that growth
can be caused by a number of factors other than LH,
including growth hormone itself. However, while bovine
growth hormone seemed to be active by itself in that it
caused a dose-dependent growth reaction of the ventral
prostate, van Rees et al. (1962) showed that after
destruction of LH without an effect being produced on
growth hormone, no prostatic growth was found. Paesi
et al. (1956) have demonstrated that non-specific growth
of the ventral prostate is almost negligible.
It has also been suggested (Chase et al., 1957;
Lostroh et al.t 1958) that prolactin might sensitise the
prostate to the action of LH. This observation was not
confirmed by Dicefaluey and Loraine (1958), MoArthur at
al. (1958) or van Rees et al. (1962).
Furthermore, Parlow (1963) and Parlow and Reichert
(1963a) stated that PSH, the one hormone tested and
considered free from interference by Creep et al. (1941)
and MoArthur et al. (1958), Induced non-specific
potentiation of the effect of LH in the VPW test. How¬
ever, Rosenberg et al. (1965) and Christiansen (1968)
convincingly demonstrated that such an interference did
not oocur.
f) Ovarian Ascorbic Acid Depletion test in immature
rata (OAAD) (Parlow, 1958): The end point of this assay
depends on the depletion of ascorbic acid by LH from the
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ovaries of intact immature rate treated with ?MSG and
HCG. Since the method was described it has been used
by many investigators to determine the LH activity of
both pituitary tissue and urinary extracts. A variety
of modifications have been used and have included varying
the strain of rat, the age of the experimental animals,
the schedules of pretreatraent, the route of administra¬
tion of standard and test material to be assayed, and
the use of one or both ovaries for the estimation of the
ascorbic acid (McCann and faleisnic, I960? Schmidt-
Blaendorff and Loraine, 1962; Sakiz and Guillemin, 1963;
et al., 1965; Bogdanove and Gay, 1967).
Instead of intact animals, the possibility of using
hypophyaectomised rate has been explored (McCann et al.,
I960; Baird et al., 1961). These workers showed that,
following hypophysecto»y, the concentration of ascorbic
acid in the luteinised ovary falla markedly and the
response to LH diminishes. However, the ovarian
ascorbic acid responsiveness could be maintained if the
hypophysectomised rats were supplied with an ectopic
pituitary graft (Baird et al., 1961). Similarly,
Guillemin and Sakiz (1963) found that treatment with
exogenous prolactin could substitute for the pituitary
graft.
The specificity of the method has been studied by a
number of investigators. In the opinion of McCann and
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Taleisnik (I960), Parlow (1961), Schraidt-Rlmendorff and
Loraine (1962), Sakiz and Guillerain (1963) and Rosenberg
et al. (1965) the method Is specific for LH activity.
However, Pelletier (1964) and De Groot (1967) claimed
that the OAAP test gave spurious results when the assay
animal was injected with plasma obtained from hypo-
physectomised rats. It would, however, be anticipated
that in the plasma of such animals LH releasing factor
(LH-RF) might be present; this has also been shown to
induce depletion of the ovarian ascorbic acid (Nallar
and McOann, 1965). It has been reported that there are
a number of substances, e.g. pitressin, vasopressin,
lysine and supernatant suspensions from homogenised
starch gel used in electrophoresis, which have signifi¬
cant activity in the OAAD test (McCann and Taleisnik,
I960; Gibson et al., 1965).
Our knowledge of the control of secretion of LH has
been based mainly on the VPW and 0AA1) assays, which are
the two most widely used tests. There are, however, a
number of facts related to these two methods that still
require to be explained. When the relative potencies
of different preparations of LH are compared by the OAAD
and VPW assays, using NIH-LH-S1 as standard, the ovine
and bovine preparations have similar potencies, whereas
the rat, equine and human preparations have apparently
higher specific activities in the VPW assay (Parlow,
28
1963a; Roaemberg et al., 1964; Be Groot, 1967;
Christiansen, 1967; Hutchinson et al., 1968).
An explanation for these findings remains difficult.
Since the test solutions are administered subcutaneously
in the VPW assay, whereas intravenous administration has
been the preferred route for the OAAD test, Parlow
(1963a) attributed the discrepancies to differences in
the biological half-life of LH from various species.
However, Reichert (1966) has shown that the discrepancies
are still apparent when the OAAI) method is compared with
the ovarian hyperaemia method, using intravenous admini¬
stration in both oases. Probably, therefore, factors
other than biological half-life must contribute to these
different estimates of potency. It should, however, be
emphasised that when urinary extracts are assayed by
these two methods in terms of a urinary standard (2nd
IRP-HMG) the index of discrimination (Gaddum, 1955) is
approximately unity and it is reasonable to conclude
that the active principle measured by the two tests is
identical (Rosenberg et al., 1964; Rosenberg, 1967).
B. Immunological Methods
1. Immunoassays of P3H
Immunoassays of PSR are at present undergoing
development. There are, however, two main problems to
be overcome. Firstly, highly purified preparations of
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human FSH are not readily available and, secondly, the
majority of anxisera raised to FSH cross react with 1H
and in many cases with thyroid stimulating hormone (TSH).
In the radioimmunoassay there arise difficulties in
preparing ^'^I-labelled FSH of sufficient purity to
compete with unlabelled antigen in the assay system
(Paiman and Ryan, 1967; Franchimont, 1968; Rosen «rt
al., 1968).
2. Immunoassays for IH
It is well established that antisera raised to HCG
will block the biological activity of LH in experimental
animals. Mougdal and Li (1961) showed that LH and HCG
have an antigenic pattern in common, an observation
which has been confirmed by other workers (Franchiraont,
1966; Paiman and Ryan, 1967). The antisera are
usually produced in rabbits by the administration of HCG
or LH.
Three types of immunological methods have been
employed for the determination of LH, i.e. the complement
fixation test, the baemagglutination-inhibition test and
radioimmunoassay.
a) Complement fixation teoti This technique was
first apolied by Brody and Carlstrom (I960). It depends
upon the ability of the antigen-antibody system to fix
complement as a linear function of antigen concentration.
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For the assay proper, antigen and antieera are incubated.
As an indicator of whether or not complement has been
fixed, sensitised sheep red blood cells are added, i.e.
red cells mixed with an appropriate amount of antibodies
(haemolysin) and the extent of haemolysis is measured
colorimetrically after a further period of incubation.
In the absence of complement no visible reaction is seen
between the erythrocytes and haenolysln. On the other
hand, when free complement is present, haemolysis will
occur. Brody (1967) pointed out that the specificity
of the method is based upon antibody homogeneity. How¬
ever, hormones presently available are not sufficiently
purified to enable specific antisera to be raised.
b) Haeroagglutination-inhibition test: The method
of Wide and Gemzell (I960) depends on the ability of a
standard or test preparation of HCG to inhibit the
agglutination reaction between "stable" HCG-coated sheep
red blood cells and HCG antiserum. "Stabilisation" of
the red blood cells is effected by treatment with
formaldehyde; they are subsequently treated by tannic
acid and finally sensitised by treatment with HCG.
However, the criticism with such methods arises when one
is dealing with an impure antigen. Hunter (1967) has
emphasised that in these techniques red blood cells will
be sensitised with contaminants as well as with the
hormone, and when the reaction is inhibited with
31.
biological fluids, a response will occur to the contami¬
nants which cannot be distinguished from that due to the
hormone.
c) Radioimmunoassays: Franchiraont (1968) reported
\
the development of a specific system for the measurement
of LH. In his technique HOG or LH preparations are
1^1
labelled with ^ I, and the denaturated fractions of the
labelled hormone are removed by filtration on Sephadex
0200. For the separation of labelled hormone from that
bound to antibody, starch gel electrophoresis is
employed. Urinary material assayed by this technique
must first be extracted to avoid non-specific inter¬
ference. As Franchimont (1968) has pointed out, the
method requires numerous precautions especially in
determining the specificity of the immunological system
employed.
The specificity of a radioimmunoassay is defined
primarily by the nature and homogeneity of the hormone
preparation used for labelling with radloiodine.
Although there are available highly purified LH prepara¬
tions, in an LH-anti-LH system, cross-reaction with FSH
still remains the main problem (Hunter, 1969). There
is evidence that a few carefully selected antisera to
HCG show cross reaction with LH but not with FSH, and
specific assays for LH may be established when these are
available (Franchimont, 1968). The radioimmunoassays
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are much more sensitive as compared with bioassays and
should make it possible to measure gonadotrophins in
snail amounts of human fluids. However, as pointed out
by Wide and Gemzell (1962), if HOG is heated to 100°C,
its biological activity is rapidly destroyed but its
immunological potency remains. Thus it is probable
that the antigenic groups are not the same as those
essential for biological activity.
33.
Aim of the Studies
The aim of these studies was to investigate the
urinary excretion of LH in the human subjects in normal
and pathological conditions.
As an essential prerequisite for thin work two bio-
assay systems, the OAAD and the YPW tests, claimed to be
specific for the measurement of LH, were examined. Many
difficulties were encountered in their performance
including lack of sensitivity, low precision and high
toxicity of routinely prepared urinary extracts.
Section A of this thesis describes methodological
studies carried out on the two assay systems together
with an examination of techniques used in the extraction
of gonadotrophlns from urine.
In Section B results obtained when the modified
assay procedures were applied to clinical problems are
described. The clinical conditions investigated
Included a study of the periraenopause and postroenopause,
and the effect of oral contraceptives and of Clomiphene
(Clomid; MRL-41), on pituitary gonadotrophic function.
In addition, studies have been made on urinary LH levels
in male subjects with a 47»XYY chromosomal karyotype and
in patients suffering from Turner's syndrome.
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CHAPTER 1
STUDIES ON THE VENTRAL PROSTATE WEIGHT (VPW) TEST
IN HYP0PHYSLCT0MI3KD IMMATURE RATS
It has been convincingly demonstrated that the VPW
method is specific for the estimation of LH activity and
that there is no interference by FSH (Creep et al., 1941?
McArthur et al., 1958? Roaemberg et al., 1965?
Christiansen, 1968), by prolactin (Dlcssfalusy and
Loraine, 1958? McArthur et al.. 1958? van Rees et al..
1962) or by growth hormone (Paeei et al., 1956? van
Hees et al., 1962).
A. Comparison of the VPW and OAAD teste in the assay of
LH in urine
Introduction
Since Creep and his colleagues described the YPW
test (Creep et al.. 1941), the technique has been used
extensively for the measurement of LH activity, in both
pituitary tissue and urinary extracts. Different
laboratories have introduced their own modification of
the original method, and these are listed in Table 1.
However, it has been reported that when measurements of
LH were carried out on pituitary tissue obtained from























































































VPW than with the OAAD test (see page 27). Thus when
an ovine oreparation (NIH-LH-S1) was used as a standard
of reference, it was found that rat, equine and human LH
preparations possessed higher specific activities in the
VPW assay than in the OAAD test (Parlow, 1963a; Rosem-
berg et al., 1964; Pe Groot, 1967a; Christiansen, 1967;
Hutchinson et al., 1968), However, Rosemberg et al.
(1964) and Rosemberg (1967) demonstrated that when
urinary extracts are assayed in terms of a urinary
standard using both methods of assay, the index of dis¬
crimination (Gaddum, 1955) was approximately unity. It
has been suggested (Gaddua, 1955) that an index of dis¬
crimination of unity gives some indication of the confi¬
dence to be placed on the results obtained by two assay
techniques both measuring the same active principle; a
result substantially greater or smaller than unity
implies that the activities estimated in the different
techniques might be due to different principles.
Since both techniques were to be employed to measure
the activity of urinary LH extracts in patients (see
Section B, page 113) it was important to confirm that
the index of discrimination approximated to unity.
Materials and Methods
(1) Bioassay Procedure
(a) VPW test: The assay procedure adopted was
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that described by Loraine and Brown (1954), except that
Sprague-Dawley instead of Wistar animals were used.
The rats. 21 days old and weighing between 35 and
45 g., were hypophysectomised using the parapharyngeal
approach. These animals were obtained from the Hormone
Assay Laboratories Inc., Chicago, and arrived in the
Unit the day after the operation. Throughout the assay
procedure, they were fed a mixture of wholemeal bread,
milk and glucose together with sliced oranges and were
provided with 0.9^ saline solution to drink.
The assay prooedure was started on the 4th or 5th
postoperative day, continued for 5 days and concluded on
the 9th or 10th postoperative day. The regimen con¬
sisted of administering the assay material, standard (S)
or unknown (U), subcutaneously daily for four days, in a
volume of 0.25 ml. of normal saline. The animals were
killed by ether on the 5th day, i.e. 9 or 10 days post¬
operatively, and the accessory sex organs were removed
and fixed in Bouin's fluid. The completeness of hypo-
physectomy of the assay animals was checked at this time
by examination of the sellae turcicae. After a minimum
period of 24 hours in fixative the ventral prostate was
dissected free from connective tissue, blotted and
weighed on a torsion balance to the nearest 0.5 rag.
A total of 152 animals were used in the experiment
and four animals were employed at each dose level of
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or MUM. All assay® were of 4 point design (Finney,
1952), and the log dose interval used was log-^Q 5
(0.69897).
QAAD test: The procedure adopted in this test
was that of Bell et al. (1965) and is described on page
64 . In this experiment a total of 220 animals were
employed and 5 animals were used at each dose level of S
or U.
(2) Material for Assay
Urine: A patient suffering from secondary
amenorrhoea,in whom LH excretion was expected to be high,
collected complete 24 hour urine samples throughout a
period of 35 days. The urine was pooled as 48 hour
specimens and the gonadotrophins extracted in the manner
described on page 92 • Each 48 hour extract was divided
into two equal parts and each part assayed by either the
OAAD or the VFW method.
(b) Standard of reference: In the present study
and in all the studies reported in this thesis, except
when otherwise stated, the standard preparation used was
Pergonal-23, designated as the 2nd IRP-HMG. Assay
results are expressed as international units (l.u.) of
the 2nd IRP-HMG per 24 hours.
Results
Forty-eight per cent and forty-two per cent of the
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animals used for the OAA]) and VP^ assays respectively,
died during the experiments. The majority of dead
animals came mainly from groups injected with the high
dose of the urinary extracts. It was also observed
that most of the animals employed in the VPW test
suffered from diarrhoea.
As a result of the high incidence of mortality the
majority of estimations were calculated as 3 point
assays. In only seven 0AA1) and three VPW assays was it
possible to test for parallelism. Five of the seven
QAAD, but none of the VPW, assays deviated significantly
from parallelism.
The working range for the VPW method lay between
3.0 and 15 i.u. while that of the OAAD assay extended
from 0.4 to 2.0 i.u.
The results of measuring urinary LM extracts by the
two bioassay techniques used are Illustrated in Figure 1.
The mean index of precision calculated from s/b (^ ) for
the YPW assays was 0.22 - 0.02 (± Standard Deviation
(S.D.)) while the corresponding value for the OAAD esti¬
mations was 0.35 ± 0.04.
The mean LH value obtained from the YPW estimations
was 160.7 t 18.9 (t S.E.) i.u. per 24 hours and the
corresponding figure for the OAAD assays was 150 1 53»P
i.u. per 24 hours. Fhen these two mean values were
compared using the Student's Mt" test they did not differ













Comparative study between OAAD and VPW test
I = fiducial limits (P = 0.95) of individual estimations
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significantly. However, when the results obtained by
both methods on individual samples are compared, signifi¬
cant discrepancies can be seen. This is represented by
the calculation of the index of discrimination snown in
Figure 2. The values calculated range from 0.03 to
12.4.
Discussion
The unacceptably high rate of mortality resulting
in the calculation of relative potencies on a 3 point
bases, the relatively low sensitivity and precision of
both methods used and the lack of correlation between
the VPW and OAAD techniques, suggested that neither
method was satisfactory under the conditions employed.
It was therefore decided that the individual steps in
both techniques should be re-examined.
Methodological studies performed on the YFW tecn-
nique will be presented in this chapter, while those
carried out in relation to the 0AA3) test will be
presented in Chapter 2.
B. Investigation of the dose-response relationship
Introduction
In the previous investigation it was observed that
the VPW method gave rather unsatisfactory results. The
majority of animals suffered from diarrhoea and a high
Figure 2
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proportion of the animals died during the assay pro¬
cedure. It was also found that the method did not
possess adequate sensitivity.
Before any attempt was made to modify the method it
was of interest to re-investigate the characteristics of
the dose-response relationship and to assess the sensi¬
tivity and the optimum working range of the procedure.
For this reason the following experiment was designed.
Material and experimental design
The assay procedure used was identical to that
described above (p. 35).
Forty-one hypophysectomised animals were allotted
to eight treatment groups. The total dose-levels of
Pergonal injected per animal were 0, 0.373, 0.75, 1.5,
3.0, 6.0, 12.0 and 24.0 i.u. Each animal received the
material over a period of four days, one injection being
given per day in a volume of 0.25 ml. saline.
Results
It was again observed that the majority of animals
were unhealthy during the assay procedure and suffered
from diarrhoea. Fifty per cent died during the test
with the greater mortality occurring on the last day of
treatment.
The results obtained are shown in Table 2 and
TABLE2























































Figure 3. The linear portion of the dose-response
curve oan be seen to lie between 1.5 and 12.0 i.u. and
the optimum working range from 3.0 to 12.0 i.u. The
mean index of precision ( ^) was 0.217.
The regression of prostate weight (y) on the log-^Q
dose (x) was calculated according to the method described
by Snedecor and Cochrane (1967)} the sample regression
coefficient (b) was calculated to be 0.81 mg./i.u.
Figure 4 illustrates the coefficient of variation
of the responses associated with each dose level of
Pergonal. As can be seen, in the absence of prostate
weight increase (vis. control, 0.375 and 0.75 i.u.) the
coefficient of variation was low and constant. However,
the corresponding values associated with increased con¬
centrations of I»H that induce growth of the ventral
prostate with the exception of the highest level (24 i.u.)
are much higher ranging from 16 to 25 per cent.
Discussion
One of the major points to emerge from this and the
previous experiment was the poor state of health of the
experimental animals. This is shown by the high propor¬
tion of animals suffering from diarrhoea and the
extremely high rate of mortality which reached its
maximum during the last day of treatment.
It was suspected that this colony of animals had a
THE EFFECT OF PERGONAL ON THE VENTRAL PROSTATE WEIGHT OF HYPOPHYSECTOMISED RATS
Figure 3
The vertical lines represent the standard errors of
individual means.
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relatively poor resistance to the experimental treatment
involving hypophyseotomy and their resistance was not
improved by feeding a high concentration of carbohydrate
in the post-operative diet. The percentage of dead
animals in this experiment was higher than in the
previous one, although the animals in the former experi¬
ment were treated with relatively crude urinary extracts.
The aetnod was again insensitive and unsuitable in
its nresent form for the assay of urinary extracts that
might prove toxic. The precision calculated in this
experiment was below optimal especially in circumstances
in which a purified material was being assayed•
In well planned bioassays the variation of the
response measured at each dose level must be independent
of the expected response (Finney, 1964? Snedecor and
Cochrane, 1967a). In the present experiment, as can be
seen, the coefficient of variation rose sharply with the
lowest effective dose of Pergonal and remained so within
the working range of the method.
The findings of both experiments described above
strongly suggested that the VP?/ method should be re¬
examined .
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C. Study on the temporal relationship between hypo-
pbvsectomy end the duration of the assay procedure
In the YP7? teat
Introduction
Sinoe the VPy test was first described, many modifi¬
cations have been introduced in an attempt to increase
both sensitivity and precision. The modifications
previously reported are inserted in Table 1. Some
workers used Sprague-Dawley animals while others pre¬
ferred Wistar rats. The age on the day of hypo-
physectomy ranged in different centres from 20 to 24
days. The weight range of the animals used was reported
by the originators of the method to be 12 g. This has
been restricted by some investigators to 5 g. The day
on which the assay was started after hypophysectomy also
varies from one centre to another (1 to 5 days) while the
duration of treatment has ranged from 4 to 7 days.
Finally, a few workers reported that they obtained
better results when the regimen of treatment consisted
of two injections daily. It should, however, be noted
that none of these investigators gave evidence to
support the modifications described.
Since, in the experiments reported herein, the
majority of animals suffered from diarrhoea and since it
was considered that this might be due to the high con¬
centration of carbohydrate in the post-operative diet,
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it was decided to examine a diet of a different consti¬
tution. Moreover, since the animals themselves
appeared to be unsuitable, it was decided to purchase
rats from a different source.
In the previous experiments it was observed that
the majority of animals died during the last day of
treatment, i.e. the 4th day. It was thought that, due
to rather long periods after hypophyeectomy (8 to 9
days), the animals became unduly insensitive and died.
The aim of the present study was to investigate the
optimal duration of treatment and the optimal time
interval from operation until the commencement of the
assay procedure. These studies were carried out in the
three separate experiments described below.
Materials and Methods
Hats (Sprague-Dawley) were obtained from the Charles
Eiver Breeding Laboratories, Boston, TT.S.A. The animals
weighed between 45 and 50 g. at 21 days of age, when
hypophysectomy was performed. They were received at
the laboratory within 50 hours of operation, and, except
for the loss of an occasional animal in a consignment of
75, they appeared extremely healthy. Postoperatively
all animals received the standard diet of rat cake used




Thirty-two animals were allotted at random into
eight groups. Again at random, four groups were
allotted to an assay to be performed over 3 days, while
the remainder were used in an assay carried out over 4
days. All groups received the same dose levels of
Pergonal, 0, 1.0 and 4.0 i.u. LH and in the same total
volume of 1.5 ml. per animal, administered suboutaneously
once daily during the 3 or 4 days of the assay.
Experiment II
Sixty-four animals were allotted at random amongst
16 treatment groups (4/group) ana the groups randomly
allotted to 4 intervals of time between hypophysectoay
and the start of the assay procedure. The time inter¬
vals selected were 2, 4* 6 and 8 days postoperatively.
In all instances the assay, using 3 dose levels of
Pergonal in each case, was carried out over a three-day
period. The log dose interval used was 3
(0.47712).
Experiment III
In this experiment thirty-two animala were randomly
allocated amongst 8 treatment groups, 4 of which were
allotted to an assay to be carried out over a period of
3 days, and four groups over a period of 6 days. Three
dose levels of Pergonal were selected, i.e. 0.4, 1.6 and
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6.4 i.u., and they were administered to the selected
groups of animals in both types of assay in a volume of
0.5 ml. per injection.
Results
In the first experiment the results obtained from
the two schedules of treatment, i.e. for 3 and 4 days,
are shown in Figure 5. No animals died during the assay
in any of the groups, and the optimum working range of
the dose-response curve obtained with a 4-day treatment
period ranged from 1.0 to 4.0 i.u. LH. When the
results of the assays performed over 3 and 4 days
respectively were analysed (see Table 3) it was found
that the dose-response curves were not parallel
(P <0.001) and that the effect of LH was significantly
lower (P<0.01) in the assay carried out over the 4-day
period.
In the second experiment none of the animals died
during the assay procedure completed on the 5th post¬
operative day. However, in the groups killed on the
7th, 9th and 11th postoperative days, the percentage of
dead animals in the respective assays was 25$, 33$ and
58$ (see Table 4). Figure 6 shows the results obtained
from each assay in which the ventral prostate weights
are plotted along the ordinate and the dose levels of
Pergonal along the abscissa. The regression equations
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12.8 14.1 t 1.2
Analysis of variance
Variations
Degree of ~ V.R.
freedom (Variance
(D.F.) 8<iuare8 89uare VHatio)
Between
preparations 1 15.65 15.65 13.99 < 0.01
Common
regression 1 206.74 206.74 184.87 < 0.001
Parallelism 1 14.06 14.06 12.57 < 0.01
Curvature 2 25.64 12.82 11.46 < 0.001
Between doses 5 262.09 52.42 46.87 <0.001
Error 15 16.77 1.12
Total 20 278.87 13.94
TABU:4
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THE EFFECT OF PERGONAL ADMINISTERED OVER A PERIOD OF
3 DAYS ON THE VENTRAL PROSTATE WEIGHT OF HYPOPHYSECTOMISED





y = 16-6 *2-9 x)
7 th P.O. DAY
(y = 9-5 * 0-7 x)
9 th P.O. DAY
-f"
(y = 9-0-0-3 x)
11th P.O. DAY
0-9 2-7 6 1
i.u. LH (Second IRP-HMG )
Figure 6
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(y » y + bx), calculated from the three dose levels of
LH, are 16.6 + 2.9x, 9.5 + 0.7xt 9.0 + 0.3x and 5.1 +
l.Ox for the assays performed on the 5th, 7th, 9th and
11th postoperative days respectively. As it is clearly
shown in Figure 6, the 4 regression lines are not
parallel. The most satisfactory assay was that
obtained from animals killed on the 5th postoperative
day (b = 2.9 rag./i.u., P <0.001) (Table 4).
In the third experiment the effect of the 3 dose
levels of Pergonal administered for either 3 or 6 days
on the ventral prostate weight is shown in Pigure 7.
The analysis of the results is shown in Table 5.
Although both dose-response curves are parallel, there
is a significant difference between the ventral prostate
weight of animals treated for 3 days when compared with
those treated for the 6-day period. This is shown by
the significant difference between preparations (P<0.05)
shown in the analysis of variance (Table 5). Also the
estimated potency (0.375 i.u.) calculated from the 6-day
schedule, instead of unity Indicated a loss of sensiti¬
vity of approximately 60?£ when this period was used.
Discussion
The results obtained with the experiments reported
above support the view that in hypophysectomised animals
the mortality rate increases proportionally after the







Control 0-4 1-6 6-4 Control' 0-4




THE EFFECT OF PERGONAL ADMINISTERED FOR 3 OR 6 DAYS













































preparations 1 148.656 148.656 8.5B <0.05
Common
regression 1 795. 018 795. 018 45..86 0.001
Parallelism 1 19. 680 19. 680 1..14 N.S.
Curvature 2 27. 363 13. 681 1,.27 N.S.
Between doses 5 990. 717 198. 143 11..43 < 0.001
Error 15 260. 021 17. 335
Total 20 1,250. 738 62. 537
.Preparation Relative Potency Fiducial 2/lmlt
6 days treatment 0.375 0.147 - 0.769
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7th nostoperatlve day. Also, the first and third
experiments clearly show that the activity of the ventral
prostate to increase in weight, after the administration
of LH, decreases progressively after hypophysectomy.
The findings of these experiments do not support the
suggestion of Paesi and de Jongh (1954), Christiansen
(1967) and Be ftroot (1967a) who claimed that 6 or 7 days
treatment gives better results. The results presented
herein demonstrated that a 3-day schedule gives better
results than a treatment period of 4 or 6 days; they
also showed that the optimal day on which to commence
treatment is the 2nd postoperative day. The latter
finding supports the suggestion of Paesi and de Jongh
(1954), Albert et al. (1961), Lostroh et al. (1963) and
Be Croot (1967a) that the best period to start treatment
is the 1st or 2nd day after hypophysectoay.
The general conclusion to be drawn from these
exoeriments was that the optimal time to begin an assay
is the 2nd postoperative day and that the duration of
hormone administration should be 3 days.
B. Completeness of hypophysectomy
It was pointed out earlier (see page 35) that the
completeness of hypophysectomy in all animals U3ed in
the VPW assay was checked, at the conclusion of the
assay, by insnection of the sella turcica. However,
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during the performance of the assays it was observed
that several animals had spuriously high prostatic
weights suggesting that hypophysectomy wbb not complete,
although no pituitary tissue could be observed in their
sellae turcicae. It was considered that some readily
available method for verifying the completeness of bypo-
physectomy should be established. Christiansen (1967)
and Hutchinson et al. (1968) reported that completeness
of hypophysectomy could be checked by extraction of body
weights, adrenal weight and the inspection of the sella
turcica* The following experiment was designed to
investigate the possibility of using these criteria in
the assay procedure.
Material and Experimental Design
Thirty-five animals were marked, weighed and allo¬
cated amongst 7 treatment groups (5/group) immediately
prior to the commencement of treatment. The animals in
each treatment group received a total dose of 0, 0.4,
0.8, 1.6, 5.2, 6.4 or 12.8 i.u. LH. The hormone was
administered subcutaneously once daily for 3 days. The
treatment started on the 2nd postoperative day and
lasted for 3 days. On the 5th postoperative day the
animals were weighed and killed under ether. The
sellae turcicae were examined histologically for remnants
of pituitary tissue. At autopsy the adrenals were
50
removed, dissected free from adhering tissue and weighed
on a torsion balance to the nearest 0,50 mg.
Results
On histological examination remnants of pituitary
tissue were observed in the sellae turcicae of three
animals and these animals were discarded. The mean
(£ S.E.) initial and final body weights of the remaining
32 animals were 47.3 t 2.8 g. and 51.1 t 2.8
respectively. Within a period of 4 days the average
increase in weight was 5 g. The mean adrenal weight
(both glands) was 7.5 t 0.2 mg.
Discussion
In order to recognise and eliminate animals that
have been incompletely hypophysectomised the value of
measuring the increase in body weight and adrenal weight
in addition to inspecting the sellae turcicae offers a
number of advantages. If an animal gained more than
5 g. from the 2nd postoperative day to the day of autopsy
it seemed probable that bypophysectomy was incomplete.
Moreover, rats having a combined adrenal weight
exceeding 7.5 mg. should be discarded even although
their sellae turcicae were found to be free from
pituitary tissue. This scheme of recognising and
eliminating animals that have been incompletely hypo-
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physectomieed has been followed routinely in the subse¬
quent performance of all the YPW assays.
The Charles River C.D. rats appeared much healthier
then and the change of postoperative diet reduced the
incidence of diarrhoea. The high mortality rate was
considerably reduced and only the occasional animal died.
The commencement of assay on the 2nd postoperative day
and the performance of the assay over a period of three
days resulted in an increase in sensitivity and precision
of the method. Finally, the establishment of a satis¬
factory system for the elimination of animals not com¬
pletely hypophysectomised enabled spuriously high values
to be discarded.
E. Further investigation of the dose-response
relationship
Modified method
In order to oonflrm the effectiveness of the modi¬
fications introduced into the YPW method and in order to
compare it with the original technique, the effect of
Pergonal on the ventral prostate weight was re-investi¬
gated .
Material and Methods
Twenty-eight animals of the Charles River C.D.
strain were hypophysectomised in Boston at an age of 21
52.
days. The body weight of the rats ranged from 45 to 50
g. They arrived in the laboratory the next evening,
and the assay procedure started the following morning.
The animals were marked and the body weights recorded.
The animals were allocated to 7 treatment groups and the
doses of Pergonal selected were 0, 0.4, 0.8, 1.6, 3.2,
6.4 and 12.8 i.u. (log^0 2/dose intervals 0.30103).
Treatment started immediately and lasted 3 days. One
injection was given daily in a volume of 0.5 ml. On
the fifth postoperative day the animals were again
weighed and sacrificed. The completeness of hypo-
physectomy was checked as previously described (p. 49).
The accessory sex organs were removed and fixed in
Bouinfs fluid. Twenty-four hours later the ventral
prostate was dissected out, dried by blotting and
weighed on a torsion balance to the nearest 0.5 mg.
Results
The results are shown in Table 6 and figure 8. The
linear range of the dose-response curve extended from
0.4 to 6.4 i.u. LH. The optimum working range of the
method appears to lie between 0.4 and 3.2 i.u. LH. In
figure 9 are shown the coefficients of variation from
which it can be seen that the corresponding values in
dose levels ranging from 0.4 to 3.2 i.u. LH are low and
constant ranging from 4^ to 9?*. Thereafter the co-
THE EFFECT OF PERGONAL OH THE VENTRAL PROSTATE
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efficient of variation rises and the corresponding value
is 21$.
The regression of VFW on log dose was also calcula¬
ted and the results are shown in Table 6. The sample
regression coefficient (b) is 3.42 mg./i.u. LH
(P <0.001). The index of precision was calculated to
be * 0.121.
Discussion
The results of the present experiment together with
those obtained earlier (see page 43) show that the modi¬
fication performed in the VPW aesay method has led to
improvements in both sensitivity and precision•
When the sample regression ooeffioient of the
original technique was compared with that estimated by
the modified method (see Table 6) there was a significant
increase in slope in the modified teohnique (P<0.01).
Moreover, sensitivity was increased eightfold and the
precision was doubled.
The variance of response associated with each dose
level was much more uniform and lower in the modified
technique (see Figures 4 and 9) and, while there was no
measurable heteroscedasticity in the responses obtained
by both techniques, the lower degree of variation
enoountered in the modified method is a significant
improvement.
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The establishment of a more satisfactory routine
for the elimination of animals suspected of being in¬
completely hypophyBectomised enables many of the
spuriously high responses to be eliminated without the
time-consuming procedure of carrying out a histological
examination of the sella turcica.
Control of toxicity
Sffect of cortisone acetate on the Increase in
weight of the ventral prostate following the
administration of Pergonal and urinary extracts
Introduction
Despite the improvements made to the VPW method the
problem of toxicity in relation to the assay of urinary
extracts still remained. It was not unusual to find
that many of the assay animals which died had been
treated with urinary extracts obtained from one
particular patient.
McArthur et al. (1964, 1967) reported that during
their assay procedure cortisone was administered to
experimental animals simultaneously with crude urinary
extracts. However, these workers did not provide
evidence to support this practice nor did they present
data to show that cortisone itself had no effect on the
weight of the ventral prostate.
Kypophysectomlsed animals are used in the assay
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system and accordingly it is reasonable to anticipate
that following this operation a progressive degeneration
of the adrenal cortex occurs. This would have the
effect of reducing the resistance of the animals to the
stress produced by the injection of materials. In
order to test this hypothesis the effect of administering
cortisone to the animals, alone or in combination with
urinary extracts, during the assay procedure was
examined.
Material and Method
In the first experiment thirty-six hypophysectomised
animals were randomly allocated amongst 9 treatment
groups. Three groups of animals were scheduled to
receive either 0, 0.4, or 1.6 i.u. LH only. A further
3 groups were to receive the identical dose levels of LH
but in addition each animal was treated with 0.1 mg.
cortisone acetate administered simultaneously with the
LH. The remaining 3 groups again received similar dose
levels of LH but the concentration of cortisone
administered simultaneously was increased to 1.0 mg.
In Experiment II 76 animals were allocated at random
amongst 19 groups each consisting of 4 animals. Three
groups were selected at random and received 0, 0.5 and
1.5 i.u. LH, while the remaining 16 groups were used to
assay 4 urinary extracts. The urinary extracts were
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prepared from 96-hour pools divided into two equal parts
and each part was administered to one of the 16 groups
of rats selected at random either with or without the
addition of cortisone (1.0 rag./day/rat) at two dose
levels. The low (L) dose levels employed were equi¬
valent to 74.9 ml* urine and the high dose (H) was equi¬
valent to 224.7 ml. urine.
In the third experiment the upper range of the dose-
response curve was extended by the inclusion of a dose-
level of 3.6 i.u.? two urinary extracts were in.lected.
They had previously been shown to be toxic in that when
equivalents of 30 and 90 ml. of urine were adminietered
over the normal period of 3 days, between 40/> and 60f> of
the animals receiving the low dose and all those
receiving the high dose had died. In the present
experiment this toxic urine was administered at dosages
equivalent to 68.7 (L) and 206.0 (H) mis. urine? these
were given with cortisone acetate 1.0 rag./day.
All animals treated with cortisone acetate were
given tap water instead of saline to drink.
Results
The effect of 3 levels of cortisone acetate, 0, 0.1
and 1.0 rag., on the dose-response curve obtained in the
VP"r test following the administration of 3 levels of LH,
0, 0.4 and 1.6 i.u. respectively, are illustrated in
THE EFFECT OF CORTISONE ON THE INCREASE IN VENTRAL PROSTATE WEIGHT OF HYPOPHYSECTOMISED
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Figure 10. The analysis of variance carried out on
this data (^able 7) showed that there was no signifleant
effect attributable to cortisone administration.
Figure 11 illustrates the results obtained in the
second experiment in which the effect of cortisone added
to urinary extracts was examined. When the results
were analysed statistically (see Table 8), it was found
that the first two dose-response curves with cortisone
(U^ and TJ^) were parallel to S, and that the preparations
did not differ significantly; the two slopes (U^ and Ug
without cortisone) were not parallel. In the case of
both slopes were parallel to that of S but the
response of the group of animals to which cortisone had
been administered was greater than the untreated group.
The difference between the two preparations of was
highly significant (?<0.001). The slope for with
cortisone showed a significant deviation from parallelism
whereas that without cortisone did not. In this experi¬
ment the urinary extract was not toxic and accordingly
none of the animals in the groups not receiving corti¬
sone acetate died.
The results of the third experiment are shown in
Figure 12. Statistical analysis of the data (Table 9)
indicated that the curves obtained for TT^, Ug and the
standard over the working range of the dose-response
curve did not deviate significantly from parallelism and
THE EFFECT OF CORTISONE ON THE VENTRAL PROSTATE WEIGHT ASSAY OF URINARY EXTRACTS
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THE EFFECT OF CORTISONE ON THE VENTRAL PROSTATE WEIGHT OF TOXIC URINARY EXTRACTS






































































































that a valid estimate of potency oould be obtained.
Discussion
These experiments demonstrated that cortisone
acetate does not exert any significant effect on the
ventral prostate weight test and that cortisone can be
administered simultaneously with urinary extracts to the
experimental animals. Moreover, cortisone administra¬
tion decreased the mortality rate of the animals when
urinary extracts were assayed. Three out of four
extracts given simultaneously with cortisone gave valid
results, whereas half of the assays in which urinary
extracts were administered alone were invalid due to
lack of parallelism between the dose-resoonse curves of
S and TJ. The results obtained with the third urinary
extract (Fig. 11 ) Indicate that the effect of urinary LH
is greater on the ventral prostate weight when cortisone
is administered simultaneously (?<0.001).
With respect to 1J^ it will be noted that the dose-
response curve of the extract along with which Cortisol
was not administered to the animals was parallel to S,
whereas the slone of the extract administered in associa¬
tion with oortisol was considerably steeper (P<0.001).
This finding might suggest that the relative potency
obtained with the extract without cortisone acetate
represents an under-estimate of the "true" activity.
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The difference between the elope of U^, with and without
cortisone acetate, oannot be accounted for readily.
Finally, the administration of cortisone acetate
appeared to be useful in the assay of LH when highly
toxic extracts were estimated. An equivalent of 30 ml.
of urine given to the animals without cortisone acetate
was sufficient to kill 50>®# whereas a concentration 9
times higher of the same urine sample when injected
along with 1 mg. cortisone per day was not associated
with any mortality among the animals.
G. Application of the modified YPW method to clinical
problems
IJBing the modified method, 22 assays were performed
for the determination of urinary LH. In the course of
these assays 1672 animals were used and 176 urinary
extracts were tested.
Figure 13 shows a frequency polygon of the distri¬
bution of lambda values obtained in the 22 YPW assays.
The figures lie between 0.05 and 0.2 and appear to be
normally distributed. It will be noted that two of the
three measures of central tendency, i.e. the mean and
median, coincide although the mode does not differ
greatly.
Figure 14 shows the frequency polygon of values
calculated for the common slope obtained in the 22 assays*
FREQUENCY POLYGON OF LAMBDA
VALUES OBTAINED USING THE MODIFIED
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Again the values appear to be normally distributed and
the three measures of central tendency differ very
little from one another.
Discussion
Since Greep and his colleagues (1941) described the
VFW assay, the method has been used in many laboratories
(see Table 1 for references) for the estimation of LH in
biological fluids.
In different centres the assay procedure starts on
different postoperative days (Table 1), and, according
to McCann (1962), the method is insensitive when the
original procedure is used. During the present study it
was found that the second postoperative day was optimal
for the commencement of the assay. Unfortunately it
was impossible to start the assay on the first post¬
operative day because the animals only arrived from the
U.S.A. 30 hours after the operation. Assays commencing
on the second postoperative day were of sufficient
sensitivity for use in clinical situations.
Paesl and de Jongh (1954), Christiansen (1967) and
De Groot (1967a) reported that by extending treatment
period to six or seven days the assay became more sensi¬
tive. This hypothesis was investigated in the course
of the present study and it was found that a 3 day
treatment period gave better results than a 6 day regime.
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It wab found that the administration of cortisone
acetate along with toxic urinary extracts resulted in an
increase in the tolerance of the experimental animals
and thus enabled valid results to he obtained.
Be Groot (1967) reported that, when the body weight
range of the experimental animals was restricted to 5
this improved the reliability criteria of the assay.
This suggestion was adopted during the present study.
The modifications which have been described herein
have resulted in an improvement in the precision of the
test together with an eightfold increase in sensitivity.
The mortality of the experimental animals injected
either with saline or with standard preparations was
markedly reduced, while the use of cortisone acetate has
virtually eliminated mortality arising from toxicity.
Summary
Some of the problems associated with the VFW assay
for LH have been discussed.
Modifications in the original method have been
described which increase precision and sensitivity. In
particular, the administration of cortisone acetate
along with urinary extracts has virtually eliminated the
mortality rate of the experimental animals.
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CHAT"PER 2
STUDIES ON THB OVARIAN ASCORBIC ACID
DELETION TEST IN HATS
INTRODUCTION
Ascorbic acid is widely distributed in the animal
organism, the adrenal cortex, pituitary and corpus
luteum having the highest concentration (Ravavenstein,
194-3-45)* The early observation of Sayers et al. (1944)
that the amount of ascorbic acid in the adrenals
decreases in response to ACTH stimulation raised the
problem of the physiological importance of ascorbic acid
in endocrine tissues. Later, a similar observation was
made with respeot to the action of LK on the ovary
(Claesson et al., 1949» Hokfelt, 1950). However, at
the time of writing the function of ascorbic acid in
ovarian physiology is poorly understood and a number of
conflicting observations have been reported. Kahnt et
al. (1952) and Staudinger et al. (1955) presented
evidence of a stimulatory effect of ascorbic acid on
steroidogenesis. On the other hand, Hayano et al.
(1956) showed that ascorbic acid inhibited the conversion
of cholesterol to progesterone in vitro.
The existing relationship between LH and ovarian
ascorbic acid concentration has served as a method of LH
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assay (Parlow, 1958). This test was an advance in the
bioassay of LH because it avoids the use of hypo-
physeotomised animals. It gives satisfactory results
with highly purified preparations derived from pituitary
tissue, but when applied to the bioaeaay of LH in urine
a number of difficulties are encountered. In urinary
assays different investigators have reported relatively
poor precision, toxicity of routinely prepared extracts
(Parlow, 1961; Schmidt-^lmendorff and Loraine, 1962;
Hutchinson and Worden, 1964)» and lack of a reproducible
dose-response relationship (Zarrow, 1961).
Nevertheless several investigators have used the
OAAI) test for the bioassay of LH in urinary extracts.
Thus Rosemberg and Keller (1965) and Stevens and his
colleagues (for reference see Steven© and Vorys, 1967)
found that the method was satisfactory for the determina¬
tion of urinary LH levels in normally menstruating women.
The latter group of investigators, together with Roy et
al. (1963) and Bell et al. (1967), reported the results
obtained when the OAAI) test was applied to the measure¬
ment of urinary LH in patients treated with drugs
affecting fertility.
The aim of the present study was to apply the QAAI)
test to the measurement of urinary LH activity in
several olinical situations. These included secondary
amenorrhoea treated with Clomiphene, the postmenopauae,
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and the effects of therapy by oral contraceptives on
pituitary gonadotrophic function.
MATERIALS AND METHODS
The assay procedure employed was that described by
Schmidt-Elmendorff and Loraine (1962) and Bell et al.
(1965).
Pretreataent of animals; Intact immature Wistar
rats from the Clinical Endocrinology Research Unit
(C.E.R.U.) oolony were used. They varied in age from
21 to 23 days and in weight from 35 to 50 g. Each
animal received a subcutaneous injection of 50 i.u. PMSG
(Gestyi - Organon) and 72 hours later a subcutaneous
injection of 25 i.u. HCG (Pregnyl - Organon). Both
preparations were dissolved in saline and the injections
were administered in a total volume of 0.5 ml./animal.
As a result of this pretreatment the animals showed
heavily luteinised ovaries, ranging in weight from 70 to
140 rag. The animals were housed in groups of three
according to the specifications of Chance (1956), the
advantages of this design having recently been confirmed
by Brown et al. (1968).
Bioaasay proper: This was performed between the
5th and 9th day after the injection of HOG. Animals
were allocated at random in groups of five.
The standard (S) (Pergonal) and unknown (U)
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materials were administered intraperitoneally in 0.5 ml.
of normal saline. The assays were of four-point design.
One group of animals was also used as control and was
injected intraperitoneally with saline (0.5 ml. per
animal). The log dose interval was log^0 5 (0.69897)
and the high dose of (U) usually represented the equi¬
valent of 125 ml. of urinary extract per animal. The
animals were killed 4 hours t 10 minutes after the
intraperitoneal injections by dislocation of the cervical
spine, and the two ovaries were removed using a dorsal
approach. The individual ovaries were rapidly cleaned
and weighed on a torsion balanoe to the nearest 0.5 rag.
Each ovary was then homogenised in a mortar and pestle
with 2.5 ml. of 2.5$ metaphosphoric acid (freshly pre¬
pared) and a trace of sand. After thorough grinding, a
further 7.5 ml. of 2.5$ metaphosphoric acid was added
and the nomogenate was filtered through Whatman No. 2
filter paper. The ascorbic acid content of the filtrate
was then estimated according to the method described by
Mindlin and Butler (1938) as follows: 2.0 ml. of the
clear metaphosphoric acid extract was mixed with 2 ml.
of standardised 2,6-dichlorophenolindophenol solution
and read immediately in a spectrophotometer (SP-600).
The 2,6-dichlorphenolindophenol solution was prepared in
the following way: 12.0 mg. of the dye were dissolved
in 40.0 ml. of distilled water which was then mixed with
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280.0 ml. of sodium acetate solution (18.16 g. of sodium ,
acetate in 400 ml. of distilled water - pH of the solu¬
tion adjusted to pH 7.0 using glacial acetic acid and
N/10 sodium hydroxide solution). The dye solution was
freBhly prepared on the day on which it was to be used
and the concentration of the dye was adjusted by
dilution with the sodium acetate solution.
The amount of reduced ascorbic acid was determined
from the calibration curve prepared with known amounts
of pure ascorbic acid solution in 2.5$ metaphosphoric
acid. The regression of X (ascorbic acid) on Y
(optical density) was calculated according to the method
described by Snedecor and Cochrane (1967) and the
regression equation (y) was 450.25 - 2.2 x (Table 10,
Figure 15).
The ascorbic acid concentration of each ovary was
expressed as jug. per 100 rag. ovarian tissue and the mean
value of both ovaries from the same animal was used as
one observation, according to the suggestion of Borth
(personal communication). The mean concentration of
ascorbic acid in the group treated with the low doee of
S was compared with that found in the control group by
using the Student's Mtw test. If there was no signifi¬
cant depletion of ascorbic acid in the former group the
assay was regarded as invalid.
A total of 58 experiments was carried out, during
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which 2,610 animals were used and the LH content of 174
urine extracts were assayed.
BKSU1TS
During these experiments 1,740 animals were injected
with urinary extracts} a total of 644 animals (37$)
died during the assays. The majority of these came
from groups injected with the high dose of the urinary
extracts. One hundred and twenty-seven samples were
assayed; 47 of these (27$) were rejected due to their
toxic effect on the experimental animals. Fifty-two of
the assays (41$) had to be rejected because of signifi¬
cant deviation from parallelism between S and U. Valid
results were obtained from only 75 samples (43$ of the
total number).
The precision of the method was poor. The mean
value calculated for % was 0.44 ± 0.15 (± S.D.). The
frequency polygon of the distribution of these values is
shown in Figure 16 from which it will be noted that
values range from 0.13 to 0.78; these were not normally
distributed, the three measures of central tendency
differing from each other.
DISCUSSION
During these studies the results obtained were un¬
satisfactory. Only 43$ of the total number of urinary
FREQUENCY POLYGON OF LAMBDA VALUES OBTAINED




samples tested resulted in valid four-point aasayB.
Lack of parallelism was more prevalent in these experi¬
ments than in previously published reports by Schmidt-
Elmendorff and Loraine (1962) and Hutchinson and Worden
(1964). According to these two groups of workers the
percentage of invalid assays due to significant devia¬
tion from parallelism between the dose response curves
of S and TJ was approximately 20$. However, in the
experience of Herbst et al. (1967) the percentage of
invalid results for the same reason rose to 58$. The
precision of the method during the present series of
studies was less satisfactory than that obtained by
Schmidt-Elmendorff and Loraine (1962), Hutchinson and
Worden (1964) and Ferbst et al. (1967); the figures for
% reported by these investigators were generally below
0.3# Moreover Herbat et al. (1967) found that the
problem of toxicity was less severe when the tannic acid
method was used for the extraction of urinary gonado-
trophins. In their limited experience the percentage
of dead animals was 4.5 per cent. However, a high
incidence of mortality appeared in the present study.
Thirty-seven per cent of the animals injected with
urinary extracts died during the assays. In addition
the results obtained in animals which survived treatment
after injection of the urinary extracts were unreliable.
Accordingly, 27$ of the assays were rejected.
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The experiments reported herein confirm the previous
observation (page 34} that the OAAD test does not give
satisfactory results when urinary gonadotrophins are
assayed. It was therefore essential to re-examine the
assay procedure in an attempt to improve the reliability
criteria and reduce the unacceptably high rate of
mortality of the experimental animals.




Facing these obvious difficulties it was considered
that the animals bred in the C.E.H.TJ. were unduly sensi¬
tive to the toxic effect of the urinary extracts and for
this reason the results obtained were generally unsatis¬
factory. Accordingly, an attempt was made to investi¬
gate whether animals from other sources of the same or
of different strains could be used. It was, however,
important to ascertain that the sensitivity of such
animals compared favourably with the C.E.R.U. colony.
Several investigators reported differences in the
reaction between strains of animals used for the OAAD
test (Koed and Hamburger, 1965* 1968), and others have
suggested that the optimal time for performance of the
assay is from the bth to the 7th day after the HC6
injection (Hutchinson and Worden, 1964; Bogdanove and
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Gay, 1967). The latter suggestion has been adopted and
the OAAD testa have been carried out on the 6th or 7th
day after the administration of HCG.
Materials and Methods
Five assays were conducted in which animals
obtained from two separate commercial sources were com¬
pared with the C.E.H.U. rats. Three assays were
conducted using Sprague-Dawley animals and one with
Wistar rats, both obtained from commercial sources.
Fifty animals were used for each assay using
Sprague-Dawley animals, while 30 and 25 rats respectively
were employed in the caBe of Wistar animals obtained
from a commercial source and from the C.E.R.U.
The assay method was the same as that described
above (see page 64) # ^he only difference being that the
bioassay proper was carried out on the 6th or 7th day
after HCG administration.
In the three assays in which Sprague-Dawley animals
were used, the standard preparation Injected was
NIH-LH-S6. In the first, the doses selected ranged
from 0.012 to 3.0 jug. and the dose interval was 2
(0.30103) while in the second and third they ranged from
0.032 to 48.83 jcig. with a dose interval of log1Q 2.5
(0.39794).
Both groups of Wistar animals were treated with
71.
Pergonal. The doses selected for the aniiaals obtained
froia the commercial source ranged from 0.1 to 62.5 i.u.
and the log done interval was log^Q 5 (0.69B97) whereas
the doses for the C.E.H.U. rats ranged from 0.3 to 2.4
i.u.} the dose interval being log-^Q 2 (0.30103).
Results
The results obtained are shown in Figures 17t IB
and 19 and in Table 11.
An analysis of variance of the results obtained for
the first Sprague-D&wley group showed that dose levels
of LH |ip to 1.5 jag. t including controls, did not produce
any significant change in the ascorbic aoid concentra¬
tion. When, in the analysis of the results, the upper
range of the dose-response curve was extended to include
the dose level of 3.0 jug. LH, a slight depletion was
shown to have occurred (P<0.05). When the concentra¬
tions of ascorbic acid at each dose level were compared
with the control value, using Student's MtM test, no
significant difference could be shown. Similar results
were obtained when the data of the second and third
Sprague-Dawley groups were analysed. Again dose levels
of LH up to 1.25 jug. and 0.5 jug. for the second and
third groups respectively did not produce any significant
effect on the ovarian ascorbic acid concentration. The
ascorbic acid depletion was initiated at a dose level of
THE DEPLETION OF ASCORBIC ACID FROM PRETREATED SPRAGUE-DAWLEY RAT OVARIES
FOLLOWING THE ADMINISTRATION OF NIH-LH-S6
Figure 17
THE DEPLETION OF ASCORBIC ACID FROM PRETREATED WISTAR RAT OVARIES
FOLLOWING THE ADMINISTRATION OF PERGONAL
Figure 18
THE DEPLETION OF ASCORBIC ACID FROM PRETREATEO C.E.R.U. RAT OVARIES
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Sum Sqs. Mean Sq. V.R. V
1st Group
0 -• 3.0 UK. NIH-LH-S6
Between doses 9 3,386.91 376.52 2.567 < 0.05
Error 59 5,717.20 146.59
Total 48 9,104.11
0 -• 1.50 UK. NIH-LH-S6
Between dosea 8 1,044.70 130.59 0.873 N.S .
Error 55 5,236.24 149.61
Total 45 6,280.94
2nd Group
0 - 48.83 UK. NIH-LH-S6
Between doses 9 27,910.41 3,101.16 6.908 < 0.001
Error 36 16,160.73 448.91
Total 45 44,071.14
0 - 1.25 UK. NIH-LH-S6
Between doses 5 664.03 132.81 0.211 U.S.
Error 23 14,475.32 629.36
Total 28 15,139.55
3rd Group
0 - 48.83 UK. NIH-LH-S6
Between doses 9 35,893.06 3,988.12 30.2 < 0.001
Error 38 5,010.97 131.87
Total 47 40,904.03
0 - 0.5 UK. BIH-LH-S6
Between dOS68 4 1,588.82 397.21 2.09 N.S.
Error 20 3,791.80 189.59
Total 24 5,380.62
TAB IT-: 11 (eontd.)
Analysis of Yarlance (contd.)
WISTAR
Variations D.P. Sun Sqs, Mean Sq, V.R.
Commercial
0 - 62.5 iiUi (2nd IRP-HMQ)
Between doses 5 6,008.4 1,201.7 2.654 <0.05
Error 23 10,411.6 452.7
Total 28 16,420.0
0 - 12,5 1»u» (2nd IRP-HMO)
Between doses 4 2,279.8 569.9 0.545 N.S.
Error 19 19,848.6 1,044.7
Total 23 22,128.4
C.E.K.U.
'J - 2.4 l.u. (2nd IRi'-HMG)
Between doses 4 8,430.08 2,107.52 14.29 < 0.001
Error 20 2,950.30 147.51
Total 24 11,380.38
0 - 0«b i.u, (2nd IKP-HMG)
Between doses 2 1,624.28 812.14 7.42 < 0.001
Error 12 1,312.80 109.40
Total 14 2,937.08
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3.125 and 1.23 Jig» LK in the second and third group
respectively and became pronounced by Inclusion of dose
levels up to 48.83 Jig* LH £?< 0.001). As before, the
results obtained for individual dose levels of hormone
were compared with their respective controls using the
MtM test.
In the second group, no significant effect could be
demonstrated. However, in the last group LH dose levels
of 19.53 and 48.83 jig, had a significant effect
(P<0.02).
Analysis of the results obtained following the
administration of Pergonal to Wistar rats from a
commercial source indicated that dose levels of LH up to
12.5 i.u. did not produce any significant alteration in
ascorbic acid concentration. When a dose level of 62.5
i.u. LH was included in the analysis a alight effect was
noted (P<0.05). Individual comparisons with the
control value, using Student's MtM test, showed no
significant difference.
The results obtained in C.1S.K.U. animals showed that
the ascorbic acid concentrations, following the admini¬
stration of a range of dose levels of Pergonal from 0.3
to 2.4 i.u., including the control differed significantly
(P <,0.001). This effect was also noted for dose levels
of LH up to 0.6 i.u. (P< 0.001). Using Student's "t"
test, as before, it was Bhown that even the lowest dose
73.
level of LH (0.3 i.u.) caused a significant depletion of
ovarian ascorbic acid (P<0.01).
Discussion
The results obtained in these experiments, in
relation to the Sprague-Dawley animals, show that the
minimal dose of LH required to produce ovarian asoorbete
depletion was 3.0, 3.125 or 1.25 jfug. LH in the first,
second and third groups respectively.
In Wistar animals, from a commercial source, the
slight depletion of ascorbic acid occurred only at a
dose level of 62.5 i.u. LH (P<0.05).
The data obtained from the last experiment showed
that the animals of the C.E.R.U. colony were piore sensi¬
tive and the variation in response at each dose level
was less than that observed for the other groups.
lioseaberg and Lewis (1966), using the OAAD assay,
reported that 1,000 jug. of NIH-LH-S1 was equivalent to
500 i.u. LH (2nd JRP-HMG). Using this conversion
figure, assuming NIH-LH-S1 and $6 to be equipotent, the
relative sensitivities of the different assays were
compared in terms of the 2nd IHJP-HMG. In the Sprague-
Dawley animals the minimal effective doses were equi¬
valent to either 0.66, 1.5 or 1.55 i.u. LH, while in the
C.JS.R.U. colony a significant depletion occurred at a
dose level of 0.3 i.u. The Wistar animals from a
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commercial source were less sensitive than those in the
other groups, a dose level of 62.5 i.u. 1H being
required to produce a response.
The present study showed that the rats of choice
for the OAAD assay were those of the C.E.K.T7. colony.
With these animals the method was reasonably sensitive
arid the optimal working range of the dose-response curve
(Figure 19) lay between 0.3 and 1.2 i.u. Except where
otherwise stated, this log^ 4 dose interval (0.60206)
has been adopted for ail the OAAD assays, instead of
that originally used (log-^ 5, 0.69897).
C""7i-?n:. OP TOXICITY
Introduction
The previous experiments demonstrated the
suitability of the animals from the C.E.R.U. colony in
the OAAD test. Ifevertheless when the technique was
applied to the measurement of LH in urinary extracts the
results obtained, as mentioned previously, were dis¬
appointing. It was considered that the experimental
animals might give more satisfactory results if they
were protected from the stress effect induced by the
toxic urinary extracts.
An attempt was made to control toxicity of urinary
extracts in a similar manner to that which has been
satisfactorily employed in the YPW test (see page 54).
75.
Thus it appeared of interest to investigate whether
cortisone acetate could be usea and whether a shorter
tine interval between the administration of S or TJ and
measurement of ascorbic acid concentration might be
beneficial•
The aim of the following four experiments was
therefore to investigate whether cortisone acetate
exerted any significant effect on the OAAD test and if a
three-hour interval was sufficient for the induction of
a significant depiction of ovarian ascorbic acid by LH
(Pergonal).
Materials and Methods
The assay procedure followed that desoribed on page
64, the only difference being that the body weight of the
animals was restricted from 35 to 45 g., the 10 g. weight
range being selected as a result of the findings of
Hutchinson and Worden (1964).
In the following four experiments, the division of
animals into groups and the allocation of treatments to
these groups was carried out on a random basis.
Experiment It Forty-five rats were divided into
nine treatment groups. Three groups of animals received
either 0, 0.4 or 1.6 i.u. LH alone. A further three
groups were treated with the identical dose levels of
LH, but, in addition, each animal was treated with 10 jug.
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cortisone acetate administered simultaneously with the
LH. The remaining three groups again received similar
dose levels o.f LH, hut the concentration of cortisone
administered was increased to 100
Experiment IIr Five groups of five rats were used.
One group was treated with saline and served as control.
The other four were divided into two main groups, one to
be killed 3 hours and the other 4 hours after the admini¬
stration of LH. The doees selected were 0.4 and 1.0
i.u. per animal for the low and high doses respectively.
Experiment Tllr Eighty-two animals were divided
into 9 groups. Groups of rats were killed either 3 or
4 hours after infection of 0.3123, 0.625, 1.25 or 2.5
i.u. LH. The remaining group acted as control.
Experiment IVt Ninety-five animals were allotted
to 11 groups. One group served as control, 5 groups
were treated with 0.4 i.u. and 5 groups with 2.0 i.u. LH.
One group of animals was killed at varying time intervals
following the injection of either dose level of hormone
and the ascorbic acid concentration determined. The
intervals selected were 2 hours 40 mine., 3 hours, 3
hours 20 rains., 3 hours 40 rains, and 4 hours.
Results
The results of the first experiment are shown in
Table 12 and Figure 20. An analysis of variance











































































































































carried out on these data showed that there was a highxy
significant effect attributable to cortisone administra¬
tion (P<0.01), and that it was linearly related to the
dose level injected (P<0.01). Furthermore, the inter¬
action between LH (linear) ana cortisone acetate (linear)
was hxghxy significant (P<0.001), demonstrating that as
the effect of LH on ascoroate depletion increases with
dose, the effect of higher doses of cortisone acetate
becomes sore pronounced and progressively more
inhibitory.
The results obtained in the second experiment are
shown in Figure 21. The dose-response curves obtained
at the two time intervals are clearly not parallel. The
sample regression coefficients (b) were calculated (see
Table 13)i at 3 hours b * -62.23 and was highly signifi¬
cant (P< 0.001), whereas at 4 hours b * -17.42 and was
not significant.
Figure 22 and Table 14 show the results obtained
from the third experiment. In the analysis of variance
it was found that the effect of LH on ovarian ascorbic
acid did not differ significantly at either time inter¬
val. The dose-response curves were both parallel and
linear.
The results of the fourth experiment are shown in
Figure 23. The 2 hour 40 ains. interval was sufficient
to induce significant depletion and at 3 hours the effect
THE DEPLETION OF ASCORBIC ACID FROM PRETREATED RAT OVARIES 3 OR 4




Con tro I 04 TO Controf
i.u. LH (Second IRP-HMG )
Figure 21
table 13
THE DEPLETION OF ASCORBIC ACID FROM PKETRKATKD RAT
OVARIES> 3 OR 4 HOURS AFTER THE ADMINISTRATION OP
PERSONA u
3 Hours 4 Hours
0.4 l.u. LH 1.0 l.u. LH 0 .4 l.u# LH 1.0 i.u. LH
124.22 87.77 94.52 106.04
117.44 75.62 108.14 90.32
124.91 91.19 126.52 120.34
116.40 80.98 111.88 108.98
122.64 83.37 128.94 91.84
121.12 11.50 83.79 1 2.99 113.96 16.61 103.50 + 5.76
Regression
3 Hours 4 Hours
b -62.23 -17.42
y * y + b(x - x) 141.66 - 62.23x 120.92 - 17.42x
sb +5.36 +14.06
t » b/8b 11.61 1.239
I).*. 8 8
P <0.001 M.S.
THE DEPLETION OF ASCORBIC ACIO FROM PRETREATED RAT OVARIES 3 OR A HOURS AFTER THE




J //_] 1 1 1 l //_i 1 L
Control 0-3125 0-625 1-25 2-5 Control 0-3125 0-625 1-25 2-5
i.u. LH (Second IRP-HMG)
Figure 22
tabu:14





































































































































































COMPARISON OF DIFFERENT TIME INTERVALS BETWEEN THE ADMINISTRATION OF PERGONAL












































































































































































































3.0*hour 3*20*hoar 3.40*hour 4.0*hour
interval interval interval interval
1.29 0.36 0.34 0.40
0.57- 0.13- 0.12- 0.15-
3.11 0.82 0.77 0.87
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was maximal. Thereafter, at 3 hours 20 mins., the con¬
centration of ovarian ascorbic acid increased and
remained constant after this time. The analysis of
variance (see Table 15) also showed that the effect of
LH on ovarian ascorbic acid varied in relation to the
time at which animals were killed (V <0.05). If the
results obtained at 2 hours 40 rains, were used ne a
reference preparation then the responses obtained at 3»
3.20, 3.40 and 4 hours showed that the highest activity
wae obtained at 3 hours. The estimated potency of 1.29
i.u. is some 80^ higher when compared with the other
three (Table 15).
Discussion
The results obtained in the first experiment show
that cortisone acetate undoubtedly affects ascorbic acid
depletion. Therefore it was not possible to consider
the use of cortisone as a method of reducing the toxic
effect of urinary extracts upon the experimental animals,
in the same manner as described earlier for the VW
assay.
The lack of significant regression of the dose-
response curve in the second experiment from the group
killed four hours after the administration of the
hormone, was probably due to the phenomenon oocaeionally
seen with the OAAP assay in whicn the animals do not
79.
react and there is no depletion of the ovarian ascorbic
acid when small doses of LH are given*
The results obtained from the third and fourth
experiments are in agreement with those of Hutchinson and
Word en (1964) who also demonstrated that a 3-hour inter¬
val between hormone administration and measurement of
asoorbate depletion produced a more acceptable dose-
response relationship.
The results obtained in the fourth experiment
indicated that the time course of ascorbic acid depletion
is such that it became maximal 3 hours after the admini¬
stration of both dose levels of LH. Aecorbate depletion
was less marked after 3 hours 20 mine, and this might
suggest that ascorbic acid may be repeated at these
later time intervals. The optimal time interval
between hormone administration and ascorbic acid measure¬
ment is 3 hours, and at this time the difference in
response to the two dose levels of hormone is also
maximal. In particular when urinary extracts are to be
assayed, the 3-hour interval is the procedure of choice,
since the experimental animals are exposed to the effect
of toxicity for a shorter period of time.
APPLICATION 0"? TIP MODIFIKD 0AA1) METHOD TO ESTIMATE
TT.wmKV LH L"T L r? TQYXC URINARY EXTRACTS
As a result of the experiments carried out in the
80.
assay procedure, it was decided to incorporate the
following modification:
1. The dose interval was reduced to log^ 4
(0.60206). In addition, the finding of Hutchinson and
Worden (1964) regarding the initial body weight range
was adopted.
2. The time interval between administration of the
hormone and estimation of ovarian ascorbic acid was
reduced to 3 hours.
The modified OAAB assay was then applied to the
estimation of LH in urinary extracts.
Three pilot experiments were performed in which
urinary extracts of proven toxicity were assayed by the
modified technique in an attempt to assess the
suitability of the method for the routine estimation of
urinary LH.
Materials and Methods
Thirty-five animals were used in each of three
assays. In each experiment rats were randomly allocated
to 7 groups, one of which served as control. The assays
were of four-point design. Six urinary extracts,
previously tested and proved to be toxic, were used.
Results
Of the 60 animals treated with urinary extracts 10
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died during the assay procedure (17$)• out of six
estimations had to he rejected because of significant
deviation fro® parallelism between the S and U prepara¬
tions. The index of precision (Jk) of the method was
0.24 t 0.09 (t S.D.).
when the results are compared with those obtained
using the original method, it is clear that some improve¬
ments have been made by reducing the interval from 4 to
3 hours. The mortality rate was reduced from 37 to 17
per cent and the index of precision was reduced from
0.44 t 0.15 to 0.24 - 0.09 but despite these improvements
approximately 1/3 of the assays had to be rejected due
to lack of parallelism between WS" and MUtt preparations.
These results demonstrated that the extraction pro¬
cedure should perhaps be re-examined and this is dis¬
cussed in Chapter 3.
AMAT;YoIf 0^ R>:SITT,7? OBTAIN!!) ?-frJiT TH>: OAAD T.V8T
IN .IT At:CAY '"R'XTPIJKB
With the improvements made to the OAAT) method and
to the techniques of extraction from urine (see Chapter
3), 38 assays were performed during which 228 samples
were tested; 2,650 Wistar C.K.R.TJ. rate were used.
Results
During these assays the mortality rate following
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the administration of urinary extracts was significantly
reduced. Five assays (13$) were invalid due to lack of
response of the animals treated with the standard
preparation. In 34 out of 198 samples significant
deviation from parallelism occurred between the dose-
response curves of S and U.
The mean index of precision (± S.D.) was 0.206 ±
0.101. Figure 24 shows the frequency polygon of the
distribution of values obtained in the 33 valid assays,
and the figures appear to be normally distributed. Two
of the three measures of central tendency, i.e. mean and
median, coincided, while the mode differed only very
slightly.
The frequency polygon of values for the common
slope (b) obtained in 33 assays is shown in Figure 25.
Again the values appear to be normally distributed and
the three measures of central tendency differed very
little from one another.
Discussion
The results obtained when improvements were made to
the OAAD assay and the extraction procedure indicated
that the method became more satisfactory and was suitable
for the estimation of LH in urinary extracts. Seventy-
two per cent of the assays performed were valid.
FREQUENCY POLYGON OF LAMBDA
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C0atTAI -THATIQIi" 0? BXTKACTS ' ITTT CORTICOSTEROIDS
"h/t p i:t t.t trine
Introduction
The observation that cortisone acetate exex'ts a non¬
specific effect on the QAAD assay made it necessary to
ascertain whether the urinary extracts prepared by the
tannic acid procedure (see page 92) were contaminated
with corticosteroids. In order to investigate this
hypothesis the following experiment was designed.
Material and Method
The OAAD method used was identical to that described
above. Two thousand ml. fresh postmenopausal urine was
split into two equal parts. To one of them were added
prednisolone tertiary butylacetate (100 rag.), hydro¬
cortisone (100 rag.) and cortisone acetate (100 rag.);
subsequently both pools were extracted by the tannic
acid procedure.
Results
The results obtained are shown in Figure 26 and in
Table 16. The analysis of variance (Table 16) demon¬
strated that corticosteroids added prior to the
extraction procedure did not exert any effect on the
OAAD assay. The two preparations did not differ signi¬
ficantly; the slopes of the dose-response curve were
THE EFFECT OF CORTICOSTEROIDS ADDED TO URINE PRIOR TO
EXTRACTION ON THE DEPLETION OF ASCORBIC ACID FROM






















Ovarian ascorbicacid concentration (;ug./100Eg. ovariantissue)
116.4 107.4 105.4 104.9 102.5
90.5 82.3 84.5 83.5 76.5
111.3 108.4 106.4 102.9 95.5
89.0 79.1 89.1 89.0 82.7
110.0 103.6 104.5 98.6 103.8


























































parallel and the index of discrimination was 1.06.
Discussion
These results showed that when urine is extracted
by the tannic acid procedure, the corticosteroids are
not precipitated with the gonadotrophic hormones.
Although the levels of corticosteroids excreted in urine,
even in pathological conditions such as Cushing's
syndrome, are seldom higher than 10 mg./24 hours (Cost,
1963a, b), the amounts added to urine in this study were
30 times greater. The results obtained demonstrated
that the urinary extracts were free from corticosteroid
contamination and it could therefore be concluded that
when the 0AA3) assay ia performed under these conditions
a specific estimation of urinary LH can be obtained.
o.-ASCrAL YAi.JATI^?T:' IN j^C'BPTC ACID CQVT"??T OF ??<:••-
d rj\- pYAhu-u ?ei,T,<riyg p^gcw Ai?rT^Tr»K/Trey
Stevens et al. (1964) reported the occurrence of a
diurnal variation in the ascorbic acid content of
ovaries pretreated with PMSG- and HCG, and emphasised the
importance of performing the assay at the same time of
the day. In their experience, the best time of day to
administer S and V was 7 a.m.
H5
Material and Method
In order to investigate whether the initial concen¬
tration of ascorbic acid in pretreated rat ovaries is
critical, the slopes obtained from standards used in 55
assays performed over a period of 12 sonthe were plotted.
The results are shown in Figure 27.
Results and Discussion
The initial level of ascorbic acid in the ovaries
of pretreated rats is probably not critical in order to
obtain a satisfactory slope for the assay. Tor example,
in the assay at the end of January, although the level
of aeeorbic acid in the control group was low (70 yug.
ascorbic acid/100 tig. tissued, the depletion was marked
and the slope was satisfactory (-23.3). On the other
hand, in the next assay, although the level of ascorbic
acid In the control group was similar, the depletion was
small and the slope was flat (-12). In April and l!ay
four assays were performed. In all of these the levels
of ascorbic acid in the control groups were high (137,
136, 146 and 130 jug. of ascorbic acid/100 mg. of tissue
respectively). The depletion of ascorbic acid in the
first 3 assays, following a dose level of 0.4 i.u. of
Pergonal, was much larger than that occurring between
0.4 and 2.0 i.u. Since the total depletion of ascorbic





between 0.4 and 2.0 i.u. was very small and the slope of
the dose-response curve was flat. In the fourth assay,
although the initial level of ascorbic acid was slightly
lower, the depletion produced with the same quantities
of Pergonal gave a much steeper slope. Similar changes
were noted at other times during the year.
In the two assays performed at the beginning of July,
the initial levels of ascorbic acid in the pre-treated
ovaries were similar. However, 0.4 i.u. of Pergonal
produced the same effect on the depletion of ascorbic
acid in the first assay as was produced by five times
that amount in the second. Thus the first assay was in¬
valid because the slope was flat (-9) while the second
assay was successful because the slope was very steep (-40).
During this period, 17.5$ of the assays were
invalid due to a lack of response following administra¬
tion of the standard preparation.
DISCUSSION
The OAAD method remains one of the two bioassay
procedures of choice for the estimation of X»H in body
fluids. Several investigators have reported that there
are important strain differences causing variation in
the precision and sensitivity of the assay and, according
to Parlow (1961) and Koch and Hamburger (1968), rats of
the Moltsman strain give the most satisfactory results.
The present study demonstrated that Wistar animals
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derived from the C.S.H.H. colony are reasonably sensitive
to LH administration and also result in the production
of assays of relatively high precision.
Hutchinson and Worden (1964), who also used rats of
the Wistar strain, found that the maximum depletion of
ascorbic acid occurred within three hours after the
administration of LM either intravenously or intra-
peritoneally. These results are in agreement with
those found in the present investigation. When the
time interval between the injections and sacrifice of
the animals was reduced from 4 to 3 hours, the mortality
of experimental animals, due to toxicity of crude
material injected, was reduced from 37 to 13 per cent.
In addition, an improvement in the performance of
the assay was noted as a result of the modifications
which have been incorporated. These include:
1. The body weight of the rats was restricted to
between 35-45 g.
2. The log dose interval adopted was log,g 4
(0.60206) instead of log10 5 (0.69897).
3. The assay procedure was performed on the 6th or
7th day after HCG treatment.
?'hen the modified assay method was applied to
clinical problems (Section B) along with the improvements
made in the extraction procedure, the mean index of
precision of the method was 0.206 and only 17^ of the
8 .
assays were rejected due to significant deviation from
parallelism between the S and U dose-response curves.
The lack of reaction in 1554 of the groups treated
with standard preparation cannot be explained.
The suggestion of Stevens et al. (1964) that the
initial concentration of ascorbic acid is critical has
not been shown during the present study. The initial
level of ascorbic acid in the rat ovary does not appear
to exert any significant effect on the results.
Throughout the whole study, when urinary extracts
were tested, the 2nd IliP-HMG was used as standard
reference preparation, merely because it was thought
essential that the standard reference preparation and
the tested material Bhould be of the same origin.
Eecently, Koch and Hamburger (1967), who compared the
dose-response curves for LH of ovine (NIH-LH-S8) and
human (2nd IKP-HMG) origin, found that the two slopes
differed significantly (P<0.01) because the latter
curve was flatter.
The observed non-specific effect of cortisone
acetate on the GAAD test does not invalidate the results
when urinary extracts are used, since it has been shown
in this study that the product extracted by the tannic
acid method is not contaminated with corticosteroids.
This finding is also supported by the fact that cortico¬
steroids are excreted in the urine either free or
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conjugated with glucuronic or sulphuric acids (Butt,
1968a). Since they are not conjugated with proteins it
ia unlikely to be precipitated with tannic acid and they
should therefore appear in the filtrate during the
extraction procedure.
SUMMARY
1. Modifications to the OAAI) method for the estima¬
tion of LH in urinary extracts have been described.
These include:
(a) Reduction of the time interval between the
injection of S and U and the sacrifice of
animals from 4 to 3 hours.
(b) Restriction of body weight to a range between
35 and 45 g.
(c) Reduction of the log dose interval used in the
assay from log5 (0.69897) to log^ 4
(0.60206).
2. Using these modifications the precision of the
OAAD method was improved and the mortality rate following
the administration of urinary extracts was reduced.
3* Cortisone acetate affected the response of the
experimental animals but when large amounts of cortico¬
steroids were added to urine and extracted, no effeot on
1H levels were found.
4. The initial level of ascorbic acid in the rat
ovary did not influence the results of the assay.
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Two methods for the extraction of urinary gonado-
trophins depending upon precipitation by tannic acid
(Johnaen, 1958) and adsorption to kaolin acetate (Albert,
1955, 1956, 1961) have been widely used in the estima¬
tion of gonadotrophic activity.
Borth and Meazi (1964) reported that Johnsen's
method yields extracts less toxic than those produced by
the kaolin-acetone method and it is to be recommended
when urinary gonadotrophins estimations are being
performed (see General Introduction, page 17). This
observation is in agreement with that reported by Wells
(1965). The latter investigator compared the effective¬
ness of several extraction methods, by means of the
mouse ovulation test (Canningham, 1962). The methods
selected for comparison were the benzoic acid of Katzman
and Boisy (1934), the benzoic and tungstic acids of Butt
(1968), the kaolin acetone methods of Brown (1959),
Loraine and Brown (1959) and Borth et al. (1961) and the
tannic acid method of Johnsea (1959). It was concluded
that the tannic acid method gave extracts with the least
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insoluble material and with a significantly higher yield
on three out of six occasions.
When the tannic acid procedure was employed for the
extraction of urinary gonadotrophins, in earlier studies
reported herein (page 79). the percentage of dead
animals, among those injected with urinary extracts, was
still high and modifications to the OAAI) technique
itself did little to improve this mortality {Y5i>).
In his original paper Johnsen (1958) pointed out
that as the method extracts all proteins it is possible
that the concentration of bacterial protein might result
in urine preparations that were toxic. Since urine
represents a very good medium for bacterial growth, it
was of interest to investigate the possibility that such
© contamination could occur when urine was collected
routinely, and to examine the effect of bacterial growth




Twenty-four hour urinary samples were collected
from a normal menopausal woman who had no symptoms of
urinary tract infection. When the specimen arrived in
the laboratory an aliquot of 20 ml. was obtained for
bacteriological study and the remainder of the sample
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was extracted by the tannic acid method.
(ii) Extraction procedure (Johnson, 1958)
(a) Acidification of urine; The pH of each 24-hour
urine sample is adjusted to 4 - 0.3 by the addition of
glacial acetic acid.
(b) Precipitation; Pollowing acidification, sodium
chloride (10 t 2 g./litre) and hyflo-supercel (10-12 g.)
are added to the urine and stirred. A solution of 10^
tannic acid (20 i 2 ml.) is then added and stirred con¬
tinuously for 3 minutes. Dissolved gases produced as a
result of acidification of the urine is removed by-
applying a reduced pressure to the flask. This prevents
subsequent breakdown of the filter oake.
(c) Formation of filter cake; Hyflo-eupercel
(2 - 0.5 &.) is suspended in 100 ml. water and poured
into a Buchner funnel lined with filter paper. The
precipitated urine is then added slowly to the Buchner
funnel in such a way that any disturbance to the 'filter
cake' of superoel is avoided.
When empty the urine flask is rinsed with 225 - 25
ml. 0.1?S tannic acid to whioh is added 2 £ 0.5 g. of
hyflo-supercel and the contents added to the Buchner
funnel. During filtration through hyflo-supercel 'cake',
suction is applied to the Buchner flask and is continued
through the next stage of the extraction.
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(d) Differentiation: 225 £ 25 ml. of alcohol (96/0
is added to the funnel before the filter cake becomes
dry. This is followed by the addition of 225 £ 25 ml.
of 10/ ammonium acetate (pH 11) in 80/ alcohol.
(e) Elution: The Buchner funnel containing the
filter cake of hyflo-supercel is next transferred to a
clean receiving vessel and 10/ ammonium acetate (pH 11)
in 40/ alcohol is added to the funnel and mixed with the
cake. Suction is then applied to the receiving vessel
and 30-40 ml. of solution is collected. The fluid is
then allowed to drain slowly through the 'cake* for
approximately 20 minutes and the remainder of the
filtrate is then collected under reduced pressure.
(f) Neutralization and repricipitation: The eluate
is transferred to a 750 ml. flaak, and is cooled for
3-4 minutes in ice-water. Then, during vigorous
shaking, 10 £ 0.5 ml. glacial acetic acid is added.
Subsequently the volume is made up to 600 £ 50 ml. by
the addition of absolute alcohol mixing carefully by
rotating the flask. The flask is stored in a
refrigerator overnight.
(g) Collection of precipitate: The precipitate is
collected by cenxrifugation at 2,000 r.p.m. for 10
minutes. The supernatant is discarded and the precipi¬
tate resuspended in 15-20 ml. absolute alcohol before re-
centrifugation. Tne alcohol supernatant i3 discarded,
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and the precipitate washed with 15-20 ml. of ether.
After centrifugation the extract is dried in a vacuura
desiccator and is then stored in a refrigerator at 4°C
until assayed.
(iii) Bloaasay
The hioassay procedure was the OAAD as described
earlier (Chapter 2).
Thirty animals were randomly allocated to 6 treat¬
ment groups. One group was treated with saline
(control) while the remaining groups were injected either
with the (8) or (TJ) preparations. The doses selected
for the standard were 0.3 and 1.2 i.u. LH, while the
three dose levels of the urinary extracts administered
were equivalent to 8.75, 35.0 or 140 rals, of urine in
each group respectively.
h. JVuTJ
The results of the bacteriological study are shown
in Table 17. The urine was heavily contaminated with
gram negative bacilli, and to a lesser extent with gram
positive bacilli, while the contamination with gram
positive cocci was the least. Following culture, a
heavy growth developed consisting mainly of Escherichia
coli and enteroccocci.
The results of the assay are shown in Table 18.
tabu; 17
BACTERIOLOGICAL STDDY OF URINE








































































The percentage of dead animals in the groups treated
with urinary extracts was 27$. The assay was invalid
because of the slope reversal in the dose-response curve
of the unknown preparation. A concentration of 8.75
equivalent millilltres of urine Induced a highly signifi¬
cant depletion, similar to that obtained in the group of
animals receiving 1.2 i.u. LH. When these two mean
values were compared using Student's MtM test no signifi¬
cant difference could be demonstrated (t * 0.393, D.P. 55
8, ? « N.S.). No depletion of ovarian ascorbic acid
was noted in animals treated with 35.0 or 140.0 equi¬
valent millilitres of urine, the readings being similar
to thoBe obtained in the control group.
DISCUSSION
This experiment indicated that when urinary samples
are collected routinely, the possibility of bacterial
contamination is great. As the bacteriological study
demonstrated (see Table 17), the contamination of the
urine was such that the tannic acid extraction procedure
could not reduce the toxicity of the urine to an
acceptable level.
When a very small concentration of urinary extract
was injected, no deaths occurred and a significant
depletion of ovarian ascorbic acid was noted. However,
with higher concentrations of urinary extracts (35 and
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140 equivalent millilitres of urine) no depletion of
ascorbic acid occurred. This could be due to the effect
of toxic Material on the experimental animal or to
unknown inhibitory factors.
It was concluded that the conditions of collection
of urinary samples should be re-examined.
COLLECTION OF UKINAKY SAMPLES LXTH A BACTERIOSTATIC
AGKNT
Introduction
Since the urine was so heavily contaminated, it was
decided to add a bacteriostatic agent to the container,
prior to collection, to inhibit bacterial growth.
The agent selected was a solution of ehlorhexidine
gluconate (Hibitane concentrate 5$, I.C.I. Pharmaceuti¬
cals). This is normally a liquid raiscible with water
and alcohol. Several investigators have shown that
ehlorhexidine is one of the most effective antiseptics
(Caiman and Murray, 1956; Lawrence, I960) and it is
usually employed as a preservative for eye-drope and for
the pre-operative disinfection of the skin.
Although it is unlixely That chlorhexidine is
extracted by the tannic acid procedure it was necessary
to investigate whether it had any effect on the 0AAI)
assay.
The aim of the following experiments was to
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determines
1. The concentration of hibitane which was required
to inhibit bacterial growth.
2. The effect of hibitane on the OAAD teat, and
3. Its effect on the gonadotrophin extraction and
bioassay of urine.
In view of the fact that, in clinical etudiea,
gonadotrophins and steroids are routinely assayed in the
same sample, it was also necessary to determine whether
the addition of hibitane to urine would affect the
steroid analysis.
Materials and Methods
Experiment Is In 7 clean containers, of one litre
capacity each, were added either 1, 2, 4, 8, 16, 32 or
64 mis. of hibitane concentrate 5$,and urinary samples
were collected from the same subject used for the
previous experiment. When a collection of 1,000 ml.
was completed, the container was kept at a temperature
of 4°C. Whan all collections were completed a specimen
of 20 ml. of urine from each container was removed for
bacteriological study.
Bxperiment lit Forty-five pretreated rats for the
OAAD test were randomly allocated amongst 9 treatment
groups. Three groups of animals received either 0, 0.6
or 3.0 i.u. LH alone. A further three groups were
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treated with identical dose levels of LH but In addition
each animal was treated with 0.2$ hibitnne administered
simultaneously with the DH. The remaining three groups
again received similar dose levels of Id? but the concen¬
tration of hibitane administered simultaneously was
increased to 2.0$.
•Phe assay procedure in this and in the following
experiment was the OAAD test as it has been described in
Chapter 2, page 79-
•Pxperlment Tilt A 24-hour urinary sample was
collected from a normal healthy menopausal woman.
During the collection special precautions were taken to
avoid, as far as possible, contamination of the urine
with bacterial (i.e. the subject washed the external
genitalia with soap and water prior to urination and
during the 24-hour period of collection the urine was
kept in the refrigerator at 4°c). Phen the sample
arrived in the laboratory the urine was split into two
equal volumes (800 ml. each) and to one of them was
added 16 ml. hibltsne concentrate 5$. Subsequently
both volumes were extracted as described earlier.
^orty pretreated animals for the OAAD test were
allocated at random amongst 8 groups. Pour groups
received 0, 0.4, 1.6 and 6.4 i.u. LH, while the remaining
four groups were used to assay the two urinary extracts,
^he low (D) dose levels employed were equivalent to 40ml.
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and the high doses (H) were equivalent to 160 ml. of
urine.
Experiment IV: A pool of 3,000 ml. of freshly
collected urine was obtained from several healthy young
female technicians and was divided into two equal parts.
One hundred and fifty ml. of hibitane concentrate
5$ or an equal volume of distilled water was added to
each. Subsequently, both specimens were divided into
six equal parts (273 ml.) and these were individually
assayed for oestrogens and pregnanediol.
Heaulte
In the first experiment the bacteriological studies
performed on the Beven urinary samples to which different
concentrations of hibitane had been added showed that no
contamination occurred with 0.4^ hibitane or above
(Table 19). Only scanty debris appeared on the film
and no growth occurred on culture.
The effect of three dose levels of hibitane on the
dose-response curve for LH is shown in Figure 28. Mo
consistent effect of hibitane was noted at any of the
levels of LH used. The analysis of variance carried
out on this date (Table 20) showed that there was no
significant effect attributable to hibitane administra¬
tion.
The results of the third experiment are shown in
table 19
BACTERIOLOGICAL STUDY 0? TTHINE
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THE EFFECT OF HIBITANE ADDED TO URINE PRIOR TO EXTRACTION ON THE














































































SumofSquaresMeanSqu reVari nceR tio
P
Betweenpreoarations2 Commonregression1 Parallelism2 Curvature1 Betweendos s6 Error28 Total34
625.53 5,062.22 54.62 283.36 6,025.73 478.28 6,504.01
312.76 5,062.22 27.31 283.36 1,004.29 17.08 191.29
18.31 296.36 1.60 16.59 58.79
c0.001















Figure 29 and fable 21. The doae-resoonse curves
obtained from the urinary extracts, in one of which 2$
of hibitane concentrate 5$ was added, were both parallel
to the standard curve. The estimated potencies of the
two unknowns were 33.6 and 41.2 i.u. W and the index of
discrimination was 1.23.
The results of the last experiment, in which esti¬
mations of ©estrone, ©estradiol, oestriol and pregnane-
diol were performed, are shown in Table 22. The mean
figures obtained for individual steroids were compared
between groups using Student's "t" test. Mo significant
effect attributable to hibitane administration was
observed.
Discussion
When hibitane concentrate 5^ was added at a concen¬
tration of 0.4$ or above, the growth of micro-organisms
in urinary samples was inhibited.
It is unlikely that the tannic acid procedure will
extract hibitane from urine, sinoe it is soluble In
water and alcohol and will presumably be removed during
the initial filtration step. On the other hand, if the
urinary extracts did contain hibitane then no effect of
this material on LH-induced ascorbate depletion could be
demonstrated.
The results of the third experiment support the
TABLE22










3.7 4.4 4.3 3.9 3.7 4.7
1.5 1.8 1.9 1.7 1.7 0
8.5 8.9 6.9 8.5 9.3 9.6
0.36 0.50 0.80 1.06 0.54 1.10
5.2 4.8 5.2 4.0 4.0 5.0
2.7 1.8 2.5 2.0 2.5 2.6
8.6 9.4 7.9 8.5 8.2 10.0





Oeatrone Oestradiol Oestriol Pregnanediol
4.12i0 23 1.43i0 8.62t0 4 0.73t17
4.70t0 27 2.35±0 21 8.77t0 48 0.61t07
1.160 1.437 0.134 0.500
10 10 10 10
N.S. U.S. 3.S. U.S.
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finding that the addition of hibitane to urine as a
preservative has no effect on^urinary LH levels, both ^
dose-response curves obtained from the "U" preparations
with and without hibitane being identical.
No effect on steroids analyses could be demonstrated
when higher concentrations of hibitane in urine were
employed.
These experiments show that it is possible to avoid
contamination of urinary samples with bacteria by the
addition of hibitane to the container prior to collection.
Hibitane, at the concentrations used, had no effect on
the OAAD test or on urinary gonadotrophins. The esti¬
mations of urinary oestrogene and pregnanediol were
similarly unaffected.
THf. KFPKOT OF DIALYSIS OP VRIKT ?KI0R TO KXTKACTION
ON URINARY LH
Introduction
Since Graham (1861) described the technique of
dialysis as a procedure for the purification of colloidal
dispersions, the method nas been widely uaed for the
separation of substances in true solution from those
forming colloidal mixtures. The method utilise® the
fact that the majority of substances in true solution
can pass through a membrane while colloidal particles
are retained. These particles diffuse very slowly, due
102.
to their relatively large dimensions, whereas the email
molecules and ions in true solution diffuse much more
rapidly (Gladstone and T>©wis, 1964)•
The following experiments were designed to investi¬
gate whether dialysis of urinary paroles prior to
extraction could improve the procedure.
Materials and J4e_thod
Experiment It Two litres of urine were collected
from a normal postmenopausal woman, In a container to
which 20 mis. hibltane had been added. ^hen the urine
arrived in the laboratory it was divided into two equal
parts (1,000 ml. each). The first was stored in the
cold-room while the second was dialysed at AO. The
urine was contained in a cellulose bag (Visking, Hudes-
Co.) and was suspended in a vessel containing 2 litres
of distilled water. The dialysing fluid was changed
every four hours over a period of 16 hours and was then
dialysed overnight after the fourth ohange, the whole
proesdure being concluded within 24 hours. Subsequently
the gonadotrophins from both urinary samples (dlalysed
and non-dialyeed) were extracted an described previously
(see page 92).
For the estimation of W the OAA7) test was employed
(Chanter 2). Fifty animals were divided into 10 treat-
xaent groups and four grouns wore selected at random to
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receive either 0, 0.46875, 1.875 or 7.5 i.u. LHt while
the remaining 6 groups were used to assay the two
urinary extracts. The three dose levels employed were
equivalent to 11.25, 45.0 and 180 ml. of urine
respectively.
Experiment II: A total of four litres of urine was
collected from the same subject, pooled and divided into
four 1 litre fractions. Three of these were dialysed
as described above. The dialysates were pooled and
retained for further processing. After dialysis, 750
ml. of each of the three urine fractions, together with
750 ml. of the undialysed urine, were extracted
separately by the tannic acid procedure.
The dialysate, totalling 24 litres, was divided
into two equal portions. No precipitate was formed
when one of these was extracted by the tannic acid pro¬
cedure. The remainder of the dialyeate was concentrated
in a rotary evaporator, but when the total volume of
dialysate was reduced to 30 ml. no further concentration
was possible because of the viscous nature of the
material. The concentrate was then centrifuged at
3000 r.p.ra. for 20 wins. It wan assumed that the super¬
natant and the precipitate contained the materials which
had been removed, by dialysis, from 1.5 litres of urine.
Both fractions were split into two equal parts.
A control dialysis experiment was also carried out
104.
in order to determine the recovery of an added quantity
of LH. One ampoule of Pergonal (75.0 i.u. LH) was
dissolved in 10 mis. saline and was dialysed against a
volume of 20 rals. of distilled water, the procedure
being the same as that described in Experiment I.
The bioassay employed was the VW test, carried out
a® described in Chapter 1. Eighty-five hypophysectomised
animals were randomly allocated amongst 17 treatment
groups (5/group). Three group® were selected at random
to receive 0, 0.9 and 3.6 i.u. LH, while the remaining
14 groups were used to assay the following preparation®
(see also Figure 30 )t
1. Preparation At Malysed Pergonal at dose levels
presumed to be 0.9 and 3.6 i.u. respectively.
2. Preparation Bt Fraction I of the dialysed and
extracted urine.
3. Preparation C: The non-dialysed urine extract.
4. Preparation B: The first fraction of the super¬
natant obtained after centrifugation of the concentrated
dialysate.
5. Preparation Ei A combination of fraction II of
the dialysed extracted urine combined with the eecond
supernatant fraction.
6. Preparation Ft The first fraction of the preci¬
pitate obtained after centrifugation of the concentrated
dialysate.



















































































Preparation 0: The second half of the precipi¬
tate combined with fraction III of the dialyeed
extracted urine.
The two doee levels employed for all the urinary
extracta were equivalent to 28.13 rale, and 112.5 mis.
respectively, while the doeee selected for the super¬
natant ae well as for the precipitate obtained after
centrifugation of the concentrated dlalysate represented
the equivalent substances reooved by dialysis from 28.13
and 112.5 ml. of urine respectively. Throughout the
assay procedure all experimental anlaals received corti¬
sone acetate (1 rag. per day).
Results
The weights of the urinary extracts in the first and
second exoeriments were as follows; 54.5 end 58.3 rag.
per litre of the non-dialysed and 16.7, 23.6, 17.0 and
20.1 mg. per litre of the dialysed urinary samples. The
corresponding mean figures were 56.4 i 2.39 and 19.35 ±
1.68 for the non-dialysed and the dialysed urine
respectively. When these two mean values were compared
by Student's *tM test it was found that the difference
was highly significant (t * 9.103» D.F. * 4, R<0.001).
when the powders were dissolved in saline orior to
injection it was observed that those which came from non-






















































































































































EFFECT OF DIALYSIS ON URINARY LUTEINISING HORMONE ACTIVITY
ESTIMATED BY THE OVARIAN ASCORBIC ACID DEPLETION TEST
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EFFECT OF DIALYSIS OH URINARV LUTEINISINC HORMONE ACTIVITY ESTIMATED BY
THE VENTRAL PROSTATE WEIGHT ASSAY
Figure 32
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prepared from the dialysed extracts.
The results from the first experiment, In which the
OAAD test was employed, are shown In Table 23 and Figure
31. The analysis of variance calculated Individually
for each WTTM against the preparation demonstrated
that dlalyaed urine gave a dose-response relationship
which was identical to that of the standard. The dose-
response curve of the non-dialysed urine was not parallel
to that of the standard (?<0.01) and the overall
difference in the responses obtained for both prepara¬
tions was significantly different (P<0.01) (Table 23).
The results obtained in Experiment II, using the
Vpw test, are shown in Table 24 and Figure 32. A
statistical analysis of these results showed that in
hypophysectomlsed rats no significant difference in
ootency was observed between the dialysed (Preparation A)
or non-dialysed Pergonal (Table 24).
The dose-resoonae curves obtained for the bioassay
of preparations B, C and 0 were all parallel to the
standard. Significantly lower ventral prostatic
responses were observed following the administration of
preparations B (P<0.01), C (P< 0.001) and 6 (P< 0.001),
in relation to those obtained following treatment with
the standard of reference. A comparison between the
responses obtained for preparations B and C (Table 25)
demonstrated that the dose-response curves were parallel,
TABLE24
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COMPARISON OP THE KESUXT8 BKWEKff THE





Variations D.P. Sum Sqs. Mean Sq. V.R. P
Between
preparations 1 184.81 184.81 75.13 < 0.001
Common
regression 1 153.71 155.71 64.34 < 0.001
Parallelism 1 0.39 0.39 0.16 N.S.
Between doses 3 340.91 113.64 46.96 <0.001
Error 16 39.43 2.42
Total 19 380.34
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but that the effect of the und3.alysed preparation (C)
was significantly less (P<0.001).
Preparation I) was extremely toxic and all animals
injected with the high dose died within a few minutes of
the Injection. A similar effeot was noted in the group
of animals injected with the high dose of preparation $5.
Nevertheless all but one of the animals survived when
the lower doses of these two preparations were
administered. The low dose of fraction J) had no effect
on the weight of the ventral prostate. However, when
preparation 55 was assayed, a significant increase in
prostatic weight was noted, the figure being similar to
those obtained with the low dose of preparations A, B and
G. ^reparation ? was less toxic and only 15 per cent
of the animals injected either with this preparation
alone or in combination with dialysed extracted urine
(Preparation 0), died during the assay procedure. The
results obtained when preparation F was administered
showed no significant difference between doses although
the mean values (11.5 ± 0 and 12.3 - 0.3 ag. respectively)
when compared with the control using Student's MtM test
were both significantly higher (P<0.001).
Discussion
Dialysis of urine prior to extraction resulted in a
highly significant reduction in the weight of powder
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produced (P<0.001). These powders were also much more
soluble than those obtained from undialysed urine. It
was demonstrated that dialysis of Pergonal did not
result in a significant loss of activity as estimated by
the YPW test.
The significantly lower effect induced by the non-
dialysed urine (Preparation C) in the OAAl) test (P<0.G1),
as well as in the YPW teat (P<^ 0.001), suggests that the
dialysis procedure removes a material which inhibits the
effect of LH in both assay procedures. Assays of com¬
bined dialysed-extracted urine with either the super¬
natant or precipitate of the concentrated dialysate
(Preparations E and 6) were compared with the results
obtained for the non-dialysed extracted urine (Prepara¬
tion C). The supernatant of the centrlfuged concen¬
trated dialysate (Preparation B) was extremely toxic and
all the animals injected with the high dose died. The
low dose of the precipitate of the concentrated dialysate
(Preparation F) induced a highly significant increase in
the weight of the ventral prostate, but the high dose
did not increase this effect. When the combined
materials (Preparation G) was assayed it produced a dose-
response curve which was parallel to that induced by the
dialysed-extracted urine (Preparation B).
Several workers have claimed the existence of a
factor inhibiting the action of LH (Futterwelt et al.,
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19635 Soffer and Pogel, 1963). However, the urine
used by these workers was initially heated to 100°C for
one hour in order to destroy any LH activity. tfnder
such conditions it is difficult to assume that this
inhibitor is a physiological substance, since it may
well be an artifact due to heating. Rosenberg et al.
(1965) reported that they were unable to find a gonado-
trophin-inhibiting material in human urine and suggested
that toxicity may account for the inhibitory properties
of certain extracts. Ota et al. (1968) re-investigated
the problem and they demonstrated that the degree of
toxicity was not related to an inhibitory factor.
The experiments presented herein demonstrated that
dialysis of the urine prior to extraction improves the
methods. However, the reason for this effect remains
obscure.
COMPARISON OF THK VPW AMD 0AA1) T?:STS IN T.H3 ASSAY
OF LH IN HRINK
Introduction
An attempt was made to compare the VPW and 0AA1)
tests in the measurement of urinary LH and the results
have been reported and discussed earlier (see page 34 ).
Subsequently methodological studies were carried out on
both bioassay techniques (see Chapters 1 and 2) which
resulted in considerable improvements in the reliability
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of both procedures. However, the toxicity of urinary
extracts following adiainiatration was still severe and
approximately 13$ of the animals used in the OAAD test
that were Injected with crude material died, This
suggested that the extraction procedure should also be
re-examined with a view to eliminating toxicity as a
problem. It has been demonstrated earlier (see page 96)
that hibitane used as a preservative during the
collection of urine inhibits the growth of micro¬
organisms and cocci without affecting the bioaseay pro¬
cedure. Moreover, dialysis of urine immediately on
arrival in the laboratory led to a smaller yield of
extract without adversely affecting the results obtained
by both bioassay techniques. The results obtained in
assays in which all these modifications were applied
routinely to clinical studies have been previously
reported in Chapter 2 (page 81).
The aim of the present study was to measure the
urinary excretion of LH by both the OAAD and VFW teets
and to compare the indices of precision obtained with
those calculated for a similar study described earlier
(page 34 ). This would serve to indicate the effect of
the various modifications made to both bioassay systems.
Material and Method
Three patients with an abnormal karyotype were
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selected. The first patient (Mr P) had a 47,XYY sex
chromosome constitution while those of Misses R.T. and
L.B. were 47,XXX and 45»X/46,XX respectively.
The 48-hour urinary extracts were split into two
equal parts and assayed by both the vpw and OAAD tests
using the modification described in Chapters 1 and 2.
Results
The results obtained are shown in Figure 53. The
mean LH value obtained for Mr P by the VPF test was
39«2 t 8.5 and by the OAAD assay was 56.7 - 18.7. The
mean LH readings for Miss E.T. were 46.1 ± 12.2 and
45.2 t 4.2 for the OAAD and VW tests respectively, the
corresponding figures for Miss L.B. being 14.5 t 0.7 and
12.0 t 1.6 i.u. per 24 hours. One LH value for Miss
L.B., estimated by the OAAD test, could not be calculated
because the animals treated with standard preparation
did not respond. The mean indices of precision were
0.21 t 0.02 (1 S.D.) and 0.08 t 0.04 for the OAAI) and
VFF tests respectively.
The index of discrimination (Figure 33) between the
OAAD and VPW estimations ranged from 0.5 to 2.0.
Discussion
The results obtained from the comparative study
between the OAAI) and VW tests, unlike those reported in
COMPARATIVE STUDY BETWEEN THE OVARIAN ASCORBIC
ACID DEPLETION ASSAY AND THE VENTRAL PROSTATE WEIGHT
TEST
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Chapter 1, are similar. The mean LH values obtained by
the OAAD and VFW assays for Kr P did not differ signifi¬
cantly and the mean readings obtained by the two methods
for the second and third patients were almost identical*
The values obtained are within the range found in
patients with sex chromosomal abnormalities (see Section
B, Chanters 5 and 6).
Finally the index of discrimination did not deviate
markedly from unity. It is therefore concluded that the
active principle measured by the two teats was identical.
SUMMARY
It was observed that urine collected routinely for
clinical studies was extremely heavily contaminated with
bacteria which resulted in toxicity of the urinary
extracts. The collection of urine with the bacterio¬
static agent Hibitane inhibited such growth. Dialysis
of the urine prior to extraction serves as a first step
of purification, removing from it materials which may
affect the mode of action of LH in bioassay procedures.
The tannic acid method for the extraction of urinary
gonadotrophins appeared to be satisfactory, when sample
is collected with a preservative and purified, prior to
extraction, by dialysis. The extracts do not appear to
be toxic and valid results can be obtained with both the




T. normal menstrual cycle and normal men
Much of the understanding" of human pituitary and
gonadal function is based upon measurements of urinary
gonadotrophins and steroid excretion.
The generally accepted view of oestrogen output in
women during the menstrual cycle has been deacribed by
Brown and his colleagues (Brown, I960; Brown and
Matthew, 1962). The amount of the three main
oestrogens, i.e. oestrone, ©estradiol and oestriol,
rises and falls together. Usually the quantity of
oestriol is greater than or equal to that for oestrone
while oestradiol is present in the smallest amount.
The output of oestrogens is lowest during the first week
of the cycle and then rises to a well-defined peak,
termed the "ovulatory" peak, which occurs on or about
the 13th day. The oestrogen excretion then falls and
rises again to a second maximum termed the luteal
maximum. This peak is usually of smaller magnitude
than the "ovulatory peak" and in some women may be ill-
defined. During the last few days of the cycle,
oestrogen excretion falls and menstruation occurs.
Another hormone which also shows a characteristic
pattern of values during the ovulatory cycle is
progesterone; in addition, changes in its chief urinary
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metabolite, pregnanediol, are also well recognised. It
has been shown that progesterone is secreted from the
pre-ovulatory graafian follicle in small amounts; it
starts to rise at ovulation with a maximum level 5 days
after ovulation (Forbes, 1930; Zander, 1958; Mikhail
et al.t 1963). Pregnanediol does not derivs uniquely
from progesterone (Tait, 1963) but its excretion pattern
is similar to that for blood progesterone. Thus in the
follicular phase of the cycle pregnanediol output is low,
but, following ovulation, a rise in its excretion occurs
with a peak 4 to 5 days after the appearance of the
ovulatory peak of oestrogen output (see Klopper, 1957;
Brown and Matthew, 1962; Loraine and Bell, 1966, 1968).
At the time of writing the literature on urinary LH
excretion, measured by bioassay methods, in normal men¬
struating women is still relatively scanty but is greater
than the corresponding information in male subjects.
There is reasonably good agreement among investiga¬
tors with regard to the pattern of urinary LH excretion
in normally menstruating women. This is characterised
by low and relatively constant levels during the folli¬
cular phase; an increase at about midcycle and low
levels is the trend toward the luteal phase (McArthur,
1959; Fukushima et al., 1964; Becker and Albert, 1965;
Stevens et al., 1965; Rosenberg and Keller, 1965;
Steven and Vorys, 1967). Detailed studies include those
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of Becker and Albert (1965) and Rosenberg and Keller
(1965). mhe former group, using The VP?' method, calcu¬
lated their mean urinary LH levels from serial ©stima-
tions performed throughout the menstrual cycle in seven
women. The results were expressed in "rat units".
They were converted into rag. equivalent of HIH-LH-S1 and
subsequently to i.u. (2nd IR^-NW}) using factors
described by Becker and Albert (1965) and Rosenberg and
Lewis (1966) respectively. The mean LH output was
16.6 ± 1.5 (F.S.K.) i.u. per 24 hours (10 observations);
the corresponding value extracted from the data of
Rosemberg and Keller (1965) was 4.3 - 0.56 i.u. 2nd IRP-
HMG per 24 hours (83 observations). When these two
mean values were compared, using Student's "t" test,
there was a highly significant difference between them
(B^O.OOl). This discrepancy between Becker and
Albert's (1965) and Rosemberg and Keller's (1965) results
may be due to differences in the design of the studies.
Thus Becker and Albert (1965) did not mention the age of
the subjects studied, but they reported that the cycles
varied from 24-36 days; they also emphasised that in
their study they included women who had previously shown
high gonadotrophin levels as measured by the mouse
uterus test. Probably in this way they incorporated
subjects with abnormally high LH levels In contrast to
the group described by Rosemberg and Keller (1965) which
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consisted of girls aged from 18 to 20 years and with
menstrual cycles quite similar in length (27 days).
Moreover, the use of factors to convert the results of
Becker and Albert (1965) from "rat units" to i.u. 2nd
IRP-HMG might alter their data. Because of the scanty
and conflicting information, it is obvious that at the
time of writing a definite conclusion cannot be drawn
regarding the range of LH output in normally menstruating
women and further work in this area is obviously
required.
Becker and Albert (1965) performed isolated urinary
LH estimations in 9 normal men ranging in age from 22 to
39 years. They used a kaolin-acetone method of
extraction (Albert, 1955) and estimated LH by the 7W
test. The results were expressed in "rat units" and
were converted, in the same manner as described above,
to i.u. 2nd IRP-HMG. The mean (M ± S.E.) LH based on 9
observations was 15.6 ± 2.7 i.u. 2nd IRP-HMG per 24
hours.
Rifkind et al. (1967)» using Albert's kaolin-acetone
technique (Albert, 1955; Albert et al., 1961) and the
same bloassay method, have studied urinary LH excretion
in normal men (10 observations). They found lower
readings for LH which were approximately four times
lower than those reported by Becker and Albert (1965),
their mean (M t R.E.) LH value being 4.7 - 0.6 i.u. per
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24 hours. The lower estimate reported by Rifkind et al.
(1967) cannot be explained solely from the fact that
they purified their urinary extracts to a greater extent
than did Becker and Albert (1965), since it has been
shown that this purification step results only in a loss
of from 10 to 40 per cent of the biological activity
(Albert et al., 1961a? McArthnr et al., 1967). The
significant higher value (?<0.01) found by Becker and
Albert (1965), as compared with that reported by Rifkind
et al. (1967), may possibly have been due to factors
used to convert the readings from rat units to mg.
NIH-1R-S1 and subsequently to i.u. 2nd IRP-HMG.
II. Periaenopauaal and postmenopausal period
At present there is a great lack of Information
regarding LH activity in women late in their reproductive
life and at or beyond the menopause. Many years ago
the very obvious alterations of gonadal function in the
aged female raised the question of whether they
represented the cause of ageing in general. However,
when in the second and third decades of this century the
leading role of the pituitary in controlling endocrine
function, and especially that of the gonads, became well
known, the idea that ageing might be caused primarily by
a decrease of pituitary function began to gain credence.
Gross morphological changes of the anterior
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pituitary with ageing have been known for many years and
the weight of the gland at different ages has been
intensively studied. There is evidence to support the
view that the human female pituitary gland increases in
weight until the age of 39 and from then onwards becomes
smaller (Simonds, 1914; Roessle and Roulet, 1932).
Furthermore, it was found that it is mainly the anterior
lobe which shows a progressive decrease after the 40th
year (Shanklin, 1953). Similar observations have been
made in dogs on the basis of which it was reported that
in senile animals the pituitary weight was decreased
(White and Faust, 1944? Francis and Mulligan, 1949).
The histology and cytology of the pituitary during
ageing were studied between 1930 and 1950. Castration
or menopausal cells have been found in the pituitary of
aged males and females? these are basophil in type and
are aggregated especially in small adenomata. The
cells contain large granules and have chromatin rich
nuclei and large vacuoles (Korenchevsky, 1961). Certain
conclusions have been drawn as to the functional activity
of the pituitary gland on the basis of the morphological
changes associated with age, but their validity remains
uncertain unless a change of hormone content or
production can be demonstrated.
Early attempts were made to elucidate this problem
by several investigators who measured the gonadotrophic
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activity of the pituitary gland in different animal
species. Thus, Lauson et al. (1939) studied the
pituitaries of rats of different ages and measured
gonadotrophic activity by the uterine weight assay.
Throughout sexual life activity remained at the puberal
level despite continued increases in pituitary size
(from 5«2 to 16.1 mg.). However, in three senile
female rats (2 b years of age) a remarkable increase in
gonadotrophic hormone content was found.
Assay of human pituitaries has not shown any
striking differences in the gonadotrophin content at
different ages. Thus, Bahn et al. (1953) using the
interstitial cell repair test in hypophysectoai3ed female
rats found that in postmenopausal women the pituitary LH
concentration was similar to that found in males and in
women during reproductive life.
Another approach to this problem has been made by
measuring the urinary excretion of gonadotrophins at
different ages. Heller and Shipley (1951), using the
mouse uterus test, reported that no significant correla¬
tion could be established between excretion values and
age. However, several workers found that the high
gonadotrophin excretion after the menopause persisted
for the remainder of the subjects life (Heller and
Heller, 1939; Albert et al., 1958; Johnsen, 1959;
Apostolakis and Loraine, I960; Rosenberg and Engel,
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I960).
A small number of investigators have attempted to
estimate urinary LH in ageing females. One study in
thiB field is that by Sherman and Woolf (1959) who were
unable to demonstrate any increase in LH output in post¬
menopausal women when compared with levels found in
normally menstruating subjects. On the other hand,
KcArthur et al. and Yahia et al. (1964) found a marked
increase in LH excretion during the postmenopausal era.
Becker and Albert (1965), Albert and Mendoza (1966) and
Keller (1966) also reported high LH levels in postmeno¬
pausal women, but these results do not agree from a
quantitative point of view.
III. Oral contraception
Since 1955 when Pincus reported some effects of
steroidal compounds on reproductive processes in humans,
the probable mode of action of oral contraceptives has
been repeatedly studied (see MacLeod and Tietze, 1964;
Diczfalusy, 1965; Mears, 1965a, 1965b; Pincus, 1965;
Borell, 1966; P.L.A., 1966; Greenblatt et al., 1966;
Haller, 1966; Maas, 1966; Rudel and Kind, 1966;
Starup, 1966; W.H.O., 1966; Lauritzen, 1967}
Diczfaluay, 1968; Loraine and Bell, 1968). However,
the mechanism of action of these compounds still remains
obscure. There are seven general Bites in the female
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organism which might be involved. Thus the compounds
might act
(1) on the centres in the central nervous system
concerned with the production of gonadotrophin-releasing
or inhibiting factors;
(2) on the anterior pituitary directly to inhibit
the secretion of PSH, LH or both hormones;
(3) on ovarian tissue affecting the rates of
steroidogenesis and the maintenance of the corpora lutea;
(4) on the fallopian tubes by altering the nature
of the tubal contractions and the composition of tubal
secretions;
(5) on the uterus myometrium and endometrium,
affecting growth and contractibility in the former and
growth and secretory processes in the latter;
(6) on implantation sites in the uterine endo¬
metrium; and
(7) on the cervical mucus rendering the latter more
hostile than previously to sperm penetration.
Animal experiments have shown that administration
of medroxyprogesterone acetate causes depletion of
pituitary LH stores while norethisterone and chlormadi-
none induce storage of LH in the pituitary gland (Brown
et al.t 1965; Labhsetwar, 1966, 1967, 1968). Schally
et al. (1968) investigated the effect of anti-ovulatory
compounds on the response to luteinising hormone
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releasing factor (LRF). Ovariectomised rats were
injected with large doses of oestrogens, gestagens and
combination of the two hormones. Plasma LH was measured
by the oaaD method and it was found that the above
steroids exerted a suppressive effect. However,
administration of 0.4 ^jug. LKF to rats treated with the
above compounds caused a highly significant elevation of
plasma LH. This might suggest that the oral contra¬
ceptives do not act directly on the pituitary but on the
hypothalamus or on higher centres.
During the past few years numerous studies have been
carried out in order to investigate the effect of contra¬
ceptive steroids on human pituitary gonadotrophic
function. In the earlier studies, gonadotrophic
activity was estimated using non-specific methods,
mainly the mouse uterus test, and different opinions
have been expressed concerning the effect of progestogens
alone or combined with oestrogens on the excretion of
"total gonadotrophic activity" in urine. borne investi¬
gators, including Heller (1957), Smith and Albert (1956),
Brown et al. (I960), Matsumoto et ai. (I960), Paulsen els
al. (I960), Albert and Smith (1961), ticArthur et al.
(1961), Moore et al. (1961), Loraine et al. (1961),
Brown et al. (1962), Loraine et ai. (1963), Fuchs et al.
(1964), Loraine (1964), Sas et al. (1964), Loraine et al.
(1963), Paulsen (1965), Apostolakis et al. (1966) and
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Starup (1967), did not find any significant reduction of
gonadotropic activity and concluded that the steroids
used might not affect pituitary gonadotrophic function
but might exert a direct action on steroid biosynthesis
in the ovary. However, other investigators have shown
that progestogens, oestrogens, or progestogen-oestrogen
mixtures, when administered to fertile women, produce a
distinct decrease in excretion values for "total gonado-
trophic activity" (Crooke and Butt, 1953; Garcia and
Rock, I960; Matsumoto et al., I960; McArthur et al.,
1961; Buchholz et al., 1962; Kaiser, 1963; Brown at
al., 1964; Demol and Ferin, 1964; "rb and Keller, 1964;
Lin et al., 1964; 0stergaard, 1964; Tayraor, 1964;
Walser et al.. 1964; Buchholz and Nocke, 1965; Paulsen,
1965; Stevens et al., 1965; Brown et al., 1966;
Dapunt, 1966; Lauritzen, 1966; 0fstergaard et al., 1966;
Pincus, 1966; Ryan et al., 1966; Schmidt-Klmendorff
and Kopera, 1966; Starup, 1966; Daume and Kaiser, 1967;
Keller, 1967; Starup, 1967). It must however be
stressed that this suppression was often not statisti¬
cally significant when the mean of serial estimations
carried out in the control cycle was compared with the
corresponding value in the treatment cycle. It seems
probable that if contraceptive compounds exert a
suppressive effect on gonadotrophin excretion then this
might only become significant in relation to the mid-
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cycle peak: studies in which specific assays for LH
hnve been conducted have tended to confirm this conclu¬
sion (see Table 33 for references).
Another attempt was made by several workers to
investigate the mode of action of oral contraceptives by
joint administration of a steroid hormone and a gonado-
trophin. It was argued that if steroids inhibit
ovarian function directly, then exogenous administration
of gonadotrophins would probably fail to overcome the
ovarian blockade; if, however, the steroids directly
inhibited pituitary function then the exogenous admini¬
stration of gonadotrophins should compensate for the
pituitary inhibition by directly stimulating the ovary.
As a result of these types of studies some authors
inferred a central effect because ovarian inhibition by
steroids was abolished by exogenous gonadotrophins
(Bettendorf, 1962; Johannlsson et al., 1965; Taymor
and Rizkallah, 1965; Starup and gfstergaard, 1966),
whilst others assumed a peripheral effect, because
administration of gonadotrophins did not restore ovarian
function (Biczfalusy, 1961, 1962; Lunenfeld et al.,
1962, 1963; Arguelles et al.. 1964; Hecht-Lucari, 1964;
lunenfeld, 1964). It should, however, be noted that
only the results of Starup and j2fstergaard (1966) are
based on observations made in normally menstruating
women (22 subjects); the other investigations were made
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on patients who suffered from amenorrhoea or the Steln-
Leventhal syndrome, and therefore these results should
he accepted with reserve.
It is ohvious that the mechanism of action of oral
contraceptive steroids is still incompletely understood.
This is in part due to the fact that many of the physio¬
logical mechanisms involved in the regulation of the
human reproductive processes have not yet been eluci¬
dated. The paucity of information on normal endocrine
regulation of these processes renders it difficult to
evaluate some of the pharmacological effects induced by
contraceptive steroids. Another source of difficulty
arises from the fact that the various types of compound,
and even the same compound at various dose levels, may
have different sites and modes of action.
TV. Clomlphene
^his compound was initially shown on the basis of
experiments in rodents to have contraceptive properties
(Holtknmn et al.t 1961). "Early studies by Greenblatt
and his colleagues, summarised in a review by Greeftblatt
and Mahesh (1965)» indicated that the effects of Clomi-
phene in human subjects were very different from those
in rodents. These workers noted that the compound
lacked anti-ovulatory activity In women and observed
that, when it was administered to patients with unduly
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short menstrtiel cycles, the letter reverted to a normal
length. Creenblatt and his associates (Creenblatt,
1961; Creenblatt et al., 1961) subsequently showed that
Olomiphene stimulated ovulation in a proportion of
sterile women.
The mode of action of Cloralphene is not yet known
with certainty. Several workers claimed that it has a
direct effect on the ovaries while others believe that
it acts through the anterior pituitary gland (see ""able
37 for references).
v• dTtXYY* Chromosomal abnormality
The first male patient with an XYY chromosome con¬
stitution was reported by Sandberg et al. (1961) and
Hausehka et al. (1962). Subsequent chromosomal examina¬
tion of randomly selected newborn moles, randomly
selected adult males, and males examined for a variety
of reasons, revealed that the XYY abnormality was rare
and was calculated to occur in approximately one out of
2,000 subjects (Court-Brown et al., 1964). ITntil the
identification of this type of patient in a State
Hospital (Jacobs et al., 1965), only 12 males bad been
described with n sex chromosome complement of this type
among the general population in various countries
*
Throughout the following cnapters the nomenclature
proposed at the Chicago Conference on Cytogenetics
(1966) will be used.
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(Court-Brown, 1967).
Jacobs et al. (1965) and Price et al. (1966) were
the firBt to indicate that there nay be characteristics
common to patients with the XYY sex chromosome
abnormality. They showed that in these subjects there
were tendencies to mild mental retardation, aggressive
behaviour which often resulted in criminal or violent
aots, and increased height.
.^rice et al. (1966) reported that in eight out of
nine XYY males the external genitalia were normally
developed. On this evidence they concluded that there
was no reason to suppose that under different circum¬
stances the XYY patients would have been subfertile.
In spite of this observation clinical findings suggest
that the incidence of hypogonadism is high in this type
of 3ex chromosomal abnormality (Balodimos et al., 1966).
To the best of the knowledge of the author no information
regarding pituitary gonadotrophic function in males with
an XYY karyotype has so far been reported.
VI. Turner's syndrome
In 193B Turner described in seven females a syndrome
of sexual infantilism, webbed neck and cubitus valgus,
associated witn short stature. At that time it was
thought that these patients had diminished ovarian
function secondary to a hypopituitary state or a defect
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In the pineal gland. Sharpey-Schafer (1941), however,
took the view that the ovaries were defective. When
tests for pituitary gonadotrophins in urine were
developed, it was found that the syndrome waa associated
with high levels of "total gonadotrophic activity"
(Albright et al., 1942; Varney et al., 1942} Schneider
and McCullagh, 1943; Wilkins and Fleischmann, 1944}
Amorose et al., 1966). The increased levels of gonado-
trophins in adult patients with gonadal dysgenesis were
presumed to reflect the lack of the normal ovarian
inhibition of pituitary gonadotrophin production.
In 1954 Polani et al. and Wilkins et al.
simultaneously demonstrated that individuals with
Turner's syndrome were cbromatin-negative. Polani ejfc
al. (1956), using evidence from nuclear sexing and
colour-blindness inheritance, suggested that such
individuals possessed a 45,X sex chromosome constitution;
this was later confirmed by Ford et al. (1959). Since
these original studies, chromosomal analyses have been
carried out in a large number of subjects with gonadal
disfunction and a variety of karyotypes have been
reported. The possible variations comprise (1) the
presence of a structurally abnormal sex chromosome (iso-
chromosome); (2) mosaicism; and (3) a combination of
(1) and (2) (Court-Brown et al., 1964). The 45,X
karyotype represents the largest entity, accounting for
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roughly half the canes; about one-third of the cases
are mosaics, and the lsochroraosome of the long arm of
the X-chroraosome represents the commonest structural
abnormality (Mittwoeh, 1967). An isochroraosome la a
chromosome in which the arms on either side of the
centromere are physically identical and bear the same
gene loci. There are two possible mechanisms by which
an isochroraoBome may be formed. If the two homologous
acrocentric chromosomes fracture at their centromeres
and the long arms reunite, an isochromosome is produced
which consists of two homologous long arms. This
mechanism is called "centric fusion". An isochromosorae
may also follow "centric fusion" involving two meta¬
centric chromosomes. In theory, such an exchange
between homologous metacentric chromosomes should produce
two isochromosoraes but not infrequently two of the frag¬
ments produced are acentric and become lost. A second
mechanism by which an isochromosome may arise is the
following? a metaphase chromosome is composed of two
identical longitudinal halves which are united at a pale
or unstained area. Each half is called a obromadi/t,
and the pale point of union is the centromere. If
transverse fission through the centromere of a metaphase
ohromosome occurs, and the fractured chromatids reunite
with their adjacent (sister) strands, one or sometimes
two isochromosomes are produced. This is called
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"sister strand reunion" (Egger, R.R., 1965).
Non-disjunction of the sex chromosomes in spermato¬
genesis which may give rise to Klinefelter's syndrome
may also result in Turner*s syndrome. It might be
anticipated that Turner's syndrome might occur more
frequently than Klinefelter's syndrome because the
former condition can arise from the lose of a chromosome
which would go into the polar body. However, the
opposite has been found to be the oase. Thus the
incidence of Klinefelter's syndrome at birth has been
estimated to be approximately 2 per 1,000 whereas that
of Turner's syndrome is roughly 4 per 10,000 (Mittwoch,
1967). The most likely explanation for this apparent
discrepancy may be found in the results of chromosomal
studies on aborted embryos. Carr (1965) reported that
among 200 spontaneously aborted embryos, eleven had a
45,X chromosome constitution, while none showed 47tXXY
karyotype. This suggests that the frequency of Turner's
syndrome at birth may be only a few per cent of that at
conception and it appears possible that the abnormalities
of the heart and blood vessels associated with this
syndrome may result in a high mortality before birth.
The classical belief has existed for many years
that the primary defect in Turner's syndrome lies in the
ovaries. However, certain observations exist in the
literature which may necessitate some modification of
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this view. It has been reported that children with
burner's syndrome showed grossly elevated urinary HPG
(Silver, 1951; Silver and Mempe, 1953; Silver and Dodd,
1957). Moreover, normal menstrual function, sometimes
for several years, has been reported in proved cases of
the syndrome (Foffenberg et al», 1957; Stewart, I960;
Bahner et al., I960). Evidence of this type suggests
that the classical view regarding the aetiology of
Turner's syndrome may represent an over-simplification
of the true situation. In attempts to elucidate this
problem the estimation of total gonndotrophic activity
does not yield sufficient information. Accordingly, in
order to give more insight into the aetiology of the
condition, the excretion values for III and FSH must be
studied separately, in order to investigate whether the




ENDOCRINE FUNCTION IN PERIMENOPAUFAL 'SOMEN
INTRODUCTION
The term menopause (emmina « menses; pafeie -
cessation; Greek terra) is used to describe a
transitional phase of a woman's life which bridges the
gap between normal reproductive function and ovarian
senescence. It usually occurs between the ages of 45
and 50, the average time of onset being 47 years (see
MacGregor, 1963).
The symptoms which arise at the menopause are often
of a psychological nature; in addition, there is
frequently evidence of vasomotor instability. Many of
the clinical features are believed to result from a
decline and eventual failure of ovarian function and a
number of theories have been adduced relating endocrine
function to the symptomatology of the menopause. The
evidence for and against such hypotheses has been
evaluated by various investigators including Loraine
(1958) and Fluhmann (1964). One of the most widely
accepted theories (see Albright, 1936) postulates that
the symptoms are caused directly by the overproduction
of human pituitary gonadotrophins, while another, that
of "oestrogen lack", proposes that the clinical features
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arise from a decrease in the levels of circulating
oestrogens (Heller et al.. 1944).
Over the past three decades much new information
has been accumulated on hormone excretion patterns in
women during reproductive life. However, there is a
paucity of similar information in women at or about the
menopause, and, in the absence of objective data of this
type, an authoritative opinion cannot be given regarding
the validity of the hypotheses mentioned above.
The aim of this study was to investigate the inter¬
relationship between LH and oestrogen output in the peri-
menopausal period, and to find out if any significant
correlation exists between hormonal excretion pattern
and symptoms that appear during the menopause. The
study was then extended to examine the effect of exo¬
genous administration of HCG on ovarian function in one
of these subjects.
Subjects Studied
Patients 2, 3 and 4 were selected either because of
their age or due to the presence of menopausal symptoms.
Patient 1 was discovered in the course of a study
designed to examine the effect of a low dosage progesto¬
gen (Chlormadinone) on endocrine function; the data
shown in Figure 34 represent the pretreatment cycle in
the investigation.
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Patient 1 - Mrs M.B.t aged 37 years, para 3+0
The menarche occurred at 14# years of age.
Menstruation was regular, the duration of the cycles
being 28 days with bleeding lasting 5 days; there were
no menopausal symptoms. One year following the hormone
assay study the subjects menstrual periods were still
regular. Her chromosomal karyotype was determined and
was found to be normal (46, XX).
Patient 2 - Mrs O.K.. aged 42 years, para 6+0
The menarche occurred at 15k years, and at the age
of 19 the right ovary was removed on account of a sus¬
pected neoplasm. Until the age of 38 menstruation was
regular (5/28)} thereafter spells of oligoraenorrhoea
alternated with periods of excessive bleeding. For
some 20 months prior to the investigation, the patient
had complained of hot flushes and depressive attacks;
these symptoms were well controlled by the administration
of large doses of Chlorpromaxine, the drug being discon¬
tinued immediately prior to the commencement of the
present investigation. On the 37th day of the study
bleeding commenced, and this subsequently developed into
substantial flooding. Dilatation and curettage were
performed on day 49? the biopsy showed a non-functional
endometrium with loose stroma and scanty mitoses. The
intermittent bleeding continued and accordingly it was
decided to perform a hysterectomy. At operation the
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regaining ovary was removed. It measured 24 x 15 mm.
and contained three cysts all with recognisable luteal
cells; no corpora albicantia were observed and there
were no developing follicles. The cervical epithelium
was normal and the endometrium proliferative in type.
Patient 3 - Mrs A.G., aged 46 years, para 6 4-0
The menarche was at age 15. Menstruation was
regular (6/28) and her previous health good. In the
months immediately preceding the study the subject had
complained of dyspareunia, hot flushes and irritability.
The patient was selected for the stimulation test with
HCG (Pregnyl, Organon), the results of which are shown
in Figure 38.
Patient 4 - Mrs 23.P.. aged 51 years, para 1 + 0
The raenarche was at age 16. Cycle length had
always tended to be slightly irregular, varying from 34
to 36 days with menstruation lasting 3-5 days. At the
time of the study there were no menopausal symptoms.
Menstruation ceased one year after the end of the study.
METHODS
All subjects collected complete 24 hour urine
samples throughout the period of investigation. Assays
were conducted on 48 hour pools of urine, results being
expressed as i.u. (2nd IHP-HKG) per 24 hour sample.
LH was extracted from urine by the tannic acid
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procedure of Johnsen (1958) and assayed by the 0AAD test
(see Section A, Chapter 2, page 79). A total of 75
assays was performed; 28$ of the assays had to be dis¬
carded either because of significant deviation from
parallelism between the slopes of the dose-response
curve of standard and unknown preparations (17.3$) or
due to failure to obtain any slope with the standard
preparation (10.7$). The mean index of precision
(/It S.D.) for the LH assays was 0.15 i 0.05.
Assays of the three classical oestrogens (oestrone,
oestradiol and oeetriol) were performed by the method of
Brown et al. (1957) while pregnanediol was measured by
the procedure of Klopper et al. (1955).
RESULTS
Patient 1 (Pig.34)
The investigation extended over a period of 33 days.
Levels of oestrone, oestradiol and oestriol were within
the normal range for a woman during reproductive life.
They rose gradually during the time of observation
reaching an ovulatory peak on day 15; thereafter there
was a luteal phase rise in oestrone and oestradiol out¬
put on days 22 and 23* Pregnanediol excretion was also
typical of the ovulatory cycle, levels being at their
maximum in the luteal phase on days 22 and 23.
The pattern of LH output was grossly abnormal,



























Hormone excretion pattern in patient 1.
Hatched areas indicate duration of menstrual bleeding.
I = fiducial limits (P = 0.95) of individual assays.
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readings being very high at the beginning of the cycle,
falling at midcycle and rising again slightly in the
luteal phase. The first three readings - 383, 227 and
199 i»u. per 24 hours - are some 15 times higher than
would be anticipated in women during reproductive life
(see Table 26). In this subject, ovulation, as judged
by oestrogen and pregnanediol assays, probably occurred
in the presence of the lowest LH excretion values.
Patient 2 (Fig. 35)
The study continued for a period of 46 days.
Oestrogen excretion was quite atypical for a woman
during reproductive life, patterns for oestrone,
oestradiol and oestnol all being dissimilar, ©estradiol
levels were generally Higher than in normally menstrua¬
ting women and fluctuated irregularly throughout.
Oestrone values were low at the commencement of the
investigation, attained their maximum from days 29 to 34
and thereafter decreased slightly. A small peak of
oestriol output occurred on days 32 to 34, some 6 days
before the commencement of bleeding. Pregnanediol
levels were all low, being within the postmenopausal
range, and, on the basis of the urinary steroid analyses,
there was no evidence to indicate that ovulation had
occurred.
Throughout the whole period of study, LH levels were
elevated as compared with women during reproductive life.
Mrs. C R : AGE 42 : PARA 6*0 MENOPAUSAL SYNDROME
Patient 2.
Figure 35
notation aa in Fig"*0
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However, the pattern of LH output bore some resemblance
to that of normally menstruating women, showing higher
levels towards the middle of the cycle and lower
readings elsewhere.
Patient 3 (Pig.36)
The duration of the investigation was 51 days. It
included the second half of an ovulatory cycle and a
complete menstrual cycle.
The first cycle terminated with menstruation on day
15. The ovulatory peak of oestrogen excretion occurred
from days 1 to 4 and the luteal phase maximum of preg-
nanediol was present from days 7 to 10. LH levels were
abnormally high for women during reproductive life,
ranging from 69 to 173 i.u. per 24 hours.
The second oycle had a duration of 28 days. The
pattern of oestrogen excretion was reasonably typical of
an ovulatory cycle, and there was a luteal phase rise in
preguanediol output maximal from days 34 to 36. LH
levels were high, ranging from 80 to 272 i.u. per 24
hours and fluctuated in an irregular manner.
Patient 4 (Fig. 57)
The study occupied a period of 30 days. Ovulation
as judged by pregnanediol assays did not occur, urinary
levels of this steroid remaining consistently below
0.6 rag. per 24 hours. Oestrone readings rose gradually
reaching a maximum of 9*0 ug. per 24 hours from days 22
Mrs. A G.: AGE 48 : PARA 6*0 MENOPAUSAL SYNDROME
DAY OF INVESTIGATION
Figure 36











Mrs.E.F : AGE 51 : PARA 1 +0
■M-
Figure 37
Patient 4« Notation as in Figure 34
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to 24; a similar increase in oestriol output took piece,
the maximum value of 9.0 ug. per 24 hours being encoun¬
tered just after the oeetrone peak. LH levels were
consistently high, ranging from 71 to 144 i.u. per 24
hours.
Comparison of results between perimenopausal and
normally menstruating women
Mean values for steroid and LH excretion in
normally menstruating women abstracted from the litera¬
ture are shown in Table 26, while the corresponding
values for the four perimenopausal subjects studied
appear in Table 27. The comparison between the two
groups is illustrated in Table 28. Figures which were
lower in the perimenopausal women are indicated by a
minus sign while those which are higher are designated
by a plus; significant differences are also shown. In
all four patients the mean LH output was much higher
than in normally menstruating women. Patient 1 showed
levels of oestrogens and pregnanediol which were essen¬
tially normal. In Patient 2 readings for oestrone and
oestradiol were significantly higher than in women
during reproductive life while pregnanediol values were
significantly lower. In Patient 3 levels of oestrone,
oestradiol and pregnanediol were reasonably normal, but
the output of oestriol and "total oestrogens" was
TABLE 26
MEAN STEROID AND LH EXCRETION












3.1 ± 0.3* jug.
9.2 1 0.7 jug.
13.8 ± 1.2 jug.
26.1 t 2.15 jug.
Pregnanediol 1.72 I 0.13 rag.
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significantly low. Patient 4 showed values for preg-
nanediol and the three classical oestrogens which were
significantly lower than in normally menstruating women.
Stimulation tests with HCO
The results shown in Table 28 suggest that in women
late in their reproductive life the reciprocal relation¬
ship normally existing between pituitary gonadotrophin
production and ovarian steroid secretion was no longer
operative. Accordingly, it appeared important to
investigate whether in the perimenopausal group the
ovaries were working at maximum capacity or were still
capable of stimulation by gonadotrophic hormones. For
this reason stimulation tests with HCG were conducted in
one of the patients (No. 3) in whom levels of urinary
oestrogens and pregnanediol indicated the presence of
continuing ovarian function. The stimulation tests
were performed one year after the initial investigation,
it having been established that at that time the
subject's oestrogen and pregnanediol output were within
the range normally anticipated for a woman during repro¬
ductive life. In view of the apparently normal ovarian
function it was decided that the total dosage of HCG
administered to the patient should not exceed 9,000 i.u.
in order to avoid the possibility of hyperstimulation.
The results of the test are shown in Figure 38.







































Effect of HCG on urinary steroid output in patient 3.
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Days 1 to 9 served as a control period and on day 10
3,000 i.u. HCG were given intramuscularly. This had no
effect on oestrogen output and, because of this, two
further injections, each of 3,000 i.u., were administered
on days 13 and 16; again there was no effect on
oestrogen excretion. It should, however, be noted that
a rise in pregnanediol output occurred as a result of
RCO administration.
DISCUSS IPIT
The constant feature in the four periraenopausal
patients described herein was the presence of very high
levels of urinary LH throughout the period of investiga¬
tion. The highest LH readings were encountered in
Patients 1, 3 and 4, but even in the case of subject 2,
in whom excretion values were significantly lower than
in Patient 3 (P^O.05) and 4 (P^O.Ol), the mean output
was still considerably higher than that reported by
Hosemberg and Keller (1965) and Becker and Albert (1965)
in women during reproductive life.
Purubjelm (1966) haB reported that in perimenopausal
women the excretion of "total gonadotrophic activity" is
often normal while Funnell et al. (1951) have stated
that in menopausal subjects LH output is low. These
results conflict with the observations reported in the
present study and with much of the published work on
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this subject. It must, however, be emphasised that the
reliability criteria of the assay methods used by
Buruhjelra (1966) and Bunnell et al. (1951) were not
entirely satisfactory and for this reason the data which
they report must be accepted with reserve.
Subject 1 in the present investigation had no meno¬
pausal symptoms and had a normal chromosomal karyotype
(46, XX). Nevertheless, her LH output generally
remained very high throughout the period of study,
suggesting that an increase in pituitary LH secretion
had antedated the onset of the clinical menopause by
some years; this interesting possibility is at present
being further explored. A further feature to note in
subject 1 was the fact that ovulation as judged by
urinary steroid output occurred in association with the
lowest LH levels encountered during the Investigation,
this being the opposite of the situation normally
obtaining in women during reproductive life.
In Patient 2, who had been treated with Ohlorpro-
mazine until just before the commencement of the investi¬
gation, abnormally high LH levels coincided with
oestrogen readings whioh were above the normal range.
It appears unlikely that this pattern of hormone
excretion resulted from Chlorpromazine therapy since
this drug is known to depress pituitary gonadotrophic
activity in animals (Barraelough and Sawyer, 1959) and
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to produce signs of oestrogen deficiency in women in
association with amenorrhoea and galactorrhoea (Polishuk
and Kulesar, 1956).
The major finding to emerge from the present
investigation is that ovulation as judged by urinary
steroid output can occur in an apparently normal manner
in the presence of very high LH levels. This is well
illustrated by the results in Patients 1 and 3, while in
Patient 2 abnormally high LH and oestrogen levels co¬
existed. These observations suggest that in women
towards the end of their reproductive life the reciprocal
relationship or "feed back" mechanism believed to exist
between the pituitary and the gonads is disturbed.
The symptoms which arise during the periraenopausal
period are generally treated with oestrogens either
because of the alleged oestrogen deficiency or to
suppress the hyperactivity of the anterior pituitary
gland. Prom the present study none of these hypotheses
can be supported. Only in the last patient (E.F. -
Table 28) was a deficiency found in oestrogen output.
On the other hand, on subject 2 (C.R.) oestrogen
excretion was significantly higher than that found in
normally menstruating women. It should be pointed out,
however, that this patient had experienced the most
severe symptoms of the menopause. The first (M.B.) and
the third (A.G.) patients showed normal oestrogenic
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activity.
It is not yet clear whether in perimenopausal women
the ovaries are under maximum stimulation by the
pituitary or whether they are still capable of responding
to stimulation with gonadotrophic hormones. Preliminary
results obtained in Patient 3 (Pig. 38 ) would tend to
suggest the former hypothesis, but the reason for the
rise in pregnanediol output in this subject in the
absence of any effect on oestrogen excretion remains to
be explained. The possibility exists that the total
amount of HCO administered (9,000 i.u.) may not have
been adequate. Oernzell et al. (1958) reported similar
hormone excretion patterns (increase in pregnanediol
output without any effect on oestrogen excretion values)
in two amenorrhoeic women with fairly normal excretion
of oestrogens who were treated with a total dose of
36,000 i.u. HCG within a period of six days. On this
evidence, together with endometrial biopsy, these authors
concluded that ovulation occurred following the admini¬
stration of HOG. On the other hand, recently it has
been shown that the ovaries of postmenopausal women, even
though twenty years beyond the menopause, are still
capable of functioning under the stimulatory effect of
HOG and to secrete much higher levels of oestrogens than
those found in normally menstruating women (Pollak et
al., 1968). It should be pointed out, however, that the
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total dose of HCG given by the above investigaxors was
50,000 i.u. within a period of 5-10 days. The latter
evidence suggests that the ovaries even though of post¬
menopausal women are capable of responding to gonado-
xrophic (HCG) stimulation.
h UMtflAHY
Serial assays of urinary oesxrogens, pregnandiol
and LH have been performed in four subjects late in their
reproductive life, and the results have been compared
with those in normally menstruating women.
In all the subjects LH levels were grossly elevated
being much higher than those normally encountered in
women during reproductive life.
In two patients ovulation as judged by urinary
steroid assays occurred normally in the presence of
elevated LH readings, while in one abnormally high LH
and oestrogen levels coexisted.
Stimulation test with HCG was conducted in one
patient, which had no effect on oestrogen output but &
rise in pregnanediol excretion occurred as a result of
it.
The evidence presented suggests that in women late
in reproductive life the reciprocal relationship believed
to exist between pituitary gonadotrophic function and
ovarian oestrogen secretion is no longer operative.
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CHAPTER 2
ENDOCRINE PACTION IK POHTHVNOPAUVAL ^OMVN
INTRODUCTION
At the present time a considerable volume of
literature exists with respect to endocrine function in
normally menstruating women (see Loraine and Bell, 1966,
1968, for references). However, there is a great
dearth of similar information in subjects beyond the
menopause.
Heller and Shipley (1951), using the mouse uterus
test, reported that no significant correlation could be
established between urinary excretion of gonadotrophins
and age. However, Heller and Heller (1939) found
previously that the high gonadotrophin excretion after
the menopause persisted permanently. Johnsen (1959)
claimed that the mean HPG excretion was found to be
higher in postmenopausal women aged from 50 to 64 than
from 65 to H? years. Albert et al. (1958), Rosenberg
and Engel (I960) and Apostolakis and Loraine (I960)
found high HPG activity in the urine of postmenopausal
women, and the first two groups of investigators also
noticed a day-to-day fluctuation.
Further attempts were made by several workers to
estimate the urinary LH or FSH and TjH using methods
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claimed to be specific. Thus Sherman and Foolf (1959)
were unable to find any increase in LH output in post¬
menopausal women when compared with the levels found in
normally menstruating women. On the other hand,
McArthur et al. (1958) and Yahia et al. (1964) found a
marked increase in LH excretion during the postmeno¬
pausal period.
The aim of the present study is to report comparable
data in the postmenopausal women by describing the
results obtained when serial assays of LH and oestrogena
in urine were conducted in four such subjects.
MATERIAL A!TD METHODS
"Patients
Details of the women who volunteered for the study
are shown in Table 29. All were normally active during
the period of investigation, and with one exception
(subject 2) none gave any previous history of endocrine
abnormalities. Subject 2 had been treated for thyro¬
toxicosis by subtotal thyroidectomy at the age of 40.
Since then she had been maintained on thyroxine at a
dose level of 0.2 mg. per day orally; she was euthyroid
at the time of the investigation.
Hormone assay methods
All subjects collected complete 24 hour urine
TABU' 29
LIHICAL DETAILS OF SUBJECTS STUDIL
. Years
Subject / < Parity History beyond the(,yea bj menopause
50 6+0 Normal
50 1+0 Subtotal thyroidectomy
for thyrotoxicosis*
treated with thyroxine
61 2+1 Normal 16
63 2+0 Normal 18
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samples throughout the period of investigation. Assays
were conducted on 48 hour pools of urine, results being
expressed as i.u. (2nd IRP-HMG) per 24 hour sample.
LH was extracted from urine by the tannic acid pro¬
cedure (see Section A, Chapter 3). The bioassay for the
hormone was the OAAD test as has been described in
Chapter 2, p. 79. A total of 44 assays were performed!
three aesays (7$) had to be discarded due to significant
deviation from parallelism between the dose response
curves of standard and unknown preparations.
In three women (1, 2 and 3) estimations of the three
classical oestrogens - oestrone, oestradlol and oestriol
- were performed by the method of Brown et al. (1957).
Pregnanediol was measured in the urine of one subject (1)
using the technique of Klopper et al. (1955).
RESULTS
The results of LH and oestrogen determinations are
illustrated in Figures 39, 40, 41 and 42.
The mean index of precision ( i S.D.) for the LH
assays was 0.18 t 0.06.
Subject (Fig. 39)
The study continued for 35 days. The pattern of
excretion of oestrone and oestriol was similar to that
observed in women during reproductive life with a well-
defined peak at the middle of the investigation and a
Mrs. B.M. . AGE 50 : PARA 6+0 POSTMENOPAUSAL
LH













LH and steroid excretion in Subject 1
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second peak for oestrone on days 31 and 32} oestradiol
levels fluctuated in an irregular manner showing no con¬
sistent pattern. Pregnanediol readings remained low,
and there was no evidence that ovulation had occurred.
Excretion values for LH were elevated throughout.
Headings were lowest at the beginning and at the end of
the study; they were at their maximum in the middle,
coinciding with the peak of oestrogen output. The last
three LH estimations were significantly lower than that
of days 14, It), IB and 19 as indicated by the lack of
overlap of the fiducial limits of estimated potencies.
- uUt-c t 2 (Fig. 40)
Two periods of investigation, one of 7 and the
other of 22 days duration, separated by 63 days, were
carried out. Oestrogen levels remained low throughout,
the figure for HtotaI oestrogens" not exceeding 10 ug.
per 24 hours. LH readings were high and fluctuated in
an irregular manner} the range was from 22.4 to 240.0
i.u. per 24 hours.
Subject 3 (Fig. 41)
The investigation was conducted over a period of 9
days. Levels of oestrogen remained low, the figure for
"total oestrogens" not exceeding 9.0 jug. per 24 hours.
LH readings were lower than in the other postmenopausal
subjects ranging from 11.0 to 50.7 i.u. per 24 hourB.
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Figure 40
LH and oestrogen excretion in Subject 2
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Figure 41
LH and oestrogen excretion in Subject 3
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qubjeot 4 ('ig. 42)
As with subject 2, this woman was studied twice, the
time of Investigation being separated by 3ir months. The
first period lasted for 7 days and the second, which is
shown In Figure 42, for 22 days.
In the first study the mean (M.S.F.) total oestrogen
excretion (1? estimations) was 5.2 - 1.4 p.g Per 24 hours
(""able 30) and the corresponding figure for LH (4 esti¬
mations) was 149 t 21.4 i.u. for 24 hours. In the
second study (Fig. 42) only FH assays were performed.
All readings were much higher than those found in women
during reproductive life. From days 1 to 14» levels
ranged from 55.7 to 132 i.u. per 24 hours; however, the
fiducial limits (P « 0.95) of all 6 estimates overlapped,
indicating the absence of any significant differences
between the individual readings. The value on days 15
and 16 (300.7 i.u. per 24 hours) was significantly
higher than the previous readings, the fiducial limits
showing no overlap.
In ^able 30 is shown the mean LH and oestrogen out¬
put in the four subjects studied and Table 31 presents
a comparison of the results in postmenopausal women with
those in women during reproductive life (see Chapter 1,
Table 26 ). Figures which are lower in the postmeno¬
pausal group are indicated by a minus sign and those
which are higher by a, plus sign; significant differences










LH excretion in Subject 4
TABLE30
HSAKOESTROGENALi)LKEXC ETIOINPO TMENOPAUSALWOME Oestro^ensfug.P®r24hour )TH
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ere also shorn. In subject 1 the output of oeetrone
and ©estradiol was within the ranee encountered in the
latter group. In subjects 2, 5 and 4 excretion values
for oestrone and oestriol were significantly lower, but
the mean figures for oestradiol did not differ signifi¬
cantly from those in women during reproductive life.
Hean levels of LR were significantly higher In all the
postmenopausal subjects.
PTHCROTCH
Tn the four postmenopausal women studied the overall
mean LH levels (t S.E.M.) was 116.8 t 10.w i.u. per 24
hours. This figure is almost identical with that found
in a series of four subjects studied late in their repro¬
ductive life (Chapter 1, p. 132) in whom the mean LH
output was 115.6 t 17.8 i.u. per 24 hours. The simi¬
larity of these mean values lends support to the view
put forward by the author that an elevation in LH output
to postmenopausal levels may precede the clinical onset
of the menopause (see page 142).
At the time of writing, few reports exist in the
literature in which estimates of LH, expressed in i.u,,
have been performed in postmenopausal subjects. Becker
and Albert (1965) studied a series of six women, in a
proportion of whom an oophorectomy had been performed
and in the remainder the menopause had occurred
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spontaneously. A total of 8 LH assays were conducted,
and, when the data were converted into i.u. in the
manner described by Rosenberg and Lewis (1966), the mean
value (M.S.E.) (131.2 t 14.6 i.u. per 24 hours) was
reasonably similar to that reported in the present study.
In a later paper Albert and Mendosa (1966) reported the
results of LH assays in 2 46-year-old patient who had
been oophorectomised seven years previously, under the
assumption that the LH secretion is similar to that
found in postmenopausal women. It is doubtful if these
two conditions are Bixnilar since it has been shown by
?oliak et al. (1968) that the ovaries of postmenopausal
women, even though 20 years beyond the menopause, are
still capable of functioning under the stimulatory
effect of HCG and to secrete much higher levels of
oestrogens than those found in normally menstruating
women. Also, Steinberger and Luckett (1966) have shown
that ?SH and LH levels in surgically induced cryptorcbid
and in orchiectoraised rats, although significantly
higher than those found in intact animals, the gonado¬
trophs values in cryptorchid rats were significantly
higher than those in orchiectoraised animals. The mean
LH output (M.S.K.) from the data of Albert and Kendosa
(1966), based on 9 estimations, was significantly lower
(P<0.01) than that previously reported, being 50.1 ±5.4
i.u. per 24 hours.
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low LH values were also found by Keller (1966) who
conducted single LH determinations in each of 7 post¬
menopausal subjects; the mean value was 28.0 and ranged
from 6.2 to 51#0 i.u. per 24 hours. The foregoing data
emphasises the small number of postmenopausal patients
in whom reliable estimations of LH output have so far
been published and stress the necessity for further
research in this field in order to establish a represen¬
tative normal range of excretion values.
The LH excretion of Patient 3 (Table 31) in the
present study was significantly lower when oompared with
the mean found either in Patient 1 (P<0.01) or in
Patient 4 (P<0.05). This discrepancy cannot be
explained on the basis of the age of the patient.
Johnsen (1959) emphasised the importance of the subject1©
chronological age and noted that the mean HPG excretion
was higher in patients aged from 50 to 64 than from 65
to 87 years. Prom his data has been extracted the mean
RPG output from each group which was 209*96 t 23*6
(M.S.K.) (24 observations) for the gi*oup aged 50 to 64
years and 141.7 ± 15.2 (M.S.E.) (20 observations) for
the group aged 65 to 87. However, when these two means
were compared using the student's "t" test they did not
differ significantly. The only possible explanation of
the low LH output found in Patient 3 is that the period
studied was rather short (3 estimations in 9 days) and
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oo higher LH readings were missed.
In contrast to LH there is now an extensive litera¬
ture on urinary oestrogen output in postmenopausal
subjects (see Loraine and Bell, 1966, 1968), and it is
generally agreed that the main source of oestrogen pro¬
duction at this time of life is the adrenal cortex. In
three of the women reported herein (2, 3 and 4) oestrogen
levels were within the range normally anticipated in the
postmenopausal period while in the fourth (subject 1)
the mean excretion was above this range (Table 30).
This finding is probably explained by the fact that in
subject 1 cessation of menstruation had occurred only
one year before the commencement of the study, and it is
therefore reasonable to expect that the ovaries as well
as the adrenals were contributing to the amount of
hormones excreted in the urine.
It is not yet known if the human pituitary ages.
efj (1953), using interstitial-cell repair in
hypophysectomised female rat test, estimated the human
pituitary LH, and they found that the concentration in
postmenopausal was similar to that found in males or in
menstruating females. Ryan (1962) claimed that he
found, using the OAAD test, an increase in LH concentra¬
tion in the anterior pituitary of females with age.
From the data that Ryan gave, this increase is not
proven to be significant due to the overlap of the
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fiducial limits of the estimated potencies.
From the present study as well as from the findings
of Poliak et al. (1968) and from the findings in the
perimenopausal group (Chapter 1, p. 132) there is
evidence to support the view that in women it is the
ovary that ages. The anterior pituitary probably works
under its maximum capacity but is unable to stimulate
ovarian function.
SlfMifAHY
Serial assays of LH and oestrogeas have been
performed in the urine of four postmenopausal women.
The mean LH output in individual cases was variable
ranging from 34.6 t 13*6 to 144.7 i 16.9 i.u. per 24
hours; the corresponding figures for "total oestrogens"
ranged from 4.5 ± 2.2 to 16.1 ± 2.5 ug. per 24 hours.
A significant difference in LH excretion was not
noted between the postmenopausal subjects and a series
of four women studied late in their reproductive life.
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CHAPTER 3
OBSERVATIONS ON TIT' BPFKCT OF OML contraceptives
on excretion values pgr luteinising hormone
INTRODUCTION
It is now generally agreed that progestogen-oestro-
gen mixtures, when administered in the "classical form"
on a short term basis, obliterate the mideycle peak of
LH excretion and produce anovulatory cycles as judged by
the pattern of oestrogen and pregnanediol output (see
Table 33 for references). When given as long term
therapy these compounds also inhibit ovulation on the
basis of steroid excretion; however, their effects on
the excretion of follicle-stimulating hormone (PSH) and
luteinising hormone (li?) have been investigated to a
much more limited extent and may well be dependent on
such factors as the composition of the tablet, its
dosage and the duration of administration (see Bell jrt
al., 1967).
The aim of the present study is to contribute to
this field by reporting results of serial assays
performed in five patients treated with oral contra¬
ceptive drugs. Pour of them were on long term therapy,
one was treated with a progestogen-oestrogen mixture,
another with a "pure" progestogen and in the remaining
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two women a sequential form of contraception was
administered. In the fifth patient the short term
effects on endocrine function of a progestogen given
continuously in low dosage was studied.
MATERIALS AND METHODS
A. Patients
Olinical details of the women studied together with
the medication given are shown in Table 32. All com¬
pounds were administered by the oral route.
Subject At Mrs K.I)., aged 26 years, Para 3 + 0
The menarehe occurred at 13 yearn of age and since
then her menstruation has been rather regular
(4-6/27-30). Previous birth control was restricted to
the use of the rhythm method.
She was treated with Ovulen (6.D. Searle & Co.),
each tablet containing 1.0 tag. of 17a-ethinyle8trone-3 -
17 -diol diacetate (ethynodiol diacetate) plus 0.1 mg.
ethinyl oestradiol-3-methyl-ether (mestranol). During
the period of time when she was taking this preparation
her lege tended to swell and during the time of study aha
developed a deep venous thrombosis.
bubject B, Mrs H.M., aged 42 years, ^ara 7+1
The menarche occurred at 13 years of age and until
therapy with oral contraceptives she menstruated
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The oral contraceptive, 17a-ethinyl-19-norxesto-
sterone acetate (norethisterone acetate), had been taken
for 67 calendar months. During the first three cycles
she tpok 5 rag. norethisterone acetate daily, but this
was subsequently reduced to 2.5 rag. daily.
Since the administration of this oral contraceptive
the patient's cycles had become irregular. The dura¬
tion of her periods varied and the menstrual flow was
generally reduced. ?/ithdrawal bleeding did not occur
after every treatment cycle, the longest period of
araenorrhoea being 2t months. Side effects during
therapy included headaches and increase in weight.
Subject C, Mrs W.D., aged 32 years. Para 3 + 0
The menarche occurred at 12$ years of age.
Menstruation was rather regular; bleeding lasted from 4
to 5 days and the duration of the cycles was from 27 to
30 days. Sne received a sequential preparation con¬
sisting of 10 tablets, each containing 0.1 rag. mefitranol,
followed by another 10 tablets containing, in addition
to 0.1 rag. raestranol, 0.5 rag. ethynodiol diacetate.
Virtually no side effects were noted during the 20
calendar month period of treatment apart from slight
weight gain and occasional headaches.
Subject D, Mrs M.J., aged 55 years, Para 2 + 1
The menarche occurred at 11 years of age. The
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length of the cycles was from 28 to 31 days and the
duration of menstruation was from 0 to 7 days. Thirty
months prior to the present study the patient was fitted
with an intra-uterine device but had been able to wear
this for 5 months only; it was removed because of heavy
and painful periods and intermenstrual bleeding. Sub¬
sequently, and for 13 months, she was under treatment
with a mixture of 19-nortestosterone and ethinyl
oestradiol (Gynovlar). For the last 12 months until
the present investigation the patient was taking a
sequential treatment. This regime consisted of 15
tablets each containing 0.08 mg. mestranol followed by 5
tablets each containing a mixture of 0.08 mg. mestranol
plus 2.0 ag. 17a-aoetoxy-6-chloropregna-4,6-diene-3,20-
dione (chlomadinone acetate). The menstrual periods
of the patient became moderate while on Gynovlar and
remained so while on sequential treatment. Side effects
during therapy included headaches, which were at their
worst during the days she was not on treatment, and
increase in weight.
; utject Krs &.B.. aged 37 years, para 3 + 0
Tha menarche occurred at 14a years of age. Men¬
struation was regular, the duration of the cycles being
28 days with bleeding lasting 5 days. The patient had
not previously received oral contraceptives and she
started treatment with 0.5 mg. chlormadinone acetate
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dally during the aecond cycle of the present investiga¬
tion.
General design of Investigation
All five women collected complete 24 hour urine
samples throughout the present investigation? episodes
of bleeding were also recorded.
Subject A (Pig» 43 ): Hormone aseyas were performed
during the 52nd cycle on oral contraception and in one
cycle immediately following withdrawal of medication.
Subject B (Pig. 44 ): The hormonal study started
on the 67th month of medication and continued for 55 days
after cessation of therapy. It should be noted that
bleeding did not occur following the last treatment
cycle.
Subject C (^ig. 45 )j This patient received a
10/10 sequential regime in which mestranol was given
alone starting on the 5th day of the cycle, this being
followed by combined treatment with ethynodiol diacetate
and mentranol. Hormone assays were performed during
the 24th cycle on medication and in two succeeding
cycles.
Subject T> (Pig. 46 )t The form of contraception
administered to this patient was a 15/5 sequential
regime in which mestranol was given alone starting on
the first day of the cycle, this being followed by
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combined therapy by chlormadinone acetate and mestranol.
Assays were conducted during the 14th cycle on treatment
and in the succeeding cycle after cessation of medication.
Subject £ ("Pig. 47 ): The aim of this study was to
investigate the short term effect of chlormadinone
acetate on the urinary hormone levels. The hormone
assays were conducted on two cycles. The first served
as the control period and the second was under the
effect of the administered low dose progestogen (0.5 mg»
daily).
B. Methods
Assays were conducted on 24, 48 or 72 hour pools of
urine and the results were expressed as i.u. (2nd
IRB-HMG) per 24 hour sample.
IiH was extracted from the urine by the tannic acid
procedure (see Section A, Chapter 5). In subjects A,
B, C and I) the bioassay method used was the VPS? test
described in Section A, Chapter 1. A total of 120
assays were performedj 7.5 per cent of these were
invalid because of incomplete hypophysectomy and 13.3
per cent were invalid due to significant deviation from
parallelism between the slopes of the dose-response
curves of S and U. In the assays in subject A only one
dose level of the unknown fell within the working range
of the dose-response curve of the S, making it necessary
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to calculate the results on a three point basis. The
mean index of precision (J 1 S.D.) of the VPW assays was
0.13 ± 0.05.
In subject S, LH was assayed by the OAAI) test (see
page 79 ). A total of 30 assays were performed; 20
per cent of these were invalid either because of signifi¬
cant deviation from parallelism between the slopes of the
dose-response curves of standard and unknown preparations
(16 per cent) or due to lack of slope of the standard of
reference (4.0 per cent). The mean index of precision
( X- R.D.) *as 0.22 t 0.07.
In subject K, estimations of the three classical
oestrogens (i.e. oestrone, oestrariiol, oestriol) were
performed by the technique of Brown et al. (1957) and in
all five subjects nregnanediol was measured by the
method of Kiopper et al. (1955).
RKSULT3
Subject A (Fig. 43 )
The study continued for a period of 70 days.
During the first 20 days, which included the last course
of treatment, excretion values for pregnanediol ranged
from 0.45 to 1.5 mg. uer 24 hours, which might indicate
absence of ovulation. The third day after the cessation
of medication menstruation occurred which lasted 5 days;
two days later bleeding reappeared and lasted for 3 days.





Hormone excretion in Subject A
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In the post-treatraent cycle, which lasted for 46 days,
the marked increase in pregnanediol readings, maximal
from days 60 to 62 of the study, indicated that ovula¬
tion had taken place.
In both cycles urinary LH was consistently low
throughout the whole period of investigation. Values
ranged from 1.7 to 4.5 i.u. per 24 hours. The fiducial
limits of individual estimations overlapped, indicating
the absence of any significant difference between them.
Subject B (Pig. 44 )
The period of investigation was 55 days. Prom day
4 to 23 norethisterone acetate was administered;
following cessation of therapy bleeding did not occur.
The treatment cycle was anovular on the basis of urinary
pregnanediol assays. LH levels at this time were low
or undetectable with the exception of a peak of activity
of 32.6 i.u. per 24 hours on days 20 and 21.
In the post-treatment period, which lasted for 32
days, the pattern of pregnanediol output was typical of
an ovulatory cycle. However, it should be noted that
the highest level for this steroid (1.1 mg. per 24 hours
from day8 47 to 49) was still below the range encountered
in the luteal phase of the normal menstrual cycle. LH
readings during the post-treatment cycle remained low
from days 24 to 32; thereafter, they rose, the highest
reading being 26.7 i.u. per 24 hours between days 37 and
38.




Hormone excretion in Subject B
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Subject C (V±E* 45 )
^he last cycle on treatment with a sequential 10/10
regime was anovular as judged by urinary pregnanediol
assays. At the commencement of the study, when
raestranol was administered alone, LF levels were above
the range normally encountered in women during repro¬
ductive life; when ethynodiol diacetate was added to
the sequential regime a significant fall in LH output
occurred.
The remainder of the study consisted of two ovula¬
tory cycles as judged by urinary pregnanediol assays.
LH readings during the first post-treatment cycle ranged
from 14.A to 37.5 and in the second from 16.6 to 22.7
i.u. per 24 hours. However, the fiducial limits of all
21 estimates overlapped, indicating the absence of any
significant difference between the relative potencies
obtained.
Subject 7) (wig. 46 )
The first 20 days of the investigation consisted of
the last treatment period of a sequential regime con¬
sisting of raestranol and chlormadinone acetate on a 15/5
regimen. The cycle was anovulatory on the basis of
pregnanediol assays. LH output was not suppressed by
the medication, levels being at the upper end of the
normal range for women during reproductive life. It
should, however, be noted that a midcycle peak of LH












Hormone excretion in Subject C











Hormone excretion in Subject D
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activity was not present.
Following cessation of treatment an ovulatory cycle
ensued, this being characterised by a luteal phase rise
in pregnanediol output. Menstruation oommenced on day
24 and lasted for 6 days. For the first 11 days of the
post-treatment cycle LH levels remained low; thereafter
a midcycle peak occurred from days 37 to 41. Following
this peak there was a marked fall in LH output during
the luteal phase, the last four readings all being below
4 i.u. per 24 hours.
Subject B (Fig. 47 )
The duration of the study was 61 days. It included
one control cycle and a period of 32 days during which
therapy with chlormadinone acetate was administered.
In the pretreatment cycle ovulation as judged by
oestrogen output probably occurred on days 15 and 16;
this was followed by a luteal phase rise in excretion
values for oestrone, oestradiol and pregnanediol. LH
readings were grossly elevated for a woman during repro¬
ductive life. Furthermore, the pattern of excretion of
this hormone was atypical, readings being high at the
beginning of the cycle, low at midcycle and high again
in the late luteal phase. It should be noted that, in
contrast to the situation pertaining in normally men¬
struating women, ovulation occurred at the time of the
lowest LH values.
Mrs. M. B. : AGE 37 : PARA 3 ♦ O ORAL CONTRACEPTION
Figure 47
Hormone excretion in Subject E
166.
During the treatment period the pattern of oestrogen
excretion was somewhat atypical, but the readings were
in the same range as those encounted in normally men¬
struating women. Pregnanediol readings remained low
ranging from 0.55 to 1.5 mg. per 24 hours, and on the
basis of the urinary steroid assays a definite conclusion
as to whether or not ovulation had occurred could not be
reached. LH output in the treatment cycle showed a
grossly irregular pattern, levels generally being con¬
siderably elevated for a woman during reproductive life.
Discussion
The first four subjects in the present investigation
received long term therapy with oral contraceptives. In
three of these (A, C and D, Figures 43, 45 and 46) ovula¬
tion as judged by urinary pregnanediol assays occurred
in the first post-treatment cycle. In the fourth (B,
Fig.44 ) pregnanediol readings in the post-treatment
period were low, but the pattern of excretion of this
steroid was typical of the ovulatory cycle. Klopper
(1957) found that during the luteal phase of an ovulatory
cycle, maximal urinary pregnanediol levels ranged from
2.5 to 6.2 mg. per 24 hourB. However, in view of the
demonstration by Prb and Ludwig (1965) and 0stergaard
and Starup (1968) that, in subjects treated with oral
contraceptives, at laparatomy fresh corpora lutea
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indicative of ovulation can coexist with urinary preg-
nanediol levels of less than 1 rag. per 24 hours, it
appears reasonable to assume that in subject B (Fig. 44)
ovulation may have taken place. Accordingly, the over¬
all results reported herein indicate the rapid resumption
of ovulatory cycles following cessation of long term
medication with oral contraceptives which are similar to
those previously reported by others (Loraine et al.,
1963, 1965; Bell et al.. 1967).
The present study has failed to provide any
definite evidence that such long term therapy produces
any marked effect on urinary LH output. Thus, in
patient A, who was treated with the progestogen-oestrogen
mixture, Ovulen, LH readings in both the treatment and
post-treatment cycles were within the normal range for
women during reproductive life (see Rosenberg and Keller,
1965). Furthermore, the fiducial limits of the assays
in the treatment cycle overlapped completely with those
in the posx-treatment cycle, indicating the lack of any
significant difference between individual readings. In
subject B, who was treated with a "pure" 19-nor-testo-
sterone compound (norethiaterone acetate), 4 of the 5 LH
assays performed in the treatment cycle were low and one
was at the upper end of the normal range; following
withdrawal of medication, readings in the immediate post-
treatment period were low and thereafter showed a
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significant increase.
In the two women who received long term sequential
therapy pituitary gonadotrophio function as judged by
urinary UI assays was not inhibited, LH levels in the
last treatment cycle of patient C being generally above
and those in patient D being within the normal range for
women during reproductive life. In neither case did
the readings in the treatment and post-treatment cycles
differ markedly, the only point of note being the
occurrence of a midcycie LH peak in the post-treatment
but not in the treatment cycle of subject I). This dis¬
crepancy on the LH readings in subjects C and B might
well be due to the different gestagens administered as
well as to the different ratio of oestrogen to the
gestagen in the two preparations used. Also this might
well be due to the different regimen of sequential
contraception employed in the two patients studied
(10/10 in subject 0 and 15/5 in subject 1)).
Vorya et al. (1965) and Stevens and Vorys (1967)
reported a composite normal cycle for PSH and LH. They
also attempted to investigate the effect of various
oestrogens, gestagens and the combination of both on the
urinary excretion values for PSH ana LH. By comparing
their results with the composite cycle they found that
gestagens in sufficient dosage exhibit a suppressive
effect on urinary LH excretion, the exception being
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norgestrol which has a stimulatory effect. They also
claimed that oestrogens are stimulants of LH output and
they concluded that the effect of oral contraceptives on
urinary I,H is dependent on the ratio of the activity of
the oestrogen and gestagen in the tablets. It should,
however, be pointed out that
(1) each compound was generally tested in one
subject only?
(2) the quantitative bioassays for FSH and LH have
a wide variation of normal range and so the effect of
any treatment must be compared with a control period
from the same individual and not with an artificial
composite cycle; and
(3) in the measurement of gonadotrophins by bio-
assay, the fiducial limits of the relative potencies
often overlap. Under such circumstances the estimates,
although perhaps widely separated, should not be
regarded as significantly different.
In Tables 33 , 34 , 35 and 36 is presented a summary of
the literature on the effects of the "classical",
"sequential" and "pure" gestagen forms of contraceptives
on urinary LH output. With the exception of the papers
by Vlowers et al. (1966), Ryan et al. (1966) and Bell at
al. (1967), short terra effects on LH excretion are
described. As can be seen in these Tables, the composi¬
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It is not reported if a control cycle was studied.
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It is not reported if a control cycle was studied
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considerably from one patient to another, and, in
general, a very small number of women have been treated
with the same compound. Secondly, in a high proportion
of the studies a control period either before or
following the administration of the contraceptive was
not incorporated, and in the absence of such a period it
is a matter of considerable difficulty to determine
whether the compound produces any significant effect on
LH activity.
At the time of writing, little information exists
regarding the mode of action of gestagen compounds,
administered continuously in low dosage, on endocrine
function. In the subject reported herein (E) chlorma-
dinone acetate did not exhibit any significant short
term effect on either LH or oestrogen output. However,
the pattern of pregnanediol excretion in the treatment
cycle was atypical, levels being less than 2 mg. per 24
hours throughout.
For the time being the mode of action of contra¬
ceptive drugs remains a difficult and complex subject
for investigation. The effects of seemingly closely
related compounds often appear to vary and the possible
sites of action for the various agents may also be
numerous. Systematic large scale studies on the various
effects of contraceptive drugs will contribute to a




Serial assays of luteinising hormone (LH) and
pregnanediol in urine have been performed in four women
during and following long term therapy with oral contra¬
ceptives. One subject was treated with a progestogen-
oestrogen mixxure, another with a progestogen alone and
two with a sequential regime. In three subjects there
was definite evidence for the resumption of ovulation in
the first post-treatment cycle; in the fourth the
evidence was less clear cut.
None of the patients showed significant suppression
of urinary LH activity as a result of medication, and in,
all four the fiducial limits of individual assays in the
treatment and post-treatment cycles overlapped to a con¬
siderable extent. One woman receiving sequential
therapy showed a midcycle LH peak in the post-treatment
but not in the treatment cycle.
In one subject the short term effect of chlormadi-
none acetate administered continuously in low dosage was
investigated. The compound produced no significant
effect on either LH or oestrogen output, but may have




STUDIKS ON THE MECHANISM OP ACTION OP CLOMIPH NK
IN "'OPPN WITH SECONDARY AMRNORRHQ'A
INTRODUCTION
Clomiphene citrate (l-p-( -diethylarainoethoxy)
phenyl)-l,2-diphenyl-2-chlorethylene) is a member of the
trieifcylethylene series of compounds to which belongs
also chlorotrianisene (TACK), a potent oestrogen.
Structurally, the compound bears some resemblance to
etilbe8trol (Pig. 48 ).
The effects of clomiphene in animals were first
investigated by HoltKamp et al. (1961). The compound
showed marked antifertility properties in female rats,
being capable of preventing conception and subsequent
pregnancy. The experiments of Segal and Nelson (1961)
demonstrated that clomiphene reduced the sperm count and
decreased fertility in male rats.
Because of its contraceptive potential, the agent
was submitted to clinical trial and unexpectedly an
interesting biologic activity in the field of repro¬
ductive physiology was encountered. The striking
differences of biologic activity in the rat and in the
human soon became evident in studies of Oreenblatt and
















Structural formulae of Stilbestrol, TACE and
CIomiphene.
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stimulate ovulation in a proportion of women in whom this
event normally failed to occur. This activity was also
shown by a compound, MEH-2^ (Tyler et al«, I960; Kistner
and Smith, 1961), but, unlike cioniphene, proved to be
too toxic for human use and was withdrawn from clinical
usage.
At the time of writing and despite recent intensive
studies (see Table 37 for references), neither the site
nor the mode of action of clomiphene is known with
certainty. Unfortunately a high proportion of our
knowledge is based on the results of animal experiments
carried out mostly in rodents. The completely contrary
effects of the drug in humans and animals limit the use¬
fulness of animal experiments and makes extrapolation to
the human situation extremely hazardous.
Some investigators have suggested that the compound
acts directly on the gonads while others believe that
the effects are produced via the anterior pituitary
and/or hypothalamus and some claimed that clomiphene has
a suppressive effect on the anterior pituitary gland
(Table 37).
^he aim of the present study is to contribute to
this field by reporting the results of serial LH assays
in the urine of five women suffering from secondary




Patient 1. Miss H»H.t aged 23 years, para 0+0
The menarche occurred at 12 years of age and she
menstruated regularly (3/28) until the age of 19. At
this time she noticed breast enlargement and
galactorrhoea. She was given stilbesterol (1 mg./day)
for periods of 20 days each month for eight months.
There was no improvement in her mammary discomfort and
at the end of this treatment she developed secondary
arnenorrhoea for 7 months. The patient was then treated
with Enorid, 5 mg. daily for 20 days monthly for five
months, which resulted in withdrawal bleeding but, after
the cessation of treatment, amenorrhoea reappeared,
further course of treatment with norethisterone acetate
(Norlutin-A) also resulted in withdrawal bleeding but
araenorrhoea followed the cessation of treatment. On
examination, except for evidence of galactorrhoea, there
was no stigmata of any endocrine disturbance. Also
there was no evidence to suspect the presence of a
pituitary tumour 3ince her vision was normal and, on
examination, no defect could be discerned as regards the
visual fields.
The present investigation started 8 months after
her last bleeding.
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Patient 2. Mrs W,?,, aged 30 years, para 2 t 0
The men&rche occurred at 13& years of age. Until
the age of 29, menstruation was regular (5/28) and she
had two successful pregnancies. Over the past three
years menstruction became irregular but amenorrhoea
never persxsted for more than two months. One year
prior to the investigation the patient had been under
treatment with Pnovid (5 mg.) for five months, for
family planning reasons, which resulted in the develop¬
ment of secondary araenorrhoea followed by some mammary
secretion. Vaginal cytology at this period showed low
oestrogen effects with a cornification index of less
than 10$. On examination the pelvic organs were normal
and, apart from mammary secretions and the secondary
amenorrhoea, she did not show any endocrine abnormality.
Ten months after the appearance of amenorrhoea the
patient was treated with clomiphene.
Patient 3. Mrs M.G., aged 41 years, para 2 + 0
The rnenarche occurred at 13 years of age and she
menstruated regularly (4-5/29) until the age of 37 years.
She had two successful pregnancies but at the time of
her second pregnancy, when she was 28 years of age, she
suffered a severe postpartum haemorrhage, although
menstruation returned to normal within the normal period
of time. When she was 37 years of age, menstruation
ceased and there was a progressive loss of libido. She
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gradually developed symptoms of hypothyroidism and was
treated with thyroxine (0.2 rag./day). This resulted in
alleviation of her symptoms and her libido returned,
although aoenorrhoea persisted. ?our years after the
development of araenorrhoea the patient was treated with
olomipbene because of her desire for a further conception.
Patient 4. Mrs H.T., n^ed 25 years, para 0 + 0
This patient had been married five years without
any children. Her menarche occurred at 12 and she had
regular periods for approximately one year, which was
then followed by amenorrhoea for a year, and then she
menstruated about every 9 months. When she was 22 years
old a wedge resection of the ovaries confirmed clinical
findings that indicated she suffered from Btein-Leventhal
syndrome. The patient at this time showed hirsutism of
face and abdomen. Three years following the wedge
resection the patient was treated with clomiphane.
Patient 9. Mrs T.K., aged 25 years, para 0^0
Her menarche occurred when she was 18 years of age.
She menstruated irregularly for about 5 years and subse¬
quently became amenorrhoeic. Her buccal smear was
normal, and in these circumstances it was not .justifiable
to proceed to blood culture for karyotype analysis.
Two years after the development of amenorrhoea the
patient was treated with cloraiphene.
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B. Methods
All five patients collected complete 24-hour urine
samples throughout the period of investigation. Assays
were conducted on 48-hour pools of urine, results being
expressed as i.u. (2nd IRP-HMG) per 24 hours.
LH was extracted from the urine by the tannic acid
procedure of Johnsen (1958) (see page 92 ). In subjects
1, 2, 3 and 4, the bioassay used was the 0AA1) test (see
page 79 ). A total of 81 assays were performed; 38.3$
of these were invalid either because of significant
deviation from parallelism between the slopes of the
dose-response curves of standard and unknown preparations
(22$) or due to lack of standard slope (16.3$). The
mean index of precision (X~ S.I).) waE 0.20 ± 0.08. In
patient 5 LH was assayed by the VFW test (see page 51 ).
A total of 38 assays were performed; 5.3$ of these were
invalid because of incompleteness of hypophysectomy in
the test animals. The mean index of precision (X - S.JD.)
was 0.14 i 0.04.
In patient 4 during the presumptive period of
gestation instead of LH, estimations of HCG were per¬
formed by the method of Loraine (1950), based on the
increase in total prostatic weight in intact immature
rats. The mean index of precision (>i 5.1).) was
0.14 i 0.04. Results for RCG were expressed in terms
of the Second International Standard for HOG as i.u. per
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24 hours.
All bioassays were of a symmetrical 4-polnt design
in which two dose levels of the standard were compared
with two dose levels of the test preparation. In a pro¬
portion of the OAAD assays only one dose level of the
unknown fell within the working range of the dose-
response ourve of the standard, making it necessary to
calculate the results on a three-point basis.
In patients 1, 3, 4 and 5 estimations of the three
classical oestrogena, oestrone, oestradiol and oestriol,
were carried out by the technique of Brown et al. (1957)
while in patients 2, 3» 4 and 5 pregnanediol was
measured by the method of Klopper et al. (1955).
RK8ULTS
Patient 1 (Fig. 49 )
The investigation extended over a period of 25 days.
Cloaiphene was administered orally from day 5 to 9 at a
dose-level of 100 rag. per day. Oestrogen levels before
treatment were within the postmenopausal range; clomi-
phene caused a rise in oestrogen excretion, the increase
in oestradiol being maximal during therapy and that of
oestrone and oestriol maximal 4 days following with¬
drawal of medication. Thereafter urinary oestrogens
outout fell and rrora day 17 of the study readings were
in the same range as those encountered during the control























IH values ranged from 2.7 - 10.7 i.u. per 24 hours
and the mean was 5.7 - 0.8 (M.3.F..) i.u. per 24 hours.
These values are within the range encountered in women
during the reproductive life. The fiducial limits
(P « 0.95) of individual estimates overlapped indicating
the absence of a significant difference between any of
the values; it was considered that clomiphene had no
effect on LH excretion levels. The treatment did not
produce an ovulatory cycle and menstruation failed to
occur.
Patient 2 (Pig. 50 )
The study continued for a period of 20 days.
Clomiphene was administered at a dose-level of 100 rag.
per day from days 3 to 8 inclusive. Pregnanediol levels
were all low being within the postmenopausal range. The
drug nad no effect on LH excretion, readings of this
hormone being consistently very low ranging from 1.0 to
less than 3.2 i.u. per 24 hours. The mean LH output
(M.S.B.) was 1.87 - 0.55 i.u. per 24 hours. The
fiducial limits (? « 0.95) for all the LH assays over¬
lapped indicating that the individual values did not
differ significantly.
Patient 3 (Pig. 51 )
The duration of the investigation was 90 days.
After the initial control period of 5 days, cloaiphene
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The effect of Clamiphene on hormone excretion in
Patient 2.
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was administered orally at a dose-level of 50 rag. b.i.d.
per day for 5 days. Thirty-one days later another
treatment of eloraiphene was given again for 5 days but
the dose-level was 100 rag. b.i.d. daily.
During the control period excretion values for
oestrogens, pregnanedioi and LH were all within the
range found in postmenopausal women. The first course
of treatment with cloraiphene did not show any effect on
endocrine funotion. Thirteen days after the cessation
of treatment, levels of oestrone and oestriol rose
gradually reaching a maximum on days 29-30 and 35-36
respectively. Thereafter they fell slightly. The
second course of clomiphene was associated with a marked
rise in oestrone and oestradiol output? readings of
12.2 and 6.7 jug. per 24 hours were noted respectively on
days 45 and 46. Following withdrawal of medication
oestrogens fell to levels found in postmenopausal women.
Pregnanedioi values were consistently low through¬
out the period studied, readings being similar to those
found during the control period.
LH levels were very high, being within the range
found in postmenopausal women. The mean LH output
(M.S.L.) was 75.9 £ 42.9 i.u. per 24 hours. This value
does not differ significantly from the mean level found
in perimenopausal and postmenopausal women. However,
the fiducial limits for all the LH assays overlapped
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The effect of Clomiphene on hormone excretion in
Patient 3#
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indicating that the individual values did not differ
significantly. It was considered that clomiphene did
not exert any significant effect on LH excretion.
Patient 4 (Pig. 52 )
This study extended over a period of 70 days.
During the control period, which lasted for 7 days,
oestrogen levels were within the range encountered in
normal women during the reproductive life. On days 1
to 3 of the study pregnanediol values were high
(3.74 mg./24 hours) but thereafter readings gradually
fell.
LH levels were very high ranging from 170.4 to
211.5 i.u. per 24 hours. These readings are at the
upper end of the limit found in postmenopausal women.
The fiducial limits of individual estimations overlapped
indicating the lack of a significant difference between
them. Clomiphene was administered from days 8 to 14
inclusive, the dose-level being 100 mg. per day. During
this time a rise in oestriol occurred but the drug had
no effect on oeatrone, oestradiol and pregnanediol out¬
put. The LH level on days 10 and 11 was significantly
lower when compared with all the others and coincided
with the oestriol rise. However, the other LH values
did not differ significantly from those found during the
control period; the fiducial limits of individual esti¬
mations overlapped, and it was considered that clomiphene
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The effect of Clomiphene on hormone excretion in
Patient 4.
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did not exert any significant effect on LH output.
On day 40 of the study the patient passed a few
clots of blood and bled for one day. It was thought
that these symptoms might indicate that an abortion had
occurred, and, since the urinary assays were carried out
at a later period, the design of the study was changed;
from the second day after the cessation of clomiphene
treatment until the day of vaginal bleeding, HCG estima¬
tions were performed instead of LII assays. Pregnanediol
values started to rise on the sixth post-treatment day
with a maximal on day 29 of the investigation (17.3 mg.
per 24 hours). A peak of liCG output of 7,520 i.u. per
24 hours coincided with the highest pregnanediol figure
(29th day of the study). Oestrogen levels also rose, a
figure for "total oestrogens" of 429.0 jag. per 24 hours
being noted on day 30 of the study. Subsequently
excretion values lor HCG, oestrogens and pregnanediol
gradually fell and by days 36 and 37 steroid and HCG
readings were in the same range as those found in non¬
pregnant subjects.
A second course of treatment with clomiphene was
started on day 56. After a control period of 6 days
the drug was administered orally for four days at a dose-
level at 200 mg./day. The medication had no effect on
endocrine function readings of oestrogens, pregnanediol
and LH being within the same range found during the
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control period. Forty-eight hours after the caseation
of treatment, on days 62-63, a rise in oestradiol output
was notedj an increase in oestrone excretion also
occurred, the maximum value being found immediately
after the oestradiol peak, A marked rise in preg-
nanediol output occurred, the maximum being from days 61
to 64. Menstruation commenced on day 71 and lasted for
five days. LH readings ranged from 40.5 to 206.8 i.u.
per 24 hours and the mean value (M.S.E.) was 147.3 ±
52.8 i.u. per 24 hours.
Patient 5 (Fig. 53 )
The investigation extended over a period of 75 days.
During the control period, which lasted 13 days,
excretion values for oestrogens were in the range
normally encountered in menstruating women. Pregnanediol
values fluctuated, ranging from 0.5 to 1.7 mg. per 24
hours. LH values were higher than those found in
normally menstruating women, ranging from 23.8 to 65.1
i.u. per 24 hours. Clomiphene was administered at a
dose level of 100 mg. per day for seven days. Treat¬
ment caused a marked effect on oestrogen output. There
was a peak of oestradiol excretion from days 17 to 20,
and this was followed some 24 hours later by a peak of
oestrone output. Oestriol levels rose in a step-wise
manner, reaching a maximum of 67.9 ,Mg. per 24 hours on
days 33 to 36; the highest oestriol figures were
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The effect of Clomiphene on hormone excretion in
Patient 5»
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associated with peaks of oestrone and oestradiol and
with a maximum of pregnanediol excretion. Menstruation
commenced on day 40 and lasted for four days. Between
days 45 and 72, readings of oestrone, oestriol and preg¬
nanediol remained relatively constant, being in the
range found in normally menstruating women during the
proliferative phase of the cycle.
Clomiphene had no discernible effect on LH
excretion. The readings of this hormone during the
period studied ranged from 21.9 to 65.1 i.u. per 24 hours
but the fiducial limits overlapped these values and it
was considered that no significant difference existed
between any of the relative potencies obtained. The
mean LH value (M.S.E.) was 33.9 t 10.3 i.u. per 24 hours.
DISCUSSION
The main and constant finding of tne present study
is the lack of any significant effect of cloraiphene
administration on LH excretion values.
At the time of writing much of the literature on
this subject (Table 37 ) is unsatisfactory because
(1) non-specific methods have been used by the
majority of investigators for the assay of HPS;
(2) a proportion of the results are based on
isolated determinations;
(3) several conclusions are based on poorly designed
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experiments; and
(4) despite the limitations related to the precision
of the assay methods used, several investigators, on the
basis of an increase or decrease in the values of
gonadotrophins estimated, drew the erroneous conclusion
that it was significant without taking into considera¬
tion the confidence limits of the estimated potencies.
Dickey et al. (1965) reported results in four
patients each of whom suffered from a different abnormal
gynaecological condition. The data in two of these
cases is almost impossible to interpret because of con-
cominant therapy by dexaraethazone and the prior admini¬
stration of HCG and ACTH. In the remaining two women
the effect of clomiphene on FSH output was variable.
In one of them FSH rose during the treatment but it is
difficult to suggest that this rise was significantly
higher than the control values. In the latter two
patients clomiphene did not exert any significant effect
on LH excretion values.
Thompson and Mellinger (1965) and Kellinger and
Thompson (1966) estimated the urinary LH output in
patients treated with clomiphene using the VFW test.
The urinary gonadotrophins were tested against NIH-LH-31
as standard. However, since it has been shown that
when the relative potencies of ovine and human prepara¬
tions are assayed by the VTW test, the latter have
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apparently higher specific activities (Rosemberg et al..
1964» Hutchinson et al., 1968), it is remotely possible
that the results of the LH assays of the above investi¬
gators are valid.
Jacobson et al. (1968) performed serial FHS and LH
assays with inadequate control observations in the
plasma of sterile women who were treated with oloraiphene.
They observed an increase of plasma FSH and LH a few
days after the cessation of treatment, and they concluded
on the evidence of these observations that this was due
to cloraipbene treatment. The lack of observations
during a oontrol period and the absence of simultaneous
urinary steroid assays make the interpretation of these
results difficult.
The initial clomiphene-induced increase in urinary
steroids may be followed, either during prolonged
therapy or after therapy has been discontinued, by an
increase in gonadotrophin excretion and it was thought
that clomiphene exhibits a delayed effect. The logical
interpretation of these findings is that the primary
site of action of the drug is a direct stimulation of
steroid biosynthesis by the gonads, with a subsequent
pituitary stimulation via the gonad-hypothalamus-
pituitary axis.
Although in none of the patients investigated in
the present study did clomiphene exhibit any significant
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effect of LH output, the findings in patients 1, 3, 4
and 5 suggest that the drug exerts a direct effect on
the gonads, These results are in agreement with those
reported by other investigators (see Table 37). Smith
et al, (1963) have shown that the pre-operative admini¬
stration of clomiphene to an anovulatory woman increased
the rate of incorporation of labelled acetate into
oestradiol by the ovary in vlxro. Furthermore the
observations by Smith and Day (1963) and Hagerman et al,
(1966) lend further evidence to the premise that the
primary effect of clomiphene is a direct one on the
ovary. The latter investigators have shown that the
precise site of action of clomiphene is to reduce the
amount of available cytochroms-C reductase. Thus more
TPNH is made available for the aromatization reaction
converting androgen to oestrogen,
Herrmann (1963) observed a further increase in
pregnanedlol excretion when clomiphene was administered
after ovulation had already occurred. Xistner (1965)
also reported that the urinary exoretion of pregnanediol
is sometimes greater following ovulation Induced by
clomiphene than that during the luteal phase of the
normal cycle. The results obtained in patients 4 and 5
do not support these views. Patient 4 when under
treatment with cloaiphene already had a functional
corpus luteura, as judged by the pregnanediol assays;
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However, the compound did not immediately increase
pregrmnediol excretion. In patient 5, although she
ovulated under the effect of clomiphene administration,
the highest pregnanediol reading was at the lower end of
the range found during the luteal phase in normally
menstruating women (Klopper, 1957).
The roo3t intensive clinical studies on the effect
of cloraiphene are those of Johnsen et al. (1966) and
MacGregor et al. (1968). According to them the
clinical conditions that respond most readily to clomi¬
phene are the Stein-Leventhal syndrome, post-contra¬
ceptive amenorrhoea, and irregular menstruation at
intervals of less than 6 months. In this type of
patient the ovulatory response varied from 75 to 80$ and
about 35$ achieved pregnancy. Finally in galactorrhoea-
araenorrhoea syndrome the ovulatory response was 41.6$.
Treatment with clomiphene in patient 1 of the
present study, who suffered from galactorrhoea-
amenorrhoea syndrome, was unsuccessful. In this
patient, although the mean LH value was within the range
encountered in normally menstruating women, oestrogen
levels during the control period were within the post¬
menopausal range.
In patient 2, clomiphene treatment apparently
failed to induce ovulation, probably due to pituitary
insufficiency. This view is supported by the mean LH
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output which was significantly lower from that found in
women during reproductive life (p^o.05) (Rosenberg and
Keller, 1965).
In patient 3, values for oestrogens during the
control period and for LH throughout the whole period of
investigation were similar to those found during the
postmenopausal life (see page 146). probably this
patient had no secondary araenorrhoea but was already
post-menopausal, and clomiphene is ineffective in this
type of patient (Riley and Evans, 1964).
Patient 4 suffered from Stein-Leventhal syndrome
and she was probably ovulating sporadically. Preg-
nanediol values were raised at the beginning of the
investigation, which might indicate that ovulation
occurred prior to the initiation of clomiphene treatment.
The patient probably conceived at or about the period of
treatment as judged by steroid and HCG assays. The
pregnancy was unsuccessful and at the end of the third
week she aborted. The second course of clomiphene
treatment induced ovulation as judged by steroid
analysis but on this occasion there was no evidence that
conception ensued. Menstruation appeared at the end of
the study.
The urinary oestrogen levels in this patient during
the control period were within the range found in women
during the reproductive life. On the other hand, the
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LH values were very high, being within the range found
in periraenopauaal and postmenopausal women (see pages
132 and 146). This observation is in agreement with
the results of Tayraor and Barnard (1962) who reported
abnormally high LH levels in patients suffering from the
Stein-Leventhal syndrome.
Another interesting feature in this subject was the
occurrence of ovulation, as judged by urinary steroid
assays, in the presence of high LH readings, an observa¬
tion similar to that found in women late in their repro¬
ductive life (see page 132).
In the last patient the mean (M.S.I.) LH value
(33.9 t 10.3 i.u. per 24 hours) is significantly lower
than that found in perimenopausal and postmenopausal
women (PCO.GQl) (see pages 132 and 146), but ie signifi¬
cantly higher than the comparable reading in normally
menstruating women (P<0.01) (Rosenberg and Keller,
1965). In this patient the main point to note in the
control period was the high LH levels in association
with oestrogen readings within the normal range for a
woman during reproductive life. In this subject cloai-
phene induced ovulation as judged by urinary steroid
assays, but conception did not ensue.
SUMMARY
Endocrine function as judged by endogenous hormone
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levels in urine has been measured before clomiphene
therapy in a series of five patients with abnormal
gynaecological conditions associated with infertility.
In all, the response to the administration of the com¬
pound was assessed by serial hormone assays.
Although clomiphene exhibited a direct effect on
the ovaries as judged by the oestrogen output, the drug
had no discernible effect on LH excretion values.
Ovulation as judged by urinary steroid assays
occurred in two of tne subjects studied.
The evidence presented herein is compatible with
the view that cloaiphene acts directly on the ovaries
rather than through the pituitary-nypothalamus axis.
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CKAPTKR 5
URINARY LUTEINIZING KORMON:■: PXCRkTION IN M:.K
WITH 47.XYY CHROMOSOME CONSTITUTION
IHTRODUCTIOH
The characteristics of phenotypic males with a
47»XYY chromosome complement have recently been described
by Jacobs et al. (1965) and Price et al. (1966). These
men were patients in a State Hospital and had a mild
mental retardation, a tendency towards aggressive
behaviour which resulted in criminal or violent acts,
and a tendency towards increased height.
As was mentioned earlier (page 126 )f the incidence
of hypogonadism is high in patients with this type of
sex chromosome abnormality and no information regarding
pituitary gonadotrophs function in these subjects has
been reported.
The aim of this study was to measure the urinary
excretion of LH in three such patients.
MATERIAL AND METHODS
Patients
Subject 1 (P), aged 16 years: His height was
181 cm. The body hair was scanty but pubic hair was
normally distributed; he lacked facial hair. He did
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not have gynaecomastia and the external genitalia
appeared normal. The patient was of average intelli¬
gence (I.Q. 100).
Subject 2 (G), aged 19 yearst Hia height was
180 cm. The body hair was scanty but of normal distri¬
bution; facial hair shaved twice per week. The
external genitalia appeared normal. The patient was
mentally subnormal (I.Q. 80).
Subject 3 (McC), aged 17 years: Height 169 cm.;
axillary and pubic hair normally developed; facial hair
shaved 3 days in 7; penis and scrotum normally
developed; both testes of normal size; mentally sub¬
normal (I.Q. 90).
Methods
Hormone assays were conducted on 48 or 72 hour
pools of urine and the results were expressed as i.u./24
hours (2nd IRP-HMG). In all three subjects complete 24
hour collections were made over a period of 10 days,
this being the maximum time during which it was possible
to obtain the collaboration of the patients.
HPG was extracted from the urine by the tannic acid
procedure (see page 92 ) and the bioassay of LH was
carried out by the OAAD method (see page 79 )• All the
assays were of a symmetrical 4-point design.
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R1'BTILTS
In the 14 assays performed the mean index of
precision (X- S.D.) for the LH estimations was
0.16 t 0.02.
The results of serial LH assays are illustrated in
Figures
Subject 1 (Fig. 54 )» Marked fluctuations in LH
output were present and a consistent pattern of
excretion was not observed. Only the last reading on
day 9 of the study was within the normal range for male
subjects, the other 4 estimations being abnormally high.
Subject 2 (Fig. 55 )t All measurements were con¬
siderably above the level expected for normal male
subjects.
Although the readings of the relative potencies
varied from 41.3 to 79.3 i.u. per 24 hours, the fiducial
limitB (95$) encompassed those values and it was con¬
sidered that no significant differences existed between
any of the values estimated.
Subject 3 (Fig. 56 ). The first two readings were
at the upper end of the normal range while the third on
day 9 of the study was grossly abnormal.
The mean (± S.K.M.) urinary LH level of the three
subjects was 77.34 i 16.6 i.u. per 24 hours.
Mr. P AGE 16 Years A7.XYY KARYOTYPE
Figure 54
Urinary LH excretion in Subject 1
Mr. C. ACE 19 Years t7.XYY KARYOTYPE
Figure 55





Urinary LH excretion in Subject 5
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pitscuss ion
Prior to the studies of Jacobs et al. (1965) and
^r*oe at al. (1966) only isolated cases have been
reported of the XYY abnormality, and knowledge of only
15 patients in the general population has been identi¬
fied. Table 38 contains a summary of cases that have
been reported in the literature. Examination of these
15 cases shows that XYY males have no consistent
physical or mental stigmata. However, the incidence of
gonadal abnormalities is high. Mine patients showed
evidence of either abnormal genital development (age
from 21 months to 12 years) or of hypogonadism. Only
two of those 15 patients were with certainty fertile.
The measurements of LH in the three patients
described herein are similar to those found in patients
with primary testicular hypogonadism (Papanicolaou et
al., 1967).
The mean LH value of the present study (77.34*16.6)
is significantly higher (P<0.001) than that found in
normal male patients (Rifkind et al., 1967) (see page 116).
It is remotely possible that the high LH values in
the 47,XYY males, as compared with the normal subjects
of Rifkind et al. (1967), could be explained on methodo¬
logical grounds since the assay procedures used in the
two investigations (the hypophysectomised prostate test
by Rifkind et al. (1967) and the OAAD method in the
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present investigation) were different. However, such
an explanation appears to be moat unlikely in view of
the observations that when parallel assays by the two
techniques are performed on urinary extracts prepared by
the tannic acid procedure of Johnsen (1958), similar
results are obtained (Rosenberg, 1967).
Reasons for the abnormal LH excretion in males with
a 47,XYY karyotype remain obscure. Findings on testi¬
cular biopsy might well throw light on the question and,
at the time of writing, such data are available in two
subjects (Balodimos et al., 1966; Nielsen et al., 1966).
The appearance of the testes was found to be similar but
not identical to that encountered in classical cases of
Klinefelter*s syndrome, being characterised by virtual
absence of speroatogenic and Sertoli cells with
relatively normal numbers of Leydig cells which were
arranged in the form of smAll clusters and showed a
moderate degree of hyperplasia.
LH is known to be the hormone which acts upon the
Leydig cells of the interstitial tissue of the testes
and regulates the secretion of testosterone (Johnsen,
1967} Lunenfeld, 1967; Gerazell, 1968). Several
investigators who performed testosterone estimations in
plasma and in urine of XYY males found the testosterone
values to be within the highest normal range (Goodman
and Smith, 1967; Price and van der Kolen, 1967; Ismail
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et al., 1968).
On the basis of these results it might be postulated
that in men with a 47,XYY karyotype the Leydig cells of
the testes are relatively insensitive to stimulation by
pituitary LH, and in order to overcome this refractori¬
ness, abnormally large quantities of this hormone must
be produced by the anterior pituitary leading to greater
quantities being excreted in the urine. In this
connection it appears worthy of comment that the normal
reciprocal relationship between the pituitary and the
gonads does not appear to be present in 47,XYY males,
and abnormally high LH output in these subjects is
associated with urinary teotosterone readings that are
at the highest normal range.
From the present study it is not possible to draw
any definite conclusions about the XYY syndrome because
of the limited number of patients and the difficulties
of co-operation with them in a more prolonged and
detailed investigation due to their aggressive behaviour.
SUMMARY
Serial assays of luteinising hormone (LH) in urine
have been performed in 3 phenotypic males with a 47,XYY
sex chromosome constitution. LH levels were grossly
elevated, being significantly higher (P< 0.001) than
those found in normal male subjects. The possible





Although the sex-chromoeomal karyotypea and the
clinical features of patients with Turner*a ayndrome have
been extensively studied (see Introduction, page 127)
there remains a great lack of information regarding
pituitary gonadotrophic function in this condition. In
the few studies reported in the literature, non-specific
methods of assay for HPO were used and it was not
possible to draw any definite conclusions from the data
presented.
The aim of the present study was to determine
urinary LH levels in four patients with Turner's
syndrome. In one of these subjects an ovarian implanta¬
tion was performed, and the effect of this procedure on
LH output was investigated, in an attempt to determine
whether the ovarian defect in this syndrome is primary
or is due to abnormal pituitary gonadotrophic function.
Patients
Subject 1 (B.W.), aged 25 years: Height 138 cm.;
primary araenorrhoea with underdeveloped genitalia; no
breast development; axillary hair absent; pubic hair
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sparse; webbing of neck; bifid left renal pelvis and
left ureter; chromosomal karyotype 46,XXq?i.
Subject 2 (J.B.), aged 18 years: Height 132 cm.;
primary araenorrhoea with absence of secondary aex
characteristics; chromosomal karyotype 46,XXqi.
Subject 3 (J.M.), aged 31 years: Height 141 cm.
Menarche at the age of 13. She menstruated for one year
and subsequently became amenorrhoeic. Her breasts were
reasonably developed, but she had no axillary hair.
There was a small uterus, but no endometrium was obtained
on curettage, and the ovaries were not palpable.
Gynaecography revealed no definite evidence of ovarian
shadows. A chromosomal analysis showed the presence of
a 46,XXqi karyotype.
Subject 4 (L.B.), aged 18 years: Height 149.9 cm.
with primary aaenorrhoea and absence of any secondary aex
characteristics. The uterus was hypoplastic and the
ovaries were not palpable. Radiological examination of
skull was normal, and there were no abnormal haematologi-
cal or biochemical findings. The chromosomal karyotype
was 45,X/46,XX.
Further investigation six months after the initial
presentation of subject 4 revealed at laparotomy that the
cervix was infantile, the uterus hypoplastic and that the
ovaries consisted of bilateral streaks along the superior
aspect of the infundibular pelvic ligaments. Bilateral
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ovarian transplantation was performed, the donor being
her mother who had a history of regular menstruation and
whose ovaries were histologically normal. The post¬
operative course of this patient was uneventful. Two
months following the operation she developed acne
affecting the face, forehead and shoulders? she also
noted lower abdominal and mammary discomfort and
leucorrhoea. Examination of the vaginal cytology at
this time showed superficial cells with pyknotic nuclei
which might indicate oestrogenlc activity.
METHODS
All four patients collected complete 24-hour urine
samples throughout the period of investigation. In the
case of subject 4, who was resident in Pittsburg, U.S.A.,
samples were deep frozen before being transported to
Edinburgh by air. Assays were conducted on 48-hour
pools of urine, results being expressed as i.u. (2nd
I8P-HM0) per 24 hour sample.
LH was extracted from the urine by the tannic acid
procedure of Johnsen (1958). In subjects 1, 2 and 4 the
bioassay was the OAAD test (see page 79 ). A total of
19 assays were performed; the mean index of precision
(A- S.B.) was 0.22 t 0.06. In patient 5 LH was assayed
by the VPW test (see page 51 ). A total of 22 assays
were performed; 27$ of these were invalid either because
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of significant deviation from parallelled between the
slopes of the dose-response curves of standard and un¬
known preparations or due to incompleteness of the hypo-
physectomy. The mean index of precision (A- S.D.) for
the VFW test was 0.11 t 0.05.
In patients 1 and 4 estimations of the three classi¬
cal oestrogens (©estrone, oestradiol and oestrlol) and of
total 17-hydroxycorticosteroids (17-OHCS) were performed
by the techniques of Brown et al. (1957) and of Appleby
et al. (1955) respectively.
RESULTS
Subject 1 (Fig. 57 )
Levels of ©estrone, oestradiol and oestriol were
either low or undetectable while readings of 17-OHCS also
tended to be low. LH values were abnormally high for a
woman during reproductive life, ranging from 38.0 to
113.0 i.u. per 24 hours. The fiducial limits (P » 0.95)
for rII the LH assays overlapped, indicating that the
individual values did not differ significantly.
Subject 2 (Fig. 58 )
LH levels were much above the range normally
encountered in women during reproductive life, readings
ranging from 103.4 to 328.6 i.u. per 24 hours. The
fiducial limits (P « 0.95) of individual estimates over¬
lapped, indicating the absence of a significant difference










































Hormone excretion in Subject 1
Miss J.B: AGE 18 YEARS TURNER'S SYNDROME


















LH excretion in Subject 2









LH excretion in Subject 3
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Figure 60
Steroid excretion in Subject 4











































Effect of Clomiphene and ovarian transplantation
on LH and oestrogen excretion in Subject 4«
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similar to those in the control period. Some eight
weeks after the operation, when leucorrhoea, mammary
discomfort and acne were present, excretion values for
©estrogens were low or undetectable and U! readings were
in the same range as those encountered pre-operatively.
Mean hormone excretion in Turner's syndrome
This is shown in Table 39. In the two subjects in
whom urinary ©estrogens were estimated, levels were very
low indicating the virtual absence of ovarian activity,
while readings for 17-OHCS were within or at the lower
end of the normal range. !H readings were very variable
being within the postmenopausal range in subjects 1 and
2, at the upper end of the normal range for women during
reproductive life in subject 4 and above this range in
subject 3.
Comparison of results in Turner's syndrome and
postmenopausal women
Table 40 showa the difference in LH levels between
the patients with Turner's syndrome and a series of four
postmenopausal women investigated concurrently (see
Chapter 2). Figures which are lower in Turner's
syndrome are indicated by a minus sign and those which
are higher by a plus sign; significant differences are
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range as in postmenopausal subjects, while in patients 3
and 4 they are significantly lower. The chromosomal
karyotype in Turner's syndrome did not appear to
influence the results.
DISCUSSION
One of the main findings in the present investiga-
tion was the variability in urinary LH levels in the four
cases of Turner's syndrome reported. Thus in two
patients, readings were within the postmenopausal range,
in one at the upper end of the normal range for women
during reproductive life (see Rosemberg and Keller, 196i>)
and in one above this range. Another point to emerge
from the study was the apparent lack of correlation
between the mean X.H output on the one hand and the
chromosomal karyotype on the other.
In the patient in whom the ovarian transplantation
was performed a marked rise in urinary LH excretion
immediately followed the operation. The reason for this
finding is not entirely clear, although the following
possibilities might be considered.
If the defect in Turner's syndrome Is primarily in
the ovaries, it might be expected that the transplant
would function normally. This did not appear to be the
case. Clinical evidence points to the view that the
ovarian transplants beoame functional, this being
205.
indicated by the presence of acne, leucorrhoea and
oestrogenic changes in the vaginal smear at the time of
examination some two months after the operation even when
LK and oestrogen levels had returned to those seen during
the pre-operative period.
Another possibility is that the increase in LH out¬
put, indicating pituitary hyper-activity, was due to the
physiological and psychological stress to the patient
occasioned by the operation. Kspiner (1966) has shown
that after surgical intervention there is a marked rise
in the urinary excretion of free Cortisol which is accom¬
panied by an increased level of ACTH. Nevertheless,
there is no evidence to support the view that in human
subjects there is an effect on the secretion of HKJ,
either by itself or caused by the increase in levels of
AOTH or corticosteroids (Mason et al., 1948j Sohval and
Soffer, 1951; Crean et al., 1963# 1966; Loraine et al.,
1967). Giuliani et al. (1961), using a specific method
of 13! assay, showed that ACTH, released as a result of
stress, does not increase LH secretion in the rat.
However, Charles et al. (1965) reported a rise in the out¬
put of HPG as a result of surgery in one out of six women
subjected to total hysterectomy and salpingo-oophorectomy
for endometrial carcinoma. It should, however, be noted
that this rise in HPG was followed by a significant
increase in urinary oestrioi outout, presumably of
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adrenal origin. The fact that auch a rise did not occur
in the present study suggests that there may be other
factors operating that affect LH excretion in these
circumstances.
Silver and his colleagues (Silver, 1951; Silver and
Kempe. 1953; Silver and Dodd, 1957) and Grossman (I960)
have shown that in children with Turner's syndrome,
ranging in age from 2^ to 9 years, urinary HPG levels
may be grossly elevated, being either within or above the
range encountered in normally menstruating women. These
results suggest that the pituitary in Turner's syndrome
may be hyperactive. Moreover, normal menstrual function
with regular periods, sometimes for several years, has
been reported in established cases of the syndrome.
Hoffenberg et al. (1957) reported two patients with
gonadal dysgenesis who had menstruated irregularly for 5
and 6 years respectively. Laparotomy was performed in
both cases one year after the cessation of menses and
the streak gonads, typical of Turner's syndrome, were
found. These consisted of fibrous stroma without
follicles or interstitial cells. Stewart (I960)
described classical chromatin-negative Turner's syndrome
in a woman who had menstruated regularly for six years.
Bahner et al. (I960) found two cases of chromatin-
negative Turner's syndrome with regular menstruation in
one of these subjects for four years. The second
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patient had menstruated regularly since the age of 16,
and at 31 years of age gave birth to a normal son.
Some light has been shed on ovarian development in
patients with a 45,X karyotype by the recent findings of
Sing and Carr (1966). Thirteen abortusee with a known
chromosomal complement of 45»X were collected ranging in
age from five weeks to four months. In all the speci¬
mens the gross anatomical appearance of the gonad was
normal and, when examined histologically, the presence
of primordial germ cells could be demonstrated. The
histological sections of the 45,X gonads were compared
with sections of gonads from known 46,XX abortuses of
similar ages. Sing and Carr (1966) found no significant
difference between the 45,X and the 46,XX gonads up to
the end of the third month in ntero. In the older
foetuses there was a relative increase in the connective
tissue of the 45,X gonads.
The cumulative evidence from all these observations
suggests that the classical view regarding the aetiology
of Turners syndrome may represent an oversimplification
of the true situation. Further work is obviously
necessary in order to determine whether other factors,
and particularly an abnormality of the pituitary-hypo-
thalamie axis, play an Important role in the patho¬
genesis of the condition.
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3UMMABY
1. Bioassays of LH hare been conducted on the urine
of four patients with Turner's syndrome in one of whom a
bilateral ovarian transplantation was performed.
2. LH levels were variable in Individual subjects
being either within or below the postmenopausal range.
3* There was no apparent correlation between the
chromosomal karyotype and the LH output.
4. A marked rise in LH excretion followed the
ovarian transplantation, but this was not associated
with an increase in urinary oestrogen output.
209.
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